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7Abbreviations and Constants 
(Q)SAR  (quantitative) structure-activity relationships 
ATP   adenosine triphosphate 
ABC   ATP binding cassette 
BOLD   blood oxygenation level dependent 
BSA   bovine serum albumin 
CBF   cerebral blood flow 
CBVrel relative cerebral blood volume 
CMC   critical micellar concentration 
CMRglu / O2 cerebral glucose / oxygen consumption 
CNR   contrast-to-noise ratio 
CNS   central nervous system 
CPP   cell-penetrating peptide 
DHb   deoxyhemoglobin 
DMEM  Dulbecco’s modified Eagle medium 
DMSO  dimethylsulfoxide 
ECAR   extracellular acidification rate 
EDTA   ethylenediaminetetraacetic acid 
EU    energy units 
FACs   fluorescence activated cell sorting (cytometry technique) 
FBS   fetal bovine serum 
Fg    fluorescent FITC bound to a spacer peptide g 
Fg-TATP  fluorescent peptide Fg linked to TATP 
FITC   fluorescein isothiocyanate 
FMRI   functional magnetic resonance imaging 
FOV   field of view 
g spacer peptide ((EA)GGGG) used for linking FITC to TATP 
GABA   (gamma)-aminobutyric acid 
GAGs   glycosaminoglycans 
GRE   gradient echo 
HIV   human immunodeficiency virus 
HS    heparan sulfate 
HSPG   heparan sulfate proteoglycans 
8IMEM   Iscove’s modified Eagle medium 
ISFET   ion sensitive field effect transistor 
ITC   isothermal titration calorimetry 
LAPS   light-addressable potentiometric sensor 
MDR   multidrug resistance 
MOS-FET metal oxide semiconductor-field effect transistor 
MTX   matrix 
NA Avogadro’s number: NA = 6.023 · 1023 mol-1 
Pgp   P-glycoprotein 
PtcO2/CO2 transcutaneous oxygen/carbon dioxide tension 
PTD   protein transduction domain 
R universal gas constant R = 8.31 J·mol-1·K-1 
R1 spin-lattice or longitudinal relaxivity (=1/T1)
R2 spin-spin or transverse relaxivity (=1/T2)
R2* effective spin-spin relaxivity (=1/T2*)
RARE   rapid acquisition with relaxation enhancement 
RF    radiofrequency 
ROI   region of interest 
SE    spin echo 
T1 longitudinal relaxation time 
T2 transverse relaxation time 
T2* effective transverse relaxation time 
TAT   trans-acting activator of transcription 
TATP   PTD peptide (YGRKKRRQRRR) of HIV-1 TAT 
TE    echo time 
TMD   trans-membrane domain 
TR    repetition time 
9Foreword 
During the present thesis, I had the occasion to study living mammalian cells with 
biophysical techniques that allowed me the fascinating observation of life through the eyes of 
modern science. What the physicists Heisenberg and Schrödinger postulated in 1926 for the 
observation of electrons ("The observation itself changes the probability function 
discontinuously") can be extended to many fields of experimental research, and was certainly 
true for the observations reported in the present thesis: although the experiments were 
conducted in living cells, the observation itself required conditions that altered the life of the 
studied cells. For example, the observation of the entire organism with fMRI required the 
application of an anaesthetic; the superfusion of the cells in the microphysiometer proceeded 
with a blood substitute and at different partial gas pressures than found in the body; etc. Such 
experimental variations are integral part of the observation and the consequences of such 
conditions are addressed also in the present thesis. 
In the last period of my work, I had the chance to work with living mice. Such models are 
nowadays routinely used for pre-clinical studies in the development of medical drugs and 
represent a fundamental step preceding phase I clinical trials. Especially the genetic 
elimination of a single protein (transgenic models) became a helpful tool to study the effects 
of such proteins on the entire organism and handling of diseases. However, such kind of 
animal experimentation is subjected to ethical and moral considerations on our rights, as 
humans, in exploiting other living organisms for our own profits. 
While a complete abolition of animal experimentation seems to be utopian at the moment, 
a concrete effort can actually be done to reduce the number of animals needed for an 
experiment, to refine the methods employed for the investigation and, where possible, to 
replace animals with alternative models. Such biocentric, or at least less anthropocentric, 
philosophy is currently officially adopted by the Swiss Federal Law, and advertised under the 
acronym RRR (Refine, Reduce, Replace). In the last part of the thesis, it was my intention to 
actively take part to the RRR effort, by contributing to the development and adaptation of less 
invasive techniques for animal experimentation. 
In summary, it was an interesting experience for me to study the diversity of metabolic 
responses in animal systems such as living cultured cells and mice, which allowed me to 
acquire experimental knowledge of the link between basic and preclinical biomedical 
research. 
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Summary 
 
The present thesis describes in three parts how living cells can be investigated on different 
biological levels, and how these techniques can be used to non-invasively evaluate the effect 
of drugs in the context of biomedical and pharmaceutical research. 
 
In the first part, Pgp activation is studied in living cells studied in culture. Here, 
microphysiometry, monolayer techniques and computer modeling were applied to investigate 
the interaction of drugs with human P-glycoprotein (Pgp). Pgp is a transmembrane ABC-
transporter that protects cells from a wide variety of toxic substances. Pgp is helpful under 
most biological conditions since it provides natural protection from toxins, but its activity can 
lead to resistance development in chemotherapy e.g. of cancers and microbes. In particular, 
the reported techniques provided a novel method to study Pgp-substrate interactions in real-
time and in living murine cellular systems in which human Pgp have been expressed. 
Investigation of Pgp-substrate interactions is then extended to the structure-activity 
relationships (SAR) of potential Pgp substrates, on the basis of a recognition mechanism 
based on intramolecular hydrogen bond acceptor patterns. 
 
In the second part, living cultured murine cells were studied under the influence of cell 
penetrating peptides (CPPs). CPPs are a class of compounds that traverse biological 
membranes very efficiently, although the precise uptake mechanism is not yet known. 
Elucidation of the exact uptake mechanism is, however, of great interest, given the potential 
of this class of compounds for pharmacological and biotechnological purposes. A CPP 
derived from the HIV-1 peptide TAT was studied using fluorescence confocal microscopy 
and microphysiometry as principal techniques. 
 
In the third part of the thesis, the biological observation level was switched from living 
cells in culture to the entire organism using magnetic resonance imaging as a non-destructive 
method to observe biological effects of drugs. In pharmaceutical research the development of 
a commercial compound requires similar observation levels during the long evaluation 
process starting from high throughput screening of potential bioactive molecules and ending 
with the launch of one selected therapeutically successful product. The intermediate steps 
include basic in vitro studies, in vivo experimentation with cell culture, pre-clinical assays 
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with intact animal models and phase I-III clinical trials with humans. For ethical and practical 
reasons, major attempts are made to replace invasive animal models by non-invasive 
techniques that can be applied in the same way to the clinical research providing thus a 
smooth transition between pre-clinical and clinical phases. This last part of the thesis adapts 
and optimizes such a recent imaging method to detect brain activation non-invasively in mice 
and to allocate the activated brain areas in mice without the need for surgery. 
 
In particular, the study focused on the activation of metabotrobic GABA(B) receptors in 
the mouse brain, upon stimulation with baclofen. The technical goal of this project was to 
adapt functional magnetic resonance imaging (fMRI) protocol at high field (7T) to the small 
size of the murine brain. The biological goal was to characterize regions in the brain, that 
show an enhanced activity under the influcence of baclofen - a know stimulator of GABAB 
receptors. 
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Part One: P-Glycoprotein 
Foreword and Context of the Project 
A search with the headword “P-glycoprotein” using the common biomedical database 
pubmed (www.pubmed.org) results in currently (2003) over 7000 scientific publications. This 
simple example gives a coarse, yet indicative illustration of the interest in this molecule and 
the effort research has made up to now, June 2003, to understand its function. 
P-glycoproteins or Pgps (P stays for permeability) belong to the superfamily of ATP-
binding cassette (ABC) proteins, also called ABC transporters or traffic ATPases. The general 
function of ABC transporters is to transport a large variety of chemicals (from peptides to 
simple ions) through biological lipid membranes against their concentration gradients, at the 
expense of ATP hydrolysis. 
 
The ABC transporter superfamily is a large gene family that has been highly conserved 
during evolution (Miyauchi et al., 1992), and which pertains to organisms from different 
phyla, from prokaryotes to eukayrotes (Descoteaux et al., 1992). It includes 51 members in 
humans, 55 in flies, 129 in plants and over 300 in bacteria so far (Cai and Gros, 2003).  
 
Human P-glycoprotein (Juliano et al., 1976; Juliano and Ling, 1976; Kartner et al., 1983; 
Riordan et al., 1985) is a 170 kDa integral protein composed of two homologous halves, each 
containing six putative transmembrane domains (TMDs) and an ATP-binding site, separated 
by a flexible linker polypeptide (Ambudkar et al., 1999). Pgp carries few N-linked 
glycosylation sites on the extracellular loop joining TMD 1 and TMD 2, and four intracellular 
phosphorylation sites on the linker domain between TMD 6 and TMD 7 (Figure I.1). 
 
Human Pgp is the product of the MDR1 gene, cloned for the first time in 1986 by Chen et 
al. (Chen et al., 1986). In the same year, similar genes were sequenced from mice (mdr 1a 
(mdr 3), mdr 1b (mdr 1) and mdr 2) (Gros et al., 1986; Gros et al., 1986) and hamsters 
(Gerlach et al., 1986), showing pronounced homology in the amino acid sequences. 
 
MDR genes owe their names to a phenomenon called multidrug resistance (MDR). The 
origins of the MDR phenotype are manifold (Beck, 1989; Cole et al., 1992; Cole et al., 1994; 
Endicott and Ling, 1989; Gottesman and Pastan, 1993), but the expression of Pgp on cancer 
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cell surfaces is probably the most studied among them. Such phenotypic peculiarities were 
reported first by Biedler and Riehm (Biedler and Riehm, 1970), who demonstrated that 
Chinese hamster cells selected for resistance to actinomycin D became also simultaneously 
resistant to puromycin, vincristine, vinblastine, mithramycin, daunorubicin, mitomycin C and 
demecolcine. With the appearance of MDR, tumor cells acquire resistance against a great 
variety of drugs, often unrelated to the compound applied initially. MDR has also been 
observed during the pharmacotherapy of epilepsia (Aronica et al., 2003; Rizzi et al., 2002; 
Tishler et al., 1995), various mycosis (Kontoyiannis and Lewis, 2002; Wirsching et al., 2000), 
bacterial infections (Putman et al., 1999; Van Bambeke et al., 2000; Van Bambeke et al., 
2003; Van Bambeke et al., 2003) and parasitosis. Under these conditions, the transporters are 
either activated and/or upregulated. This leeds to an efficient export of the intruding 
chemicals resulting in an increased detoxification (in the case of chemical hazards), but a 
reduced efficiency of drugs. Indeed, Pgp-like efflux transporters have been found in different 
pathogenic microorganisms, and in several parasitic protozoa such as Plasmodium,
Leishmania and Entamoeba, and have been shown to contribute to the drug resistance 
phenotype (Howard et al., 2002; Ullman, 1995). 
 
Figure I.1. Secondary structure of human P.glycoprotein. Two homologous halves of 6 
putative TMD are connected by a flexible linker  peptide. Two ATP binding sites are 
highlighted  (circles). Phosphorylated groups and point mutations are shown (black dots). 
Adapted from (Ambudkar et al., 1999) 
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To reduce MDR there are also attempts to express Pgp mutants in sensitive tissues (bone 
marrow) of cancer patients, in order to target tumors with higher drug concentrations while 
protecting normal tissues (Gottesman, 2003; Podda et al., 1992). 
Beyond its inauspicious role, mainly in cancer treatment Pgp plays an important 
physiological function in healthy organisms. In mammals, Pgp is expressed constitutionally in 
cells specialized in selective transport, e.g. the apical membrane of small intestine enterocytes 
(Benet et al., 1999), the endothelial cells of brain capillaries involved in the constitution of the 
blood-brain barrier (BBB) (Schinkel et al., 1996; Thiebaut et al., 1989), the luminal 
membrane of hepatocytes (Silverman and Schrenk, 1997), and generally in all tissues in 
which a highly selective compartmentalization is needed, such as kidney, pancreas, adrenal 
glands, colon, jejunum, liver, brain (Thiebaut et al., 1987). Functional expression of Pgp is 
also observed in the luminal surface of secretory epithelial cells of the pregnant uterus 
(Piekarz et al., 1993) and in the placenta (MacFarland et al., 1994). 
 
The basic challenges in fundamental research consist in understanding how Pgp 
recognizes its substrates, how the ATP-driven catalytic cycle leading to drug extrusion 
functions, and how the molecular pathways inducing and modulating Pgp expression on the 
cell surface are triggered.  
The apparent lack of specificity for substrates has been a veritable mystery for a long time. 
The only accepted homologies among Pgp substrates were their hydrophobic and amphiphilic 
nature (Ford and Hait, 1990; Gottesman and Pastan, 1993). However, the incompleteness of 
such an interpretation has been pointed out by the observation that compounds such as 
morphine, which is rather hydrophilic, can also be recognized by Pgp (Fischer, Gottschlich 
and Seelig, unpublished results). Based on the analysis of 100 compounds interacting with 
Pgp a recent model suggests a further common property (Seelig, 1998). According to this 
model, the ability of a compound to act as a Pgp substrate, inhibitor or inducer of Pgp 
overexpression is determined by the presence of specific intramolecular electron donor or 
hydrogen bond acceptor patterns. The patterns consist of two electron donor groups (or 
hydrogen bond acceptor) with a spatial separation of 2.5 ± 0.5 Å (called type I pattern), and 
three electron donor groups with a spatial separation of 4.6 ± 0.6 Å between the outer groups 
(called type II pattern). Recently, Ekins et al. (Ekins et al., 2002) reported three dimensional 
quantitative structure-activity relationship (3D-QSAR) models for various Pgp inhibitors, 
outlining again the requirement of multiple hydrophobic and hydrogen bond acceptor features 
for molecules interacting with Pgp.  
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It is now commonly accepted that the interaction between Pgp and its substrates takes 
place from the inner leaflet of the lipid membrane. For this reason, the thermodynamics and 
kinetics of substrate transport is determined (i) by the lipid-water partition coefficeint, 
depending in turn on the packing density of the membrane, T, and the cross-sectional area of 
the substrate molecule, AS, as well as by the direct interaction of the substrate with Pgp via 
hydrogen bond formation within the membrane (Seelig et al., 2005). 
After a compound is intercepted by Pgp, an allosteric transition, induced by the hydrolysis 
of one molecule of ATP is likely to take place, however, no direct structural observation 
exists yet. As a result, the substrate is transferred from the inner leaflet to the outer leaflet of 
the lipid membrane, and thus can be released extracellularly. Once the molecule is released, 
Pgp recovers its original conformation at the expense of a second ATP molecule (Sauna and 
Ambudkar, 2000).  
 
In the absence of xenobiotics, Pgp keeps its ATPase activity, even though at a lower rate, 
most likely due to the transport or “flip flop” of endogenous substrates such as phospholipids. 
Pgp thus may play a role in keeping the asymmetry of the lipid membrane (Higgins, 1994; 
Romsicki and Sharom, 2001).  
 
For the study of the catalytic cycle of Pgp e.g., vanadate trapping (Dey et al., 1997; Kerr et 
al., 2001; Urbatsch et al., 1995) was used. To monitor substrate transport kinetics, several 
techniques have been employed, e.g. the calcein-AM assay (Hollo et al., 1994; Liminga et al., 
1999), inorganic phosphate release from ATP hydrolysis in inverted plasma membrane 
vesicles and monoclonal antibody staining (Schinkel et al., 1993).  
We developed a method to monitor P-gp-substrate interactions in living cells and in real-
time, based on microphysiometry (McConnell et al., 1992). First human uterus sarcoma cells 
were used (Fisher, PhD thesis; (Nervi, 2000) and later pig kidney cells and mouse embryo 
fibroblasts (Landwojtowicz et al., 2002) were used. The technique consists in measuring 
modulations of the cellular metabolism associated with the ATPase activity of Pgp, by 
microphysiometry (Mcconnell et al., 1992). The following chapters will focus on two aspects 
(Landwojtowicz et al., 2002; Nervi, 2000): (i) The coupling between Pgp ATPase activity and 
the extracellular release of H+ and (ii) the interaction of drugs and surfactants both carrying 
appropriate H-bond acceptor groups with Pgp. 
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Chapter 1. Pgp-substrates Interactions in Living Cells 
1.1 Introduction 
An efficient inhibition of multidrug resistance (MDR) represents a great hope for various 
pharmacological treatments. This requires a detailed understanding of the mechanisms 
underlying the MDR phenomenon. In the past, transmembrane ABC-transporters have been 
identified as main elements responsible for the appearance of MDR phenotype in almost all 
kinds of living organisms. Human P-glycoprotein, a 170 kDa 12 TMD ABC-transporter coded 
by the MDR1 gene (Chen et al., 1986), is probably the most extensively studied among them. 
A detailed understanding of Pgp-substrate interactions would provide useful information for 
the appropriate design of inhibitors and for improved drug delivery to target organisms. 
 
We measured standard drugs known to be Pgp substrates (Landwojtowicz et al., 2002; 
Nervi, 2000), in order to test the microphysiometry technique and to assess the correlation 
with data obtained with conventional ATPase activation assays (Litman et al., 1997). In 
parallel, our investigation has been extended to compounds generally not or barely 
acknowledged as specific Pgp substrates, such as detergents (Nervi, 2000). 
 
Already fifteen years ago, observations have been made that surfactants reveal some 
activity in the reversal of multidrug resistant (MDR) phenotype (Friche et al., 1990; Sehested 
et al., 1989; Woodcock et al., 1992), and few years later in the alteration of Pgp ATPase 
activity (Doige et al., 1993; Orlowski et al., 1998; Zordan-Nudo et al., 1993). 
 
In the earliest studies, the hypothesis of a direct interaction of surfactant with Pgp was 
suggested (Friche et al., 1990; Loe and Sharom, 1993). However, in following studies, the 
inhibition of Pgp by detergents was considered to rather be the result of an indirect 
mechanism involving the alteration of the physical chemical properties of the cytoplasmic 
membrane (Batrakova et al., 2001; Bittner et al., 2002; Buckingham et al., 1996; Hugger et 
al., 2002; Hugger et al., 2002; Regev et al., 1999).  
Despite the lack of a precise understanding of the effect of detergents on Pgp function, 
recent research focuses on the simultaneous application of nonionic surfactants (and similar 
molecules) with compounds that have proven to inhibit Pgp: novel applications of Pluronic 
block copolymers (= a detergent) in the treatment of drug-resistant tumors have been 
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reviewed by Kabanov (Kabanov et al., 2002). Also preclinical (Jagannath et al., 1999) and 
clinical trials (Martin-Facklam et al., 2002; Rischin et al., 1996) using these compounds for 
cancer treatment have already been described. 
 
The use of Pluronics (poly(oxyethylene)-poly(oxypropylene) block copolymers) as a 
vector for drug delivery emerged in 1992, (Kabanov et al., 1992). This investigation showed 
that pluronic P85 was able to produce a drastic enhancement of the efficiency of cell loading 
with a fluorescent dye linked to Staphylococcus aureus enterotoxin B (SEB), and suggested 
endocytosis as possible transport mechanism. 
 
In the following years, several reports described that combinations of pharmacological 
agents and polyethoxylated surfactants, or similar ester derivates, could improve the oral 
bioavailability of the drug and lower the multidrug resistance activity of Pgp (Banerjee et al., 
2000; Cornaire et al., 2000; Dintaman and Silverman, 1999; Komarov et al., 1996) and related 
transporters (Miller et al., 1999). By means of flow cytometry with Caco-2 cells it was shown 
that nonionic detergents, such as Tween 80, reverse MDR even more efficiently than standard 
non-detergent Pgp-modulators, such as verapamil, trifluoperazine and reserpine (Lo et al., 
1998). 
 
Nevertheless, the mechanism of action of detergents on Pgp remained unclear, (see 
(Kabanov et al., 2003) for a review). Some studies suggest that MDR reversal by Pluronics 
and other surfactants could occur, apart from membrane fluidization, also through effects on 
buffer osmolarity, via direct transporter inhibition, or mitochondrial toxicity leading to an 
induction of energy depletion in the cell, i.e., a decrease of intracellular ATP available for Pgp 
(Batrakova et al., 2001; Batrakova et al., 2001; Johnson et al., 2002). Other investigations 
support the assumption, that membrane fluidization is not the only explanation for surfactant-
induced Pgp inhibition (Rege et al., 2002). A biological explanation for the cellular uptake of 
polysorbate 80-coated nanoparticles (Kreuter, 2001) was recently given by Aliautdin and 
coworkers. They described how drugs could cross the blood-brain barrier (BBB) by 
endocytotic inclusions from endothelial cells of cerebral vessels, through the adsorption of 
apolipoproteins of the blood plasma to the particles surface and their interaction with 
receptors of low-density lipoproteins on endothelial cells (Aliautdin et al., 2003). 
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Support for a direct interaction of surfactants with Pgp was recently provided by a 
comparative study that showed selective Pgp versus MRP2 modulation by nonionic 
polyethoxylated compounds, including polysorbate 80 (Tween 80) (Bogman et al., 2003). 
 
At concentrations below their critical micellar concentration, detergents were generally 
considered as biologically inactive compounds and, as such, of no or little toxicity (Lo, 2003). 
However, toxic effects have been reported recently, at a pharmacological as well as at the 
environmental level. At the pharmacological level, it has been shown that the use of 
surfactants in drug delivery formulations can produce toxic side effect, e.g., acute 
anaphylactoid hypersensitivity reactions, peripheral neuropathies (ten Tije et al., 2003; van 
Zuylen et al., 2001), hyperlipidaemia, abnormal lipoprotein patterns and aggregation of 
erythrocytes (Gelderblom et al., 2001). At the ecological level, the unceasing accumulation of 
surfactants, mainly originating from cleaning industry, is an inauspicious reality. Cultured fish 
hepatocytes P-gp-function was shown to be altered by non-ionic detergents, such as the 
alkylphenolic surfactant nonylphenol diethoxylate (NP2EO), suggesting that water pollutants 
most probably can impair the organismal defence of ichthyic fauna against xenobiotics (Sturm 
et al., 2001). 
 
Very few studies approached the investigation of Pgp-surfactant interaction on a physical-
chemical basis. Correlation between surfactant biological activity and their critical micellar 
concentration have been proposed (Miller et al., 1997; Zastre et al., 2002).  
 
The common characteristic of surfactants interacto with Pgp, despite their more or less 
pronounced amphyphilic nature, is the presence of a variable number of ethoxylated groups. 
The length of the ethoxylated chains was recently shown to play a role in the efficiency of the 
Pgp-modulatory activity of pluronics (Batrakova et al., 1999; Batrakova et al., 2003; Lo, 
2003) and other polyethoxylated compounds (Sauna et al., 2004). These results were 
interpreted on the basis of classical physical chemical features, such as the variable 
hydrophobicity and the sterical properties of the compounds. It was further shown that 
ethoxylated surfactants, which are commonly used detergents in industry and home care 
products, interact with human Pgp, whereas alkylphenols, which are toxic environmental 
polluants derived from anaerobic biodegradation of alkylphenol ethoxylates, did not show any 
effect on Pgp activity (Loo and Clarke, 1998). 
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The aims of the present work were i) to establish the microphysiometer technique for the 
study of standard Pgp substrates, ii) to correlate the measured extracellular acidification rate 
in vivo with previous measurements of Pgp ATPase activity in reconstituted systems, and iii) 
to investigate Pgp activation by surfactants and to then correlate activation with the ability of 
surfactants to act as H-bond donors. 
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1.2 Theory 
The Cytosensor® Microphysiometer System: Biological Foundations 
Chemo-organo-heterotrophic systems (definition: require organic substrates to get their 
carbon for growth and development), such as mammals, utilize sugars, amino acids and fatty 
acids as primary carbon sources for metabolic energy. Under natural aerobic conditions, 
energy is extracted from glucose and stored in the form of ATP via the cytosolic Embden-
Meyerhof pathway coupled with the mitochondrial TCA cycle and oxidative phosphorylation. 
Hypoxic conditions, such as commonly present in in vitro cell cultures (Mandel, 1986), as 
well as tumoural features (Warburg, 1926), have been shown to induce a switch in the cell 
metabolism of pyruvate from the oxidative phosphorylation toward lactic fermentation 
(Gebhardt et al., 1978). The yield of the latter reaction is 19 times lower in terms of ATP 
production per glucose molecule (2 ATP/glucose versus 38 ATP/glucose). The rate of acid 
production of the fermentative pathways is much more pronounced than aerobic respiration, 
with a yield of 1 H+/ATP compared to 0.167 H+/ATP, respectively.  
 
Mammalian cells in culture can also obtain 30 to 100% of their metabolic energy from 
glutamine oxidation (Zielke et al., 1984), which leads to an energy yield of 29 ATP/glutamine 
and a proton production of 0.111 H+/ATP (Owicki and Parce, 1992). 
 
In previous studies it has been estimated that adherent mammalian cells in culture can 
produce ~ 1 ·108 H+s-1cell-1 (Parce et al., 1989), corresponding to at least 108 ATPs-1cell-1 
(Owicki et al., 1990). 
 
The extrusion of acidic metabolites from the cell is performed passively or through several 
facilitated mechanisms. Some lactic acid and CO2 can exploit the permeability of the lipid 
membrane and be evacuated by passive diffusion. Lactic acid is also excreted by means of the 
monocarboxilic acid transporter. Bicarbonate can cross the cytoplasmic membrane through 
several anion transporters, e.g. the chloride-bicarbonate antiporter. Protons are transported via 
several H+-channels and pumps, such as the Na+/H+-ATPase (Fischer et al., 1999). 
 
External stimulation, e.g. exposure to a toxic agent or the activation of a receptor, can induce 
physiological alterations in the cell, such as changes in the ionic equilibrium or the metabolic 
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activity. As a consequence, the cellular ATP consumption changes. Since ATP hydrolysis is 
coupled with the production of acidic metabolites, a variation of the extracellular acidification 
rate (ECAR) results in parallel. The Cytosensor® Microphysiometer allows a precise detection 
of the latter parameter. 
 
Figure 1.1. Schematic representation of cellular metabolism and its relationships to 
physiological processes such as receptor activation. The principal features of cellular 
proton economy are shown. Not all the indicated pathways are necessarily used by all cells. 
The putative contribution of P-glycoprotein (P-gp) is shown.  
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The Cytosensor® Microphysiometer System: Physical Basis 
The Cytosensor® Microphysiometer System is essentially a very sensitive pH-meter 
connected with a thermoregulation and a network of peristaltic pumps. Its core is composed 
by a so called “sensor chamber”, which consists of a teflon container with a silicon chip on 
the bottom. The physical principle of the sensor is similar to that of an ISFET (“Ion Sensitive 
Field Effect Transistor”). Living cells, which continuously produce acidic metabolites from 
their metabolic activity (see previous section) act as proton source, S.  
 
The surface of the chip exposed to the aqueous environment is covered by a SiO2 insulator 
layer, as for normal MOS-FET (“Metal Oxide Semiconductor-Field Effect Transistor”). The 
Si plate is much thicker (order of mm) than a normal industrial transistor (order of µm) and is 
formed by a pure single-crystal (commercial transistors are contaminated with metals from 
the chemical periodic system III or V group). To induce an electrical flow, IR-light is used 
instead of metal contaminations. Indeed, the single-crystal of Si has a very specific 
absorbance of Electromagnetic (EM) radiation with a wavelength [ = 900 nm and, when 
excited by an amplitude-modulated light-emitting diode (LED), it becomes a conductor. As a 
consequence of these features, the sensor is called light-adressable potentiometric sensor 
(LAPS). 
 
An external electronic circuit (connection between ohmic contact and aqueous 
compartment) controls the potential, \, applied from the Si to the aqueous solution and 
measures an alternating photocurrent, Ip. Such a photocurrent is alternate current (ac)-coupled 
and is generated when the LED illuminates the underside of the Si chip. 
 
The potential from the Si to the solution can be adjusted so that the sensor can become (i) 
forward biased or (ii) reverse biased. In the first case no photocurrent is produced, while in 
the second a depletion layer, resulting in a potential gradient, is created under the insulator. At 
the atomic level, this corresponds to a hole-electron pair creation upon radiation absorption 
from the LED. Because an electric field is present in the chip, holes and electrons move in 
opposite directions, producing the local current. This situation is similar to a p-/n-channel in 
transistors. No direct current passes through the insulator.  
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The applied potential, \, at which the photocurrent begins to flow is defined as the sum of 
several contact potentials of the hardware (which are constant) and the surface potential of the 
solution-insulator interface. A determination of the changes in \ required to produce the 
photocurrent permits thus to measure the variations of the surface potential. 
The insulator surface is partially covered by silanol groups (SiOH) and few amino functions 
(SiNH2), both of which can be titrated as a function of pH. The surface is neutral at pH ~ 3.5. 
Consequently, at physiological pH the surface becomes negatively charged. This feature 
makes the surface potential pH-dependent. Such a dependence is Nernstian (= the plot of the 
potential difference vs. the logarithm of the ionic activity is linear with a slope of 2.303 
RT/zAF, e.g. 59.16/zA mV per unit change of paH at 298.15 K).) and linear from pH 2 to 11 
(Hafeman et al., 1988). 
 
Figure 1.2. Raw data and Rate data from Cytosensor™ Microphysiometer measurements. In 
the upper scheme, the applied voltade (VPIP, mV) is plotted versus time. During cyclic 
pump-off periods (OFF), the ECAR is calculated from the derivative of the photocurrent 
drop recirded in raw data (blue line) and plotted as a function of time (-µV ·s-1). 
 
The raw data and rate data recorded during the experiments are based on variations of the 
photocurrent (see Figure 1.2). The system sweeps the applied voltage every second, producing 
a curve of photoresponse (Ip) versus the applied voltage (Vp). The inflection point (IP) of the 
curve is characterized by particular IPIP [µA] and VPIP [mV]. In raw data VPIP is plotted versus 
time. When the pumps are off, the extracellular acidification causes a weakening of the 
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surface potential. The corresponding electric field also diminishes and the photocurrent drops. 
At 37 °C, the VPIP shift corresponds to about 61 mV per pH unit. The derivative of the slope 
generated in the raw data, during the ECAR -dependent photocurrent drops, is calculated and 
plotted versus time to illustrate the rate data [-µV ·s-1]. 
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Surface Activity and the Gibbs Adsorption Isotherm 
 When an amphyphilic compound is injected into an aqueous solution, a distortion of the 
surrounding water cluster occurs, leading to a decrease of the entropy of the system. To reach 
a more stable energetic state, the amphyphilic molecules tend to be extruded from the bulk 
phase and accumulate at the air-water interface. Such an entropy-driven process is called the 
Hydrophobic Effect. The presence of surfactant molecules at the air-water interface, can be 
observed macroscopically as a lowering of the interfacial tension of the aqueous solution, 
defined as 
 
0   = , (1) 
 
where `0 is the surface tension of pure water ( 72 mN/m at 20 °C), ` is the surface tension of 
the surfactant containing solution, and T is the surface pressure. The latter can be determined 
experimentally with the Wilhelmy vertical plate method (see material and methods). 
The thermodynamics of the adsorption of a surfactant to an air-water interface can be 
described by the Gibbs adsorption isotherm. According to Gibbs, the change in the interfacial 
tension of the solvent can be described as 
 
i id d µ =  , (2) 
 
where µi and ai are the chemical potential and the surface excess concentration of any 
component of the system, respectively. 
At equilibrium between the interfacial and bulk phase, the change of the chemical potential of 
any component of the system, dµi, can be expressed as 
 
lni id RTd aµ = , (3) 
 
where ai is the activity (mole fraction · activity coefficient) of any component of the system, 
and RT the thermal energy. For solution concentrations < 10-2 M containing only one non 
dissociating surfactant, the activity of the solvent and the activity coefficient of the solute can 
be considered as constant and the mole fraction of the solute can be replaced by its molar 
concentration, CS (Rosen, 1989) . Equation (1) can thus be written as 
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lnS Sd RT d C d =  = (4) 
 
which corresponds to the commonly used form of the Gibbs equation, for aqueous solutions 
of nonionic surfactants. 
The surface excess concentration, aS, is defined as the excess, per unit area of interface, of 
the amount of any component actually present in the system over that present in a reference 
system of the same volume in which the bulk concentrations in the two phases remain 
uniform up to a hypothetical (Gibbs) dividing surface (Rosen, 1989): 
 
( ) 1S A S
n N A
A
 = =  (5) 
 
where As is the area per molecule required at the interface. In the absence of electrostatic 
interactions AS is identical with the cross-sectional area, Ad, if the limiting value, ac, defined 
as 
 
ln S
d
RTd C


 = (6) 
 
is reached. Under these conditions the surface pressure, , increases linearly with the 
logarithm of concentration, Cs. The cross-sectional area of the surfactant molecule can thus be 
directly calculated from equations (5) and (6), and the plot of H versus lnCS which yields a 
straight line. 
The surface excess concentration, a, can also be expressed according to the Langmuir 
adsorption isotherm, by the following equation: 
 
1
aq
aq
aw S
aw S
K C
K C

 =
+
(7) 
 
where Kaw is the air-water partition coefficient. The combination of an integral form of 
equation (6) with equation (7), gives rise to the Szyszkowsky equation, which relates the 
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change in the surface tension, d`, (or surface pressure, T) with the air-water partition 
coefficient, Kaw, as  
 
( )ln 1 aw SRT K C 
=  + (8) 
 
Monolayer experiments determine directly the lowering of the surface tension, , or the 
increase in surface pressure, T, as a function of the concentration of the surface active 
compound injected into the aqueous solution. From the fit of the T/logC plot, Kaw can be 
obtained. 
The air-water interface can be regarded as model system for the membrane-water interface 
system due to (i) the similarity of dielectric constant of air (dair ~ 1) with that of the interior of 
a lipid membrane (dlipid ~ 2), (where the dielectric constant of water is dwater ~ 80) and (ii) its 
ability to orientate amphiphilic molecules in an anisotropic manner. From these points of 
view, the air-water interface represents a much better model for lipid membranes, than 
organic solvents, which are isotropic and have higher dielectric constants.  
The penetration of a compound into a lipid bilayer requires work which is proportional to the 
lateral packing density of the lipid bilayer, Tbi ~ 32-34 mM ·m-1 (Fischer et al., 1998; Seelig, 
1987), and the cross-sectional area of the inserting molecule: 
 
eW = Tbi · AS (9) 
 
The lipid-water partition coefficient has to take into account those impeding factors and can 
thus be expressed as 
 
0
S bi
B
A
k T
lwK K e
 
  
 = (10) 
 
where K0 corresponds approximately to the air-water partition coefficient, Kaw, if the surface 
pressure of a surfactant concentration CS = Kaw-1 is negligibly small. 
 
Type I/II Units 
 According to a model developed by Seelig (Seelig, 1998), compounds can be recognized 
by Pgp through H-bond acceptor (or electron donor) groups (e.g. carbonyl-, ether-, hydroxy-, 
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tertiary amino groups, T-electrons systems, and certain halides),arranged in specific special 
recognition patterns. Such recognition patterns consist of (i) two electron donor groups at a 
distance of 2.5 ± 0.5 Å, (ii) two electron donor groups with a spatial separation of 4.6 ± 0.6 Å 
or (iii) three electron donor groups with the two outer groups separated by 4.6 ± 0.6 Å, 
defined as Type I Units (i) and Type II Units (ii and iii). A graphical representation of 
hydrogen bond acceptor patterns is shown in Figure 1.3. 
 
Figure 1.3. Type I and II Units. Type I: two electron donor groups distributed at a distance 
of 2.5 ± 0.5 Å. Type II: two electron donor groups with a spatial separation of 4.6 ± 0.6 Å 
or three electron donor groups with the two outer groups separated by 4.6 ± 0.6 Å (Seelig, 
1998). 
 
Hydrogen Bond Acceptor Strength 
 For simplicity hydrogen bond acceptors were divided into two groups: strong ones (“A”, 
e.g., >C=O, -OR, contributing one energy unit, EU, corresponding to maximally 20 kJ/mole) 
or weak ones (“a”, e.g., -NR3, -N=, -RX, -SR, -C6H5, contributing ½ EU). “AA”, “Aa” or “aa” 
Type I Units correspond thus to 2, 1.5 or 1 EU, respectively.The number of EU of a molecule 
determines the strength of its binding to the H-bond donor side chains of the TM h-helices of 
Pgp, which most probably represent the binding sites of the transporter (Seelig et al., 2000). 
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1.3 Material and Methods 
Compounds 
The nonionic surfactants n-ethyleneglycol monododecylether (C12EOn=3, C12EOn=8), 
Triton X-100, polysorbate-80 (Tween 80), and the zwitterionic detergent Chaps (3-
[(cholamidopropyl)dimethylammonio]-propanesulfonate), were purchased from Fluka 
(Buchs, Switzerland). Amiloride, chlorpromazine, colchicine, trifluoperazine, (R/S) 
verapamil, and vinblastine were from Sigma (Steinheim, Germany), and calcein 
acetoxymethyl ester (calcein-AM) from Molecular Probes (Leiden, The Netherlands). 
Amitriptyline and cyclosporin A were gifts from Merck (Darmstadt, Germany) and Novartis 
(Switzerland), respectively. For stock solutions, compounds were dissolved in water, except 
for cyclosporin A, vinblastine, calcein-AM and C12EO3, which were dissolved in DMSO. 
Final solutions were prepared in DMEM, and actual solvent concentrations were i 0.5%. [u-
13C6]-D-glucose was purchased from Cambridge Isotope Laboratories, Inc. (Andover, 
MA,USA). The P-glycoprotein-specific antibody MRK16 was a gift from Dr. M.M. 
Gottesman (National Cancer Institute, Bethesda, U.S.A.). Purified mouse standard isotype 
IgG2a,k and FITC-labeled anti mouse IgG2a were from Pharmingen (San Diego, U.S.A.). Cell 
culture media and additional compounds required for cell culture were from Gibco-BRL 
(Basel, Switzerland). 
 
Cell Lines 
Mouse embryo fibroblasts, both wild type (NIH3T3) and transfected with the human 
MDR1 gene (NIH-MDR-G185) (Cardarelli et al., 1995), were a kind gift from Dr. M.M. 
Gottesman (National Cancer Institute, Bethesda, U.S.A.). Pig kidney cells LLC-PK1 and 
MDR-LLC, were provided by Dr. P.Borst (The Netherlands Cancer Institute). 
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Cell Culture 
Cells were grown as monolayer cultures in sterile cell culture flasks (Costar, 25-75 cm2), 
and incubated at 37 °C in a Heraeus Incubator, in an air atmosphere supplemented with 5 % 
CO2 and humidity saturation of 100%. DMEM was chosen as cell culture medium, 
supplemented with 1% L-glutamine (0.3 g/L), 1% penstrep (100 units/mL) and 10% FBS 
(v/v). NIH-MDR-G185 cells were kept under growth selection with 0.15 µM (60 ng/mL) 
colchicine. 1:10 passages were performed twice a week, from confluent cultures, after 
treatment with trypsin-EDTA (Gibco). Cellular stocks aliquots of 107 cells/ mL were prepared 
in DMEM, 10% DMSO, 10% FBS and kept in 1.8 mL Nunc CryoTubes frozen in liquid 
nitrogen. Detailed protocols for cell handling are reported elsewhere (Nervi, 2000). 
 
Cell Doubling Time Determination 
Exponentially growing NIH3T3 and NIH-MDR-G185 cells were seeded into 30 mm 
dishes (2 for each cell line and for each day), in amounts of 104 cells/2.5 mL DMEM/dish. 
Every 24 hours, the number of cells was determined by averaging the amount of cells counted 
in two dishes for each cell line, after trypsinization with 0.5 mL trypsin-EDTA solution, using 
a cell Coulter counter. The latter procedure was repeated for 8-10 days, until a plateau 
(confluence) was reached. 
 
Cell extraction 
Approximately 108 living mouse embryo fibroblasts (NIH-MDR-G185) were grown for 
12 h in DMEM medium containing [u-13C] glucose (5 mM) and then removed from the tissue 
culture dishes by using trypsin-EDTA, as described above. The cells were rinsed twice with 
PBS and immersed in 5 mL of 6% perchloric acid to precipitate/inactivate all proteins 
including enzymes that could have metabolized the compounds even after cell lysis. 
Subsequently, the cells were lyzed by subjecting them for 15 min on an ultrasonic bath 
(Branson Sonifier, Danbury, CT; 50 W/mL) under a nitrogen atmosphere (at 4°C). Then, the 
precipitated proteins were removed by centrifugation (Eppendorf, 14000 g) and the 
supernatant, containing the water-soluble metabolites was neutralized with 4% KOH. KOH in 
combination with HClO4 was chosen as base-acid system because the solubility for KClO4 is 
much smaller than any other salt from acid base neutralization, which is important for later 
residual salt contents in NMR (line broadening). The precipitate of KClO4 was removed by 
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centrifugation (16000 g) and the supernatant was lyophilized overnight. The lyophilized 
metabolites were resolved in 0.5 mL of 99.9 % D2O for further analysis by high-resolution 
13C- and 1H-NMR spectroscopy. The pH of the solution was adjusted to 7.4 (uncorrected pH 
reading for deuterated water) using deuterated perchloric acid and potassium deuteroxide 
(KOD). Five µL of a 0.5 M solution of [2,2,3,3-D4]-3-(trimethylsilyl)-propionic acid sodium 
salt (TSP) was added to provide an internal concentration standard and chemical shift 
reference.  
 
In vitro high-resolution 13C and 1H NMR spectroscopy 
In vitro high-resolution 13C-NMR spectra (at 9.4 Tesla, 100 MHz) of cell extracts were 
obtained on a Bruker Avance 400 NMR spectrometer using the following settings: 50,000 
scans, 45° pulses, 250 ppm spectral width, 1H broadband decoupling and a repetition time of 3 
s. In vitro high-resolution 1H-NMR spectra were acquired at 400 MHz using the following 
settings: 64 scans, 90° pulses, 12 ppm spectral width and a longer repetition time of 20 s to 
avoid saturation of the proton signals. 
 
Detection of P-gp Expression 
The cellular expression level of P-gp was estimated by FACs analysis. Aliquots of 2-3j105
cells were incubated in IMEM containing 5% FBS at 37 °C for 30 min in the presence of the 
human Pgp-specific monoclonal antibody MRK16 or the mouse standard isotype antibody 
IgG2a,k. After washing, cells were reincubated at 37 °C for 30 min in the dark, in the presence 
of FITC-labeled anti mouse IgG2a. Cells were then washed (IMDM), centrifuged (1000 rpm, 5 
min) and resuspended in PBS (supplemented with 1% BSA) and FACs analysis was 
performed using a FACscalibur flow cytometer (BD Biosciences). 
 
ATPase Assay 
 Reagents: 
1) Pi reagent.1% ammonium molybdate (or molybdic acid, ammonium salt) in 2.5 N 
sulfuric acid and 0.014% antimony potassium tartrate. Then 50 mL distilled water and 
6.9 ml concentrated sulfuric acid (36.2 N) were added in a 250 ml beaker. To the 
mixture, 1 g ammonium molybdate (powder) and 14 mg of antimony potassium 
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tartrate were added and stirred for 20 min in a hood. Distilled water was then added to 
reach a total final volume of 100 ml. The final solution was stored at room 
temperature, in a glass bottle covered with aluminum. 
2) 100 mM MES-Tris, pH 6.8. 100 mM MES solution (1.95 g/100 mL). PH adjusted to 
6.8 with Tris solution (2M). 
3) 2x Assay buffer (5 mL). 4.12 mL 100 mM MES-Tris (pH 6.8); 0.5 mL of KCl (1 M); 
0.2 mL sodium azide (0.25 M), 0.16 mL EGTA (0.125 M, pH 7.0); 7.5 mg ouabain 
powder; 20 µL DTT (1M). Before use, 50 µL MgCl2 (2 M) was added per 5mL buffer. 
4) 5% SDS solution 
5) 1% ascorbic acid (100 mg/10 mL water; freshly prepared and stored on ice) 
6) 10 mM sodium ortho-vanadate: 9.2 mg/5 mL water. Freshly prepared solution 
incubated at 100 °C for three min (calibration: OD=3.6 at [=268 nm corresponds to 1 
mM). 
7) 100 mM ATP (disodium salt, pH 7.0, stored at –80 °C). 
8) 1mM potassium phosphate (stored at –20 °C) 
9) several Pgp substrates dissolved in DMSO or water. 
 
For the ATPase assay, all reactions were performed in 15 mL glass tubes immersed in a water 
bath at 37 °C. In one tube, 50 µL buffer, 31 µL H2O, 3 µL vanadate (10 mM) or water, and 10 
µL membrane extracts (~ 1 mg membrane/mL; ~ 20 ng proteins) were mixed and incubated 
for 5 min. After addition of 1 µL Pgp substrate or an equivalent amount of solvent, the 
solution was again incubated for 3 min. In a third step, 5 µL ATP (100 mM, pH 7.0) was 
added. The final solution was incubated for 20 min, during which ATP hydrolysis occured. 
To stop the reaction, tubes were rapidly removed from the bath, 100 µL SDS (5%) were 
added and the tubes were quickly vortexed. After addition of 400 µL Pi reagent, 500 µL H2O
and 200 µL ascorbic acid (1%), the system was incubated for 10 min at room temperature. 
Finally, optical density was measured at [=880 nm. Inorganic Pi concentrations were 
calculated from the absorbance values, according to a standard phosphate curve 
(multiplication of absorbance by a factor ~ 61). The turnover of ATP hydrolysis was then 
obtained in nmoles Pi · min-1 · (mg protein)-1, by normalizing the Pi concentration obtained 
(multiplication by a factor 5). 
One complete assay for one substrate concentration, required 10 glass tubes, i.e., A) two 
negative controls (no vanadate, no membrane extract, no drug), B) two controls for basal 
endogenous ATPase activity (only membrane extract), C) two controls for the inhibition of 
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endogenous ATPase activity (vanadate, membrane, no drug), D) two assay for drug induced 
ATPase activity (no vanadate, membrane extracts, active compound) and E) two controls for 
inhibition of drug-induced ATP hydrolysis (vanadate, membrane and active compound). 
Where no drug was added, the same volume of solvent alone (1 µL DMSO or water) was 
injected in test tubes. For the determination of the drug-induced Pgp activation (fold), data 
obtained from the difference between D) and E) were divided by the difference between B) 
and C). 
 
Cytosensor Measurements 
Extracellular acidification rates (ECAR) of cells were monitored in real time using a four 
or eight channels Cytosensor® Microphysiometer (Molecular Devices, Menlo Park, CA, 
U.S.A.) (Mcconnell et al., 1992). This device is based on silicon technology and allows 
detection of pH changes down to 0.001 pH units/min by means of a light addressable 
potentiometric sensor (LAPS). Protons excreted by cells upon stimulation come into contact 
with the LAPS and induce a change in the applied voltage in the order of a few µVolts/sec. 
The instrument was calibrated at 37 °C, and a correspondence of 1 pH unit = 60.37 ± 1.28 mV 
was measured. 
 
Aliquots of 3-4 ·105 cells were seeded into capsule cups (12 mm diameter plates with a 
microporous polycarbonate membrane bottom) and were left in the incubator overnight for 
sedimentation in the presence of the same medium used for culture (see above). For the 
cytosensor measurement, capsule cups were transferred into the sensor chambers, adequately 
covered with capsule spacers and inserts, in order to create a void volume of 6 mm diameter 
and 50 µm height. Thus, the actual number of cells available for the measurement is reduced 
to ~1/4 of the total amount. The system was stabilized at 37 °C and cells were superfused by 
peristaltic pumps with ~ 100 µL/min DMEM without sodium bicarbonate, to limit pH 
buffering.  
 
Peristaltic pumps were programmed to function for 1 min 40 sec, and then to stop for a 
period of 20 sec, in a periodic cycle. During the 20 sec pause interval, acidic metabolites 
accumulated in the sensor chamber. ECAR measurements, in µV/sec, started 5 sec after pump 
stop and lasted for 13 sec. All data were directly processed by the software Cytosoft for 
Macintosh (Molecular Devices, Menlo Park, CA, U.S.A.). Before P-gp stimulations, cells 
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were allowed to reach a stable ECAR (30 min to 1 hour). For stimulations, the normal running 
medium was switched to the drug containing medium for 2 min 40 sec. During this period, 
two ECAR data points were recorded, one after 40 sec (transient situation) and the second two 
minutes later (steady-state conditions established). For data analysis, the cellular ECAR 
change corresponding to the latter point was considered, normalized to the basal activity, and 
therefore expressed in percentage (or fold) of the basal ECAR. 
 
Cytosensor microphysiometry detects pH changes as a function of time in the sensor 
chamber solution. For a quantification of H+ release rate the measured ECAR was corrected 
for the buffering capacity of the superfusing medium. To this purpose, the phosphate buffer of 
DMEM was taken into account, and the buffer capacity was calculated as  = 0.35 mM for 
1mM buffer at pH 7.40. The buffer capacity of other medium components, such as amino 
acids, was neglected. The calculated  corresponds thus to the lower buffering limit. 
 
Kinetic Model. 
The drug concentration dependent ECAR modulations were fitted with a modified 
Michaelis-Menten equation, described in detail by Litman et al. (Litman et al., 1997; Litman 
et al., 1997). The model assumes a transporter activation, if one substrate molecule (S) per 
transporter (T) binds, and it assumes inhibition after a second substrate molecule per 
transporter binds as described by the following scheme: 
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where T(ATP)St and T(ATP)St2 are Pgp-ATP complexes with one and two substrate molecules 
bound, respectively. T(ADP) is the Pgp-ADP complex, Pi is the inorganic phosphate released 
into the cytosol, and Srel is the substrate molecule released extracellularly. 
As reported in scheme (1), the kinetic parameters describing the ATPase hydrolysis during the 
substrate transport by Pgp can be obtained either from the quantification of Pi release or from 
the quantification of H+ release according to equation (2): 
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where VSaq is the ECAR as a function of the substrate concentration in solution, CSaq, V0 is the 
basal activity in the absence of substrate, V1 is the maximum transporter activity (if only 
activation occurred), and V2 is the activity at infinite substrate concentration. 
 
Surface activity measurements 
Surface activity measurements of surfactants were performed at room temperature, with 
the Wilhelmy vertical plate method, as described in detail elsewhere (Nervi, 2000; Seelig et 
al., 1994). Stock solutions were prepared in pure water and serial aliquots were injected by 
means of Hamilton syringes into a home built 20 ml or 3 ml teflon trough filled with 10 mM 
Tris/HCl buffer (pH 7.40) and 114 mM NaCl. 
 
Estimation of Hydrogen Bond Energy 
The models of the three-dimensional structures of the compounds as well as the spatial 
distances between hydrogen bond acceptor groups in Pgp recognition patterns were obtained 
using a modified version of the Allinger’s MM2 force field approach (Burkert and Allinger, 
1982) implemented in the software ChemOffice (CambridgeSoft Corporation, Cambridge, 
MA, U.S.A.). The hydrogen bond acceptor strength of the compounds was estimated in 
arbitrary energy units (EU), according to the model described in section 3.2 (Seelig, 1998). 
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1.4 Results 
Cell growth characterization 
In order to investigate the behavior of mouse embryo fibroblasts under the culture 
conditions chosen, the growth rate of cells has been followed during 8 days. From the 
exponential growth phase, the doubling time has been calculated for NIH3T3 and NIH-MDR-
G185. The latter were grown in DMEM (1% Penstrep, 1% L-glutamine, 10% FBS) or in the 
presence of DMEM and the selecting agent colchicine (60 ng/mL), to take into account 
potential alterations in the cell cycle under selection pressure. 
Results are reported in Figure 1.4. 
Figure 1.4. Cellular Growth Curve. The number of cells grown in culture is plotted against 
time. (A) NIH3T3 cells, (B) NIH-MDR-G185 cells grown in DMEM, (C) NIH-MDR-G185 
cells grown in DMEM supplemented with 60 ng/ml colchicine. 
 
From an exponential growth fit of the plots, the population doubling rate was determined as 
22.7 ± 1.2 hours for NIH3T3, 25.2 ± 2.1 hours for NIH-MDR-G185 grown in DMEM and 
27.2 ± 4.3   hours for NIH-MDR-G185 cells grown in the presence of colchicine. 
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The growth curves show that transfected cells (~ 1.10 · 105 NIH-MDR-G185/cm2) become 
confluent at a lower density than wild type cells (~ 2.15 · 105 NIH3T3/ cm2) and that 
colchicine does practically not affect cell growth. 
 
Assessment of the Expression Level of P-glycoprotein on the Cell Surface 
To assess the expression of Pgp in the plasmamembrane of MDR1 transfected cells, an 
immunocytochemical assay was performed using the human Pgp specific antibody MRK16. 
After appropriate antibody staining (see section 1.3) NIH-3T3 and NIH-MDR-G185 mouse 
fibroblasts were analyzed by FACS. For comparison, the same essay was applied to pig 
kidney LLC-PK1 and LLC-MDR cells (Landwojtowicz et al., 2002). 
Figure 1.5 shows that the relative fluorescence intensity of wild type mouse embryo 
fibroblasts NIH3T3 (A) is negligibly small in comparison to that of Pgp expressing NIH-
MDR-G185 cells (B, blue line) and that the fluorescence resulting from NIH3T3 staining with 
MRK16 (blue) does not differ from the unspecific binding with the control antibody (green) 
or the FITC-labeled anti-mouse IgG2ak (black). The slightly shifted position of the stained cell 
populations, from the endogenous fluorescence of untreated cells (red), is a normal effect 
resulting from unspecific binding. Possible differences in the integrals of curves are a 
consequence of the choice of the region of interest in the dot plot obtained from the 
cytometric assay (plot not shown), which can include a variable number of events for different 
samples. Transfected fibroblasts NIH-MDR-G185 (Figure 1.5B), however, showed a relative 
fluorescence intensity three orders of magnitude higher than that of the corresponding 
untreated or Pgp unspecifically stained cell populations. Distribution curves in Figure 1.5B) 
did not show any overlapping region, indicating that almost all NIH- MDR-G185 cells were 
stably transfected and thus expressing a high level of human Pgp. 
 
The situation of wild type pig kidney LLC-PK1 cells (Figure 1.5C) is similar to that of 
NIH3T3. Despite a generally broader Gaussian distribution of the fluorescence, no significant 
distinction could be made between MRK16-stained cells (blue) and unspecific binding 
controls (green and black). However, in analogy to NIH-MDR-G185 cells, MRK16 labeling 
of transfected pig kidney LLC-MDR-PK1 cells (Figure 1.5D, blue and magenta lines) 
revealed a relative fluorescence intensity of almost three orders of magnitude higher than 
observed in control populations (green, black and red). Interestingly, the fluorescence 
distribution of LLC-MDR-PK1 cells grown in DMEM without the presence of vinblastine as 
38 
selecting agent (Figure 1.5D) blue line) shows two distinct peaks at relative fluorescence 
intensities of ~ 101 and ~ 103, respectively. This corresponds to two distinct cell populations: 
the peak with fluorescence intensity ~ 101 shows that 30-40% of cells were not transfected (or 
had lost the MDR1 gene). Indeed, in MRK16-stained LLC-MDR-PK1 cells, grown in the 
presence of selective agent, the lower peak disappeared. 
 
Figure 1.5. Assessment of P-glycoprotein Expression by Immunocytochemical Staining and 
FACs Analysis. Plots report the number of events versus the relative fluorescence intensity, 
reported in arbitrary units (logarithmic scale). Cell lines: mouse embryo fibroblasts A) wild 
type NIH3T3 and B) human MDR1 transfected NIH-MDR-G185; pig kidney cells C) wild 
type LLC-PK1 and D) transfected LLC-MDR-PK1 grown with (magenta) or without (blue) 
selecting agent vinblastin. Colored lines correspond to (red) untreated cells, (black) control 
antibody, (green) FITC-labeled anti-mouse IgG2ak, and (blue and magenta) MRK16.  
 
For comparison, the measurements of all cell lines with immunocytochemical MRK16 
staining are summarized in Table 1.1. 
 
A B
DC
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Table 1.1. Quantification of fluorescence intensity upon MRK16-staining. Peak: relative 
intensity corresponding to the top of the distribution curve. Mean: average of relative 
fluorescence intensity of the cell population. Events: number of cells representing the 
population included in the region of interest. 
 
Glycolytic Predominance in the Metabolism of Cultured Cells. 
 The predominance of glycolytic metabolites in cultures of mouse embryo fibroblasts, 
NIH-3T3, was investigated by 13C-NMR spectroscopy. For this experiment, 3.5 g/L [u-13C]-
D-glucose was added to the culture medium DMEM (containing 1 g/L normal D-glucose). 
After 24 hours incubation, cells were removed from culture and metabolites extracts were 
analyzed as described in section 1.3. 
 
Figure 1.6. In vitro 13C-NMR Spectroscopy of cell metabolite extracts. Metabolites extracts 
of NIH3T3 fibroblasts after 24 hours incubation with 3.5 g/L [u-13C]-D-glucose. The 
predominance of glycolysis is demonstrated by the incorporation of 13C in the resonance of 
lactate (C1: 179 ppm (doublet, 56 Hz coupling), C2: 69.5 ppm (doublet of doublet), C3: 21 
ppm (doublet, 36 Hz coupling)). TSP (tetrasilanephosphate) was used as reference.  
 
The uniformely 13C-labeled [u-13C6]-D-glucose was chosen, because the resulting 
homonuclear 13C spin coupling allows the unambiguous assignment of every metabolite that 
is produced from the glucose. As shown in Figure 1.6, most of the 13C was detected in the 
resonance of lactate (C1: 179 ppm (doublet, 56 Hz coupling), C2: 69.5 ppm (doublet of 
doublet), C3: 21 ppm (doublet, 36 Hz coupling)) and not in TCA cycle derived metabolites. 
Indeed, the signal at 34 ppm, corresponding to C4-glutamate, is not higher than 2% of the C3-
lactate signal, demonstrating that the cells prefer the anaerobic glucose metabolism over the 
NIH3T3 LLC-PK1 NIH-MDR-G185 LLC-MDR-PK1 (vin) LLC-MDR-PK1
peak 5.94 13.34 1027.35 632.09 620.82
mean 9.14 19.69 1044.49 475.44 248.51
events 8542 6655 9311 6485 7044
C1-lac
C3-lacC2-lac
TSPC1-gly
C2-gly
C4-glut
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oxidative metabolism. The singlet resonances at 52, 59, 62 and 181 are assigned to a natural 
abundance compound not originating from the u-labeled glucose (13C-13C couplings) and is 
most likely pyro-glutamate formed by intramolecular condensation of supplemental glutamine 
from the cell culture medium. (Willker et al., 1995). 
Determination of Physical Chemical Parameters of Surfactants 
As cited above, Pgp recognizes and binds its substrates directly from the inner leaflet of 
the lipid membrane. Passive diffusion is thus an important step in the kinetics of binding of 
compounds from the aqueous extracellular surroundings to the transporter. To characterize 
Pgp substrates from a physical chemical point of view, surface activity measurements have 
been performed (see section 1.3). From the Gibbs adsorption isotherms (T/logC plots) the 
following parameters have been obtained, i.e., the concentration of surface activity onset, C0,
the surface excess concentration, ac, from which the cross-sectional area, AS, can be 
calculated, the critical micellar concentration, CMC, and the air-water partition coefficient, 
Kaw, from which the lipid-water partition coefficient, Klw, can be evaluated. Measurements of 
every single parameter are described in detail elsewhere (Nervi, 2000).  
Figure 1.7. Gibbs Adsorption Isotherms (T/logC plots). The surface pressure, , is plotted 
versus logC. () Triton X-100, () C12EO8, () Chaps. From the plot, surface activity 
onset concentration (1), critical micellar concentration (2), surface excess concentration (3), 
cross.sectional area (4) and air-water partition coefficient (5), can be obtained. 
 
The air-water partition coefficient, Kaw, the critical micelle concnetraiton, CMC, and the 
cross-sectional area, As, of the compounds are relevant for the present investigation and are 
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therefore listed in Table 1.2. Figure 1.7 shows T/logC plots of three nonionic surfactants i.e., 
Triton X-100 (), C12EO8 () and Chaps () as an example.  
 
Pgp-substrates Interactions observed in Living Cells by Microphysiometry. 
A Transient Metabolic Change Occurs in Pgp-Overexpressing Cells Exposed 
to Pgp Substrates. 
In our experiments, the extracellular excretion of acidic metabolites in NIH3T3 and NIH-
MDR-G185 mouse fibroblasts was used to monitor the cellular metabolism associated to Pgp 
ATPase activity. The extracellular acidification rate (ECAR) of cells was recorded in real 
time by microphysiometry. The ECAR of NIH3T3 and NIH-MDR-G185 in the presence of 
cell culture medium alone (see section 1.3) was considered as basal metabolic rate and 
defined as was defined as 100% (percent) or 1 (fold). All modulations of the ECARs induced 
by Pgp substrates were thus reported as fold or percentage variations of the basal rate. 
Wild type NIH3T3 (n=13) and transfected NIH-MDR-G185 (n=25) cells induced an 
electrical potential variation of -66±(SD18;SE5) µV·s-1 and -64±(SD22;SE4) µV·s-1,
respectively, corresponding to a pH variation of 1.1±0.3(SD) mpH·s-1 (NIH3T3) and  
1.06±0.4(SD) mpH·s-1 (NIH-MDR-G185) on the silicon chip, where n is the number of 
experiments made. The number of cells in the measuring chamber was ~ 4·105. Considering 
the phosphate buffer capacity of DMEM, a quantification of the ECAR leads to values of 
(7.42 ± 2.0)·106 H+·s-1·cell-1 for NIH3T3 and (7.15 ± 2.7)·106 H+·s-1·cell-1 for NIH-MDR-G185 
cells. Such values illustrate the minimum amount of possible proton release, since the buffer 
capacity of other compounds, e.g. amino acids, has been neglected.  
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Figure 1.8 shows the reaction of wild type 
and transfected fibroblasts to the exposure of 10 
µM verapamil (A), 10 µM triton X-100 (B), or 
10 µM Tween80 (C), during and interval of 2 
minutes and 40 seconds. The administration of 
these compounds induced a transient ECAR 
increase in Pgp-overexpressing, but not in wild 
type cells. For verapamil, a maximum ECAR of 
~170% was reached in NIH-MDR-G185 cells 
after 40 sec, which returned to the basal value 
after ~30 min. Triton X-100 induced a 
maximum ECAR increase to ~160% after 40 sec 
and the recovery time was ~20 min, whereas 
Tween80 induced a maximum ECAR of ~145% 
after only 20 min and required ~90 min for 
complete recovery to the basal rate. For wild-
type NIH3T3 cells, the drug-induced ECAR 
modulation of all compounds is much lower, if 
not negligible. 
Drug- and detergent-induced ECAR 
modulations in NIH-MDR-G185 cells were 
investigated over a wide concentration range. 
The ECAR variation induced after 2’40’’ of 
exposure to the compound was chosen for data 
evaluation (see section 1.3). In a first step, we 
screened several well-known Pgp-substrates, 
such as amitriptylin, cyclosporin A, verapamil 
and vinblastin, in order to asses the relationship 
between Pgp ATPase activation and ECAR. 
Data are reported in Figure 1.9.  
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Figure 1.9. Extracellular Acidification Rate (ECAR) of NIH-MDR-G185 Cells, as a 
Function of Drug Concentration. Amitriptylin (), vinblastin (n), cyclosporin A (o), and 
verapamil (p). Dashed and continuous lines describe fits of the measurements according to 
a modified Michaelis-Menton model assuming activation with one and inhibition with two 
substrate molecules bound to the transporter (see equation 1 in section 1.3). Vertical bars 
show standard deviations. 
 
Amitriptyline and verapamil showed a bell-shaped dependence of the ECARs as a fuction 
of concentration with maxima of about 1.8 - 2.0 times the basal activity. In one experiment, 
amitriptyline stimulation of cells led to very high ECAR values (V1 > 4.5), which explains the 
high values for standard deviation. Vinblastine increased the ECAR of NIH-MDR-G185 less 
than 1.1 fold, whereas cyclosporine A (0.02 µM and 10 µM) did not induce any relevant 
ECAR modulation. Data were evaluated with a multiparameter fit (dashed and continuous 
lines) based on a modified Michaelis-Menton model (see Material and Methods) developed 
for previous investigations of inorganic Pi release upon ATPase activity of Pgp (Litman et al., 
1997). The kinetic parameters obtained from the fits are reported in Table 1.2. The 
comparison of data obtained in the present work, with data obtained from a parallel work 
(Landwojtowicz et al., 2002) with LLC-PK1 cell line, and from previous measurements of 
inorganic Pi release data (Litman et al., 1997) is discussed in the next section. 
 
0.01 0.1 1 10 100 1000
0.9
1.0
1.1
1.2
1.3
1.4
1.5
1.6
1.7
1.8
1.9
2.0
2.1
2.2
2.3
2.4
vinblastine
cyclosporin A
amitriptyline
verapamil
 
A
ci
di
fic
at
io
n
R
at
e
[F
ol
d]
Concentration [µM]
44 
Detergents can Act as Specific Modulators of the Cellular Metabolism 
Associated to Pgp ATPase Activity. 
To assess a possible specificity of the surfactant effect on Pgp ATPase activity, one 
zwitterionic detergent (chaps) and four nonionic detergents were chosen, i.e., two n-
ethyleneglycol monododecylethers (C12EOn , n=3 and n=8), triton X-100, Tween 80,. 
Experiments were performed the as for standard Pgp substrates in NIH-MDR-G185.  
Whereas transient ECAR modulations were specifically induced by Triton X-100, Tween 
80, and C12EO8 (see Figure 1.10B) and C)), no consistent selective ECAR modulations were 
produced with C12EO3 and Chaps. 
 
Figure 1.10 shows the ECAR modulations induced by surfactants on NIH-MDR-G185, 
over a concentration range of four orders of magnitudes. On average (n=10 experiments) 
triton X-100 showed the ability to increase the ECAR of NIH-MDR-G185 cells up to ~ 1.4-
1.6 fold of the basal activity, at a concentration around 10-12 µM. For higher concentrations, 
a progressive, reversible inhibition was observed. Likewise, C12EO8 enhanced the ECAR of 
NIH-MDR-G185 cells, with a maximum of ~ 1.8 fold of the basal activity at a concentration 
of ~ 6 µM. Tween 80 had also a specific effect on NIH-MDR-G185 cells (see also figure 
1.8C), even though at a different time scale compared to triton X-100 and C12EO8. In contrast, 
C12EO3, induced a very low concentration-dependent ECAR modulation which was, however, 
observed in both transfected and wild type cells, and therefore was considered as not related 
to Pgp activity. Chaps which is known to be a non-substrate for Pgp, did not induce any 
ECAR modulation both in wild type and transfected fibroblasts, in a concentration range 
between 0.5 µM and 100 µM. Data could be fitted to the modified Michaelis-Menten model 
used for standard substrates. The kinetic parameters are reported in Table 1.2. 
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Figure 1.10. Extracellular acidification rates (ECAR) of NIH-MDR-G185 cells, as a 
function of surfactant concentration. Solid symbols represent: Triton X-100 (q), C12EO8 
(p), Tween 80 (o), C12EO3 (), and Chaps (r). Dashed and continuous lines report 
measurements fit according to the modified Michaelis-Menton model described as in figure 
2. Standard deviations are shown. 
 
The evidence for a direct interaction with Pgp was further investigated for Triton X-100. 
In Figure 1.11 the ECAR modulation induced by 8 µM Triton X-100 is shown in the presence 
of increasing concentrations (0 µM (A), 1 µM (B), and 10 µM (C)) of cyclosporin A. In the 
presence of 10 µM cyclosporin A, the effect of triton on NIH-MDR-G185 cells could be 
suppressed. This argues in favor of a specific competition mechanism. 
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Figure 1.11. Inhibition of Triton X-100-induced ECAR Increase by Cyclosporin A. ECAR 
modulations in NIH-MDR-G185 (q,p) and NIH3T3 () cells are shown, after 2’40’’ 
exposure to 8 µM triton X-100 alone (A), and in the presence of 1 µM (B) and 10 µM (C) 
cyclosporin A, respectively. 
 
Membrane Solubilizing Effect of Triton X-100.  
So far, the effect of detergents on the ECAR of Pgp overexpressing cells were investigated 
at concentrations below the critical micellar concentration (CMC). Under these conditions the 
effects of detergents were fully reversible. Figure 1.12 shows the response of NIH-3T3 and 
NIH-MDR-G185 cells to an exposure of Triton X-100 (0.3 mM) above the critical micelle 
concentration (CMC = 0.23 mM) during the same period of time as applied in experiments 
shown in Figure 1.8 (2’40’’). This lead to a rapid and irreversible ECAR decrease in both, 
wild type and transfected cells and can be attributed to cell lysis. 
Figure 1.12. Cell lysis upon detergent action. Exposure of NIH-MDR-G185 (q,p) and 
NIH3T3 cells to 300 µM triton X-100 during a period of 2’40’’ (outlined area). ECAR 
modulations are expressed in fractions of the basal activity, which is arbitrarily defined as 
1.0. 
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Substrate MW HAP HA EU pKa 1/Kaw CMC Gam AD K1 K2 V1 V2 K1 K2 V1 V2 K1 K2 V1 V2
[g/mol] Type Dist. [a.u.] [uM] [uM] [kJ/mol] [Å] [uM] [uM] [fold] [fold] [uM] [uM] [fold] [fold] [uM] [uM] [fold][fold]
[Å] pH7.4 pH7.4 pH7.4 pH8.0 * * * * ** ** ** ** *** *** *** ***
Amitriptyline 277.4 aa (1, 3) 2.55 2 9.4 277.8 5000 -6.96 52 ± 4 50.00 550 2.2 0.75 80 400 1.47 0.8 108 110 2.3 0.9
aa (1, 4) 2.86d
C12EO3 318.5 AA(1;7) 0(2) - 1.35 50 35 1 36.25 0.95 1.19 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
C12EO8 538.8 AA(1;7) 6 - 0.455 110 58 1.67 57.5 2.1 0.3 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
AA(1;10)
AA(1;13)
Calcein-AM 994.9 AA (1, 3) x 9 2.28 23 5 0.38 3 -4.88 69 7.2 10 1.29 1.24 0.12 0.25 0.8 1.1 n.d. n.d. n.d. n.d.
AAa (1,3,7) x 2 4.54
Chaps 614.9 - - 29.16 600 93 - - - - n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Cyclosporine A 1203 Aa (1, 3) x 7 2.27 12.5 - 0.05 n.d. n.d. n.d. 0.05 7 1.06 0.98 0.02 2 1.08 0.8 0.1 1.7 1.1 0.6
AA (1, 5) 4.74
Diltiazem 414.5 AA (1, 3) 2.28 3.5 8.06 37.15 480 -6.13 70 ± 3 n.d. n.d. n.d. n.d. 25 190 1.45 0.8 73 677 3.3 0
Aa (1, 3) 2.28
Progesterone 314.5 Aa (1, 3) 2.63 1.5 - 28.82 80 -2.22 100±10 n.d. n.d. n.d. n.d. 17 200 1.41 0.6 18 294 2.6 0.3
Trifluoperazine 407.5 aa (1, 3) 2.14 3 3.91 5.13 170 -8.33 58 n.d. n.d. n.d. n.d. 12 100 1.33 0.7 6.5 24 2 0.6
aa (1, 3) 2.6 8.09
aa (1, 4) 2.94
Triton X-100 647 AA(1;7) x2 6 - 0.81 230 54 4.24 150 1.63 0.3 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
AA(1;22)
Tween 80 1310 AA (1, 3) 6(+2n) - 0.12 10 69 41 200 2.1 0.7 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
AA (1, 4)
AA (1, 5)
AA (1, x) xn
R/S-Verapamil 454.6 AA (1, 4) 2.69 5 8.6 6.02 320 -9.47 71 ± 2 0.8 210.8 1.89 0.8 1.5 100 1.25 0.9 2.5 99 2.1 0.6
AA (1, 4) 2.69
aa (1, 7) 4.73
Vinblastine 811 AAA (1, 3, 5) 3.54d 8.5 5.4 2.14 100 -9.21 140 ± 4 5.33 40 1.12 0.93 7 55 1.11 1 1.3 17 1.5 0.5
AA (1, 3) x 2 2.28 7.4
Aa (1, 5) 4.95
* Scientist: Pierluigi Nervi; Cell Line: NIH-3T3/NIH-MDR-G185; Method: Cytosensor
** Scientist: Ewa Landwojtowicz; Cell Line: LLC-PK1/LLC-PK1-MDR; Method: Cytosensor
*** Scientist: Thomas Litman; Cell Line: Caco-2; Method: Reconstituted vesicles, Pi release Ta
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1.5 Discussion 
The aim of the present project was to contribute to the elucidation of the multidrug 
resistance (MDR) phenotype, associated to the expression of Pgp in the plasma membrane of 
living cells by studying the interactions between the human MDR1 gene product, P-
glycoprotein (Pgp), and its substrates. To this purpose we established a method based on 
microphysiometery which allows studying standard Pgp-substrate interactions in living 
cultured mammalian cells.We then applied this technique (i) to investigate the relationship 
between ECARs in MDR1 transfected cells in vivo and Pgp ATPase activity in inverted 
plasma membrane vesicles (Litman) both induced by well-known Pgp substrates and ii) to 
analyze surfactants, as potential Pgp substrates in living cells. (iii) The kinetic data obtained 
for the interaction of detregents with Pgp were then related to their physical chemical 
parameters, conformational properties and hydrogen bond acceptors patterns (Seelig, 1998). 
 
P-glycoprotein ATPase Activation can be monitored on-line in Living Cells 
 
Conventional studies of drug-induced Pgp ATPase activity are usually based on 
measurements of inorganic phosphate (Pi) release as a result of ATP hydrolysis and are 
performed either in reconstituted systems, or in inverted plasma membrane vesicles extracted 
from cells overexpressing Pgp (Litman et al., 1997; Sauna and Ambudkar, 2000). Here, we 
adapted a technique that allows, real-time monitoring of the metabolic activity of intact living 
cells, to the investigation of drug-induced stimulation of Pgp ATPase activity. 
The turnover of energy production and consumption through the complex metabolic 
network of a cell is coupled with the production of waste acidic metabolites which need to be 
excreted into the extracellular environment, in order to keep a favourable intracellular pH. 
Using a Cytosensor™ Microphysiometer System (McConnell et al., 1992), it has been 
possible to detect the extracellular release of acidic metabolites (H+), by measuring 
extracellular pH changes during cell stimulation with various compounds as a function of 
time, with a sensitivity of 0.001 pH units/min. Extracellular acidification reflects the overall 
cellular metabolism. Therefore, to monitor activation of a specific transporter or receptor, 
such as Pgp, reference and model systems with background activity as similar as possible are 
required. Wild type mouse embryo fibroblasts, NIH3T3, and the same cell line transfected 
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with the human MDR1 gene, NIH-MDR-G185, showed to be an ideal system for the study of 
Pgp-substrates interactions with the microphysiometer. In NIH-MDR-G185, FACs analysis 
showed a stable Pgp expression level higher than that in NIH3T3 by a factor of 103, while the 
amount of Pgp in NIH3T3 cells was insignificant (see Figure 1.5 A) and B)). 
 
As shown in Figures 1.8 and 1.9, ECAR changes were induced in NIH-MDR-G185 cells, 
after exposure to Pgp substrates, but not in wild type cells. Since the Pgp expression level is 
the main difference (other minor differences in gene expression may have been induced by 
the transfection; M. Gottesman, personal communication) between wild type and transfected 
cells, one can conclude that extracellular acidification is a response to the drug induced 
ATPase activation of the transporter. Moreover, the drug induced ECAR modulations 
measured as a function of concentration in Pgp expressing cells could be fitted with a 
modified version of the Michaelis-Menten equation, a model initially proposed by Litman and 
coworkers (Litman et al., 1997) for the assessment of inorganic phosphate release in CR1R12 
inverted membrane vesicles. This model assumes activation with one substrate molecule 
bound, and an inhibition after a second drug molecule binds to the transporter (see section 
1.3). A linear correlation between the activation constants, K1, and the maximum velocities, 
V1, derived from ECARs and phosphate release measurements,respectively, were also 
observed for LLC-MDR1 pig kidney cells, (Landwojtowicz et al., 2002). Interestingly, 
consistent shifts of the maximum velocities, V1, induced by different Pgp substrates were 
observed depending on the system used for the measurements. For example, the 
concentration-dependent ECAR profile induced by verapamil stimulation, showed a shift of 
V1 by a factor of ~ 1.55 between NIH-MDR-G185 cells (V1 ~ 1.8-1.9 · basal rate) and LLC-
MDR1 cells (V1 ~ 1.2-1.3 · basal rate). This difference was assumed to be correlated to the 
different amount of Pgp expressed in the model employed. To test this assumption, we 
investigated the Pgp expression level in NIH-MDR1 and LLC-MDR1 cells. As shown in 
Figure 1.5 (data reported in table 1.1), FACs analysis by MRK16 monoclonal antibody 
staining (see section 1.3) showed that the Pgp expression level in NIH-MDR-G185 cells is a 
factor ~ 1.6 higher than in LLC-MDR1 cells, which is in good agreement with the difference 
found for the maximum ECARs in the two cell lines. From this, it was concluded that also the 
difference between V1 in LLC-MDR1 cells (Landwojtowicz et al., 2002) and reconstituted 
vesicles was related to different Pgp expression levels. 
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The validity of microphysiometry as a method for on-line monitoring of drug-induced Pgp 
ATPase activation in living cells was further supported by a quantitative determination and 
comparison of the turnover numbers of Pgp, calculated from our ECAR data (NIH-MDR-
G185 fibroblasts) and previous data obtained from Pi release experiments. In a previous study, 
the amount of Pgp molecules/cell was estimated as ~ 1.95 · 106 Pgp copies/cell ( 0.56 pg
Pgp/cell) for NIH-MDR-G185 cells by Ambudkar and coworkers (Ambudkar et al., 1997), by 
titrations with Pgp-specific monoclonal antibody UIC2. From these values, the same group 
determined the turnover of Pgp during pumping of verapamil, in terms of Pi release. At 
maximum activation, the turnover was estimated as ~3.26 Pi · s-1 · Pgp-1 (Kerr et al., 2001). 
We thus calculated the corresponding turnover number from ECAR data obtained by 
microphysiometry. Taking into account the number of cells (~ 1-4 ·105) contributing to the 
observed acidification rate in the capsule cups and the minimal buffer capacity of the running 
medium, turnover numbers at basal rate and maximum activation were calculated. For 
verapamil, a turnover at maximum Pgp activation was estimated as ~ 3.2 H+ · s-1 · Pgp-1,
which is in striking agreement with the number determined for Pi release. Data are reported in 
Table 1.3. It should be noted that these calculations involve several approximations. For 
example, the actual buffer capacity of DMEM would be higher, taking into account the 
contribution of compounds other than phosphate buffer (e.g. amino acids). Nevertheless, these 
results provide a reasonable estimation of the Pgp turnover, and support the assumption of a 
direct correlation between ECAR and intracellular Pi release from ATP hydrolysis by Pgp. 
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Table 1.3. Turnover numbers for P-glycoprotein activity during maximum activation upon 
interaction with substrates. The maximum velocity (Vmax, fold of basal value) was 
determined in Pgp overexpressing living mouse embryo fibroblasts, NIH-MDR-G185, by 
fitting drug concentration-dependent ECAR profiles with a modified Michaelis-Menton 
model. The turnover numbers, expressed in terms of extracellular proton 
release/cell/second, is calculated assuming the presence of ~ 0.56 pg Pgp/cell. 
 
Direct involvement of Pgp in the substrate transport-coupled proton excretion. 
 
Several factors reported here suggest a direct coupling between Pgp ATPase activity 
(therefore Pi and substrate transport) and the drug-modulated excretion of protons by cells, i.e. 
i) the linear correlation between kinetic constants obtained from extracellular H+ release and 
intracellular Pi release in independent studies (Landwojtowicz et al., 2002); ii) the 
correspondence between the maximum velocities for drug-induced proton transport and the 
cellular Pgp expression level; iii) the quantitative correspondence of turnover numbers 
obtained independently from ECAR and Pi release data (see above); iv) the possibility to 
competitively inhibit the compound-induced ECAR change with Cys A (see Figure 1.11 here 
and Figure 5 in (Landwojtowicz et al., 2002)), and v) the exclusion of the contribution of 
other important pH regulating transporters, such as Na+/H+ and Cl-/HCO3- antiporters, to the 
drug-induced ECAR (Landwojtowicz et al., 2002) 
Moreover, we have shown that lactate is the main acidic product resulting from wild type 
cell activation, pointing to an essentially glycolytic pathway of ATP synthesis. It can therefore 
be assumed that ATP for driving Pgp activation in MDR1 transfected cells is also produced 
via the glycolytic pathway.  
 
Compound Vmax Turnover ECAR
fold H+*s-1*Pgp-1 H+*s-1*cell-1
amitriptyline 2.2 4.324 8579640
C12EO3 - - -
C12EO8 2.1 3.964 7864670
Calcein-AM 1.29 1.045 2073413
Chaps - - -
Cys A - - -
Triton X-100 1.63 2.27 4504311
Tween 80 2.1 3.964 7864670
verapamil 1.89 3.21 6005748
vinblastine 1.12 0.432 857964
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The Effect of Drugs on Pgp ATPase Activity is related to their Hydrogen 
Bonding Potential and their Partition Coefficient for Lipid Membranes.  
 
As described previously (Seelig and Landwojtowicz, 2000), the inverse of the 
concentration required for half-maximum activation of the transporter (K1) can be linearly 
correlated with the air-water partition coefficient (Kaw) of the substrate molecule, in a double 
logarithmic plot. Moreover, Kaw provides a good estimation of the lipid-water partition 
coefficient, Klw (see section 1.2) It was therefore assumed that the membrane insertion step,is 
rate limiting for the interaction of a substrate with Pgp.  
 
Pgp substrates structural features were further screened according to the recognition 
pattern model proposed earlier (Seelig, 1998). Figure 1.13 shows the maximum (V1) and 
minimum (V2) ECARs induced by drugs and surfactants in living Pgp-overexpressing cells, 
plotted as a function of the number of H-bond acceptor patterns (HAU’s) on substrates. The 
maximum activity, V1, is high for compounds with a low affinity for the transporter (=low 
number of H-bonding (or energy) units, see section 1.3) and decreases exponentially with 
increasing substrate affinity for the transporter (=higher H-bonding strength (see Table 1.2)). 
For example, compounds like cyclosporin A, which is considered as a Pgp inhibitor, 
possesses 12.5 EU’s, and gives almost no ECAR activation. On the other hand amitriptyline, 
which has only 2 EU, induced an ECAR increase up to ~ 2 fold, compared to the basal 
metabolic activity.  
The comparison of these kinetic data obtained from the two cell lines, namely LLC-MDR1 
(Landwojtowicz et al., 2002) and NIH-MDR-G185, reflects the different Pgp expression 
levels detected by FACs analysis (see Figure 1.5). Although the shapes of the curves are 
similar, NIH-MDR-G185 induces consistently higher V1. A less distinct correlation is 
observed for V2. This is most probably due to the fact that the minimum rate is obtained 
mathematically from the fitting procedure and can not be measured.  
From the combination of these parameters, i.e., maximum ECAR activation and H-
bonding strength, the potential of a substrate to act as modulator or inhibitor can be assessed. 
As shown in Figure 1.10 of the present study and elsewhere (Landwojtowicz et al., 2002), 
further experiments demonstrate a direct competition between two compounds for H-bonds 
formation with the transporter. In this sense, inhibitors like cyclosporin A would block the 
action of other substrates, by occupying much more “binding sites” of Pgp per drug molecule. 
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Indeed, the higher the number of EU of the competing molecule, the weaker the inhibitory 
effect of cyclosporin A. 
 
Figure 1.13 Influence of the H-bonding energy on the rate of drug-induced ATPase 
activation in living MDR1 overexpressing cells. The maximum (V1) (open black squares, 
solid red circles) and minimum (V2) (open blue circles, solid black squares) extracellular 
acidification rates (ECAR) are plotted as a function of the H-bonding energy. 1) 
amitriptylin; 2) C12EO3; 3) C12EO8; 4) calcein-AM; 5) cyclosporine A; 6) diltiazem; 7) 
progesterone; 8) trifluoperazine; 9) Triton X-100; 10) Tween 80; 11) verapamil; 12) 
vinblastin. Circles indicate data from NIH-MDR-G185 cells, while the squares correspond 
to data from LLC-MDR1 cells taken from (Landwojtowicz et al., 2002) for comparison. 
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Surfactants as specific modulators of P-glycoprotein ATPase activity 
 
The successful development of microphysiometry for the study of Pgp-substrate 
interaction with standard substrates, suggested the possibility to investigate the role of 
surfactants as potential substrates for Pgp. To this purpose, we screened four nonionic 
detergents, e.g. Triton X-100, C12EO8, C12EO3, Tween 80 and a zwitterionic, Chaps, for 
their effect on the ECAR of NIH3T3 and NIH-MDR-G185 cells. In agreement with previous 
observations, Chaps showed to be a non-substrate for Pgp, as no ECAR change was observed. 
From a physical chemical point of view, two characteristics make this compound a non-
substrate for Pgp. Indeed, i) Chaps is a zwitterionic molecule and therefore the rate of flip-
flop into the inner leaflet of a biological membrane (an essential step for the recognition from 
Pgp) is extremely low, and ii) in agreement with the reported recognition pattern model 
(Seelig, 1998) no H-bond acceptor patterns are present on this compound. 
Polyethoxylated nonionic surfactants, e.g, Triton X-100, Tween 80, C12EO8 and C12EO3 
are in contrast electrically neutral, which allows a fast flip-flop. In addition, polyethoxylated 
detergents carry a variable number of hydrogen bond acceptor groups. 
Triton X-100 showed an evident concentration dependent effect on the ECAR of NIH-MDR-
G185 cells, as shown in Figure 1.10. Such molecule carries several (7 to 15) ethoxylated 
groups in the hydrophylic tail, which could form H-bonds with Pgp. However, in contrast to 
other Pgp substrates, like most drugs which show rather rigid H-bond acceptor patterns the 
highgly flexible polyethoxylated chains most likely form only transient H-bond acceptor 
patters. Therefore the number of EU’s given has to be considered as an upper limit. Computer 
3D-modelling and the comparison of the maximum velocity, V1, with standard compounds 
such as verapamil, allowed an estimation of the potential H-bond energy of Triton X-100 of ~ 
5-6 EU.  
The hypothesis of a direct interaction of Triton X-100 with Pgp was supported by 
competition experiments with cyclosporin A. Stimulations with Triton X-100 (8 µM) were 
performed after 20 min incubation with cyclosporin A (1 µM  and 10 µM, respectively). 
While 1 µM cyclosporine A had little effect on the Triton X-100 induced ECAR, 10 µM of 
the same compound could inhibit the Pgp response to Triton X-100 stimulation almost totally 
(see Figure 1.11). 
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The octaethyleneglycol monododecilether, C12EO8, showed an effect on Pgp ATPase 
activity similar to Triton X-100, even though with higher V1 values. Even though an 
analogous number of EU’s has been evaluated by computer modelling simulation in vaco, the 
broad range of the length of the ethoxylated chains in Triton X-100 (n = 7 to 15) may lead 
effectively to different number of EU. Moreover the two compounds, C12EO8 and Triton X-
100, differ in the structure of the hydrophobic cores, resulting in different amphyphilicities. 
 
To reduce the influence of structural differences and to thus assess the role of H-bond 
acceptor patterns for the interaction with Pgp more precisely, we also investigated the non-
ionic detergent triethyleneglycol monododecylether, C12EO3. This surfactant differs from 
C12EO8 due to its shorter ethoxylated, hydrophylic tail. Despite its detergent action 
(Heerklotz and Seelig, 2000), C12EO3 had almost no influence on the ECAR of NIH-MDR-
G185, arguing again in favour of a direct detergent-Pgp interaction through a specific 
recognition pattern as a basis for the ECAR increase. 
 
Finally, Tween 80, which carries four polyethoxylated tails with totally 20 ethoxylated 
groups, produced a selective increase of the ECAR of NIH-MDR-G185 cells, similarly to 
C12EO8 and Triton X-100. The higher hydrophilicity of Tween 80, compared to that of the 
other nonionic detergents was evident in surface activity measurements. In addition the time 
required to reach a stable surface pressure was much longer than for Triton X-100 or C12EO8 
(data not shown). The slow partitioning into the air-water interface most likely reflects the 
slow partitioning into the membrane-water interface. As a result the membrane concentration 
has not reached its maximum value at the stimulation time appropriate for the other 
compounds invsdtigated ( 40s + 2min) as seen in figure 1.8C.  
 
The maximum ECARs induced by detergents in NIH-MDR-G185 cells are plotted 
together with standard Pgp substrates, in Figure 1.13. It is evident that the detergents fit the 
exponential curve drawn through standard Pgp substrate quite well, except tween for which 
the number of effective H-bond acceptor patterns seems to be clearly over estimated. 
Considering the flexible structure of these ethoxylated detergents and thus the lack of rigid H-
bond acceptor patterns, the V1 can be traced back to the exponentially decay tendence, as for 
standard compounds. Probably, the actual HAU number of such detergents is a bit less than 
what determined by vacuum 3D-modelling, considering the restriction of freedom when 
inserted in a membrane. Finally, as mentioned in several works, the action of detergents in 
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disturbing Pgp activity indirectly by changing the order parameters of a biomembrane, is well 
possible. However, this feature is also observed in standard Pgp substrates (Schuldes et al., 
2001).  
Our findings show that the presence of H-bonding donor groups plays a role in the 
interaction of detergents with Pgp, similarly to that found for standard Pgp substrates. Most 
probably, the exact description of the mechanism of action of these molecules in alterating 
Pgp ATPase activity involve the synergistic contribution of both solubilizing effect and a 
specific H-bond mediated interaction with the transporter (Seelig and Gatlik, Minireviews, in 
press). 
In conclusion, our results suggest therefore that not only drugs, but any compound 
which has recognition patterns, e.g. drug additives, can interact with P-glycoprotein. Drug 
additives with such features may have profound effects on drug absorption and should 
therefore be considered carefully for the development of drug formulations.  
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Part Two: The Cell Penetrating Peptide HIV-1TAT-PTD 
 
Summary 
The aim of the present work was to find possible interaction mechanisms of the cell-
penetrating peptide (CPP) HIV-1 TAT-PTD with living cells. Recently, it has been postulated 
that the penetration mechanism observed in several studies is, actually, an artifact occurring 
during cell fixation with paraformaldehyde or methanol, a commonly used treatment for the 
preparation of cells for epifluorescence microscopy analysis. Our intent was to perform 
observations of the interaction of the CPP with cells, while preserving in vivo conditions 
without the use of fixation. Microphysiometry and confocal microscopy turned out to be 
adequate methods for our purpose. By means of these techniques, we measured (i) the ability 
of HIV-1 TAT-PTD to penetrate into non-fixated living mouse embryo fibroblasts, NIH-3T3, 
(ii) the kinetics of the uptake process, (iii) the inhibition of the peptide uptake with exogenous 
heparan sulfate or by enzymatic digestion of the extracellular glycosaminoglycans with 
heparinases, and (iv) the possible occurrence of structural alterations on the cells, as well as 
(v) functional changes, e.g., metabolic modulations. Our experiments showed clearly that 
HIV-1 TAT-PTD penetrates into intact cells, thus excluding the hypothesis of a fixation 
artifact: the penetration occurred in a time scale of seconds. However, not all cells integrated 
the peptide. 
 
Morphological alterations appearing as dense dark aggregates, to which the trivial 
denomination of “dark spots” was attributed, were observed on the cell surface using 
differential interference contrast (DIC) microscopy. Such aggregates were present exclusively 
on fibroblasts presenting TAT-PTD uptake and their size increased during the uptake process. 
The enzymatic removal of extracellular heparan sulfate, as well as the simultaneous addition 
of exogenous heparan sulfate with TAT-PTD reduced the uptake of TAT-PTD and the 
appearance of aggregates. Moreover, in the case of simultaneous addition of heparan sulfate, 
the appearance of small aggregates in the surrounding medium was observed. The latter 
observations argue in favor of the theory that the aggregates are composed of TAT-PTD 
bound to the GAG heparan sulfate. 
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The experiments in vivo were supported by measurements in vitro. The binding constant 
of the fluorescent CPP interaction with heparan sulfate, K = 4.6·104 M-1, was determined by 
isothermal titration calorimetry (ITC). The interaction of Fg-TAT-PTD and heparan sulfate in 
vitro induced fluorescence quenching and formation of aggregates, in analogy to the 
observations with confocal microscopy. Finally, we found that the administration of TAT-
PTD specifically induced alterations of the extracellular acidification rate (ECAR) of NIH-
3T3 fibroblasts, which reflects a disturbance of the overall cellular metabolism. These latter 
findings allow at the same time some considerations on the potential toxicity of such a 
compound to mammalian cells. 
 
Chapter 2. Interactions of HIV-1 TAT Protein Transduction 
Domain with Living Fibroblasts. 
2.1 Introduction 
A biological lipid bilayer constitutes an efficient barrier against the intracellular 
penetration of biomolecules. This property is essential for the protection of tissues and for the 
appropriate compartmentalization of different biological environments inside an organism. 
However, such a protective mechanism can represent a disadvantage during the 
pharmacological treatment of diseases, by reducing the bioavailability of therapeutic and 
diagnostic agents. Therefore, during the last half century, pharmacological research has been 
directed towards the development of drugs and pharmaceutical delivery formulations that 
optimize the passage of the drug through the cell membrane in order to reach biological 
targets (organs, tissues, cells). The developed administration strategies include encapsulation 
of the active compounds into liposomes or their linkage to so called cell-penetrating peptides 
(CPPs, not yet commercialized). The latter are polypeptides with many positively charged 
amino acids, which enhance the intracellular transport of almost every kind of covalently 
attached molecule, from proteins (Schwarze et al., 1999; Stein et al., 1999) to nucleic acids 
(Eguchi et al., 2001), from small drug molecules (Nori et al., 2003; Rothbard et al., 2000; 
Wender et al., 2002) to large liposomal or metal particles (Lewin et al., 2000; Torchilin et al., 
2001). If Fe is taken up by the cells, then the MRI image contrast changes in analogy to the 
intravascular contrast agent endorem used in chapter 3. 
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The first report on the involvement of polycationic peptides as enhancers of drug delivery 
appeared in 1968. Twenty years after the first observation of genetic transformation in 
pneumococci (Avery, 1944, J. exp. Med. 79, 137), attempts were made to achieve genetic 
transformation of higher organisms by means of nucleic acids extracted from infectious or 
oncogenic viruses, in order to initiate infection or malignant transformation. Focusing on the 
biological effect of infection or transformation, little importance was attributed to the specific 
physiology of uptake of the exogenous molecules. This gap was clearly highlighted in a report 
of H. J.-P. Ryser (Ryser, 1968) who showed interest in the details of adsorption and uptake of 
macromolecules by mammalian cells. In his work (Ryser, 1968), Ryser discovered that 
incubating cultured mammalian cells with natural histones (Lys-rich) or synthetic 
polycationic peptides, such as polylysine, polyarginine or polyornithine, led to an improved 
cellular uptake of exogenous proteins. 
 
Twenty years later, a natural compound with similar physical chemical features was 
discovered. A natural polycationic peptide was derived from the HIV-1 tat protein, an 86-
amino acid protein that was identified as the trans-acting activator of the transcription (TAT) 
of the human immunodeficiency virus (HIV-1) (Frankel and Pabo, 1988; Frankel and Pabo, 
1988). This peptide was able to cross efficiently the cytoplasmic membrane of mammalian 
cells in culture (Frankel and Pabo, 1988; Green et al., 1988) and, moreover, was able to carry 
and transport covalently attached heterologous proteins and fluorescent dyes into cells (Fawell 
et al., 1994; Mann and Frankel, 1991). More recently, further polycationic peptides with 
membrane translocating activities were discovered, both of synthetic or natural origin, e.g. 
transportan (Pooga et al., 1998; Soomets et al., 2000), antennapedia (AntP) (Derossi et al., 
1994; Lindsay, 2002), and herpes simplex virus HSV-1 VP22 (Bennett et al., 2002). These 
compounds have different primary structures and different natural biological functions. 
However, because of their common functionality in the enhancement of cellular uptake, they 
all have been classified as cell-penetrating peptides (CPPs) (Lindgren et al., 2000) or trojan 
horse peptides (Derossi et al., 1998). In spite of its similar physical chemical features, 
polylysine is less efficient and has not been included in this group (Mitchell et al., 2000). 
 
The proper physical mechanism of uptake of CPPs is actually still unknown (Silhol et al., 
2002). It is also not known whether all these different peptides penetrate into a cell by means 
of the same mechanism. Early studies showed that uptake mechanisms, such as classical 
endocytosis, receptor- or transporter-mediated active import, can probably be excluded 
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(Derossi et al., 1996). The transport also seems to be energy-independent, as it could be 
observed even at 4 °C (Derossi et al., 1996). On the other hand it was reported that sodium 
azide-induced inhibition of oxidative phosphorylation could block CPPs translocation 
(Mitchell et al., 2000). The uptake of CPPs by passive diffusion through the cytoplasmic 
membrane can also be rejected, because of the highly positively charged nature of these 
peptides. Recent theories suggested alternative mechanisms for CPPs uptake, based on 
complex formation of the polycationic peptides with anionic molecules on the cell membrane, 
such as glycosaminoglycans (Frankel and Pabo, 1988; Sandgren et al., 2002; Tyagi et al., 
2001) or lipids (Derossi et al., 1996; Prochiantz, 2000), which would reduce the electrical 
charge of the peptides and allow the intracellular translocation in some way across the lipid 
bilayer . Recently, it has also been suggested that the uptake of CPPs is only an artifact caused 
by chemical cell fixation with paraformaldehyde, which is a widely adopted procedure for 
epifluorescence microscopic analysis (Lundberg and Johansson, 2001). Skeptical reports 
(Lundberg and Johansson, 2001) clash therefore with other works that share an optimistic line 
of thinking and suggest potential applications involving CPPs in pharmacology and 
biotechnology (Zhao and Weissleder, 2004). As mentioned above, there is hope, that linking 
CPPs covalently to other molecules could enhance the cellular uptake of these compounds and 
thus increase the efficiency of drug delivery, improve biotechnological techniques, or provide 
gene therapy strategies without the employment of viral vectors (Schwarze et al., 2000). 
However, prior to clinical applications, the import mechanisms and the exclusion of possible 
toxic effects of CPPs should be clearly ascertained. 
 
The present work focuses on one particular cell penetrating peptide, namely the HIV-1 
TAT-PTD. The trans-acting activator of transcription, TAT (Sodroski et al., 1985), is one of 
the 15 proteins encoded by the human immunodeficiency virus type 1, HIV-1. It is an 86 (or 
101 in human blood (Rana and Jeang, 1999)) amino acids long polypeptide specified by a 
regulatory gene composed of two coding exons. TAT plays an essential role in the 
upregulation of viral DNA transcription. It acts in the nucleus by binding to a specific viral 
RNA stem-loop called tat-responsive element (TAR) and to other host cell kinases that 
enhance the processivity of RNA polymerase II at early elongation steps (Clavel et al., 1986; 
Karn, 1999). Indeed, in the absence of TAT, the RNA pol II complex interrupts prematurely 
the transcription after about 100 nucleotides (Laspia et al., 1989). 
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The TAT sequence can be subdivided into several distinct regions on the basis of its 
amino acid composition, i.e., a N-terminal activation acidic region (amino acids 1 - 19), a 
cysteine-rich domain (amino acids 20 - 31), a hydrophobic core region (residues 32 - 47), a 
basic region (residues 48-57), a glutamine-rich region (residues 60-71), and a RGB motif 
(residues 72-86). The cysteine-rich fragment plays a role in the activation of the RNA pol II 
transcription complex, whereas the basic region together with the hydrophobic core are 
responsible for the binding of TAT to the TAR sequence of viral mRNA (Long and Crothers, 
1995; Luo et al., 1993; Weeks et al., 1990). 
 
A number of studies showed that small regions of TAT were able to enter cells within 5 -
10 minutes and to import covalently attached compounds of various nature (Frankel and Pabo, 
1988). The minimal amino acid sequence of TAT required for cellular internalization was 
found to be the sequence of amino acid 47-57 (H3N-YGRKKRRQRRR-COO-) in the basic 
region, and was called TAT protein transduction domain, TAT-PTD (Ho et al., 2001; Vives et 
al., 1997). 
 
In a number of studies the potential toxicity of TAT-PTD was tested for cultured cells, by 
exposing them to different amino acid sequences of the peptide (for variable period of time). 
For example, residues 31-61 of the TAT peptide (82 amino acid residues) were shown to 
cause concentration-dependent neurotoxicity (Mabrouk et al., 1991; Nath et al., 1996; 
Sabatier et al., 1991). However, no neurotoxic effects were observed for the TAT-PTD 
(residues 48-82) (Fawell et al., 1994). Two other studies investigated the toxicity of TAT-
PTD on cell cultures (Hallbrink et al., 2001; Vives et al., 1997). Long (24 hours) exposures of 
cells to TAT-PTD at concentrations of 20 – 100 µM induced necrosis in 60 % of cells (Vives 
et al., 1997), whereas no acute toxic effect were observed for short incubation times (i 30 
minutes). 
 
Considering the biomedical potential of CPPs, and given the controversial aspects 
summarized above, the interaction of the TAT-PTD was studied in living cells to elucidate the 
mechanisms of action of TAT-PTD. Recently, thermodynamical analysis have been 
performed, to prove the interactions between TAT-PTD and three different 
glycosaminoglycans, e.g., heparan sulphate, heparin, and chondroitin sulphate B, in vitro 
(Ziegler et al., 2003; Ziegler and Seelig, 2004). These studies provided first quantitative data 
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for the evaluation of the possible uptake mechanisms based on a CPPs–GAGs complex 
formation. 
 
The aim of the present study was to further characterize the TAT-PTD interaction with 
living cells. For this purpose, a fluorescent derivate of TAT-PTD was employed to study in 
vivo the possible translocation mechanism by confocal laser scanning fluorescence 
microscopy (CLSM), without taking recourse to fixation techniques. In parallel, several 
experiments were performed in order to assess the role of the GAG heparan sulfate in the 
uptake of TATP. Moreover, information on the metabolic activity of cells in vivo when 
exposed to TAT-PTD and heparan sulfate were obtained by means of microphysiometry. 
The experiments reported here provided dynamical, morphological and functional 
information on the interactions of TAT-PTD with mammalian cells that can contribute to an 
understanding of the behavior of CPPs and their potential for possible future biological and 
clinical applications. 
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2.2 Theory 
The Confocal Laser Scanning Microscope 
 The Leica TCS SP confocal microscope is equipped with three lasers for the simultaneous 
excitation of three different fluorescent wavelenghts and three different detectors. Each 
detector (photomultipliers) can be independently controlled for gain and offset in order to 
obtain an optimal image quality. The lasers (power ~ 25 mW) connected to the instrument 
include an argon laser (488 nm excitation line), a krypton laser ([ex = 568 nm), and a helium 
neon laser ([ex = 633 nm). These laser allow the collection of fluorescent images in the green 
range (FITC, GFP), near red range (rhodamine, TRITC, Texas red), and far red range (Cy5). 
In addition, the lasers can be used to obtain bright field images with differential interference 
contrast (DIC) optics or phase contrast. The Leica TCS SP, equipped with individual 
spectrophotometers for up to 4 detection channels eliminating the need for emission filters in 
the scan head, allows continuous selectable wavelength bands for various fluorescent dyes. 
Images are first viewed on a Leica DMIRBE inverted microscope equipped with an UV filter 
set, FITC filter set and a rhodamine filter set. The lasers are interfaced to the microscope via a 
fiber optic cable. Images are collected through acoustical optical tunable filters (AOTF) which 
provide a precise control of the laser intensity and can also turn the laser beams on or off at 
exactly the correct time and place. Attached to the Leica inverted microscope is a multiphoton 
laser that allows acquisition of fluorescent images in the UV to near red range. The control of 
data collection and manipulation of the scan parameters can be performed through the Leica 
TCS SP software running under Windows NT. Images are stored as TIFF files with 
resolutions ranging from 256 x 256 to 2’048 x 2’048 pixels (Leica Microscopy and Scientific 
Instruments Group, Heerburg, CH). 
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2.3 Material and Methods 
Cell Line 
Mouse embryo fibroblasts, NIH-3T3, were a kind gift of Dr. M.M. Gottesman (NCI, NIH, 
Bethesda (MD), USA).  
Cell Culture 
NIH-3T3 cells were grown in DMEM supplemented with 10% (v/v) fetal bovine serum, 
0.3 g/L L-glutamine, 100 units/mL penicillin, and 100 units/mL streptomycin and incubated 
in standard cell culture conditions, i.e., humidity saturated air supplemented with 5% CO2 and 
temperature of 37 °C.  
Compounds 
Heparan sulfate, sodium salt (fraction I17, average MW = 14.2 ± 2 kDa; sulfate content of 
6.44 %; about 30 sulfated disaccarides units) was purchased from Celsus Laboratories 
(Cincinnati (OH), USA). Heparinase III and all other compounds of HPLC grade were 
obtained from Fluka (Buchs, Switzerland). 
Peptide Synthesis 
The synthesis of TATP (H3N+-YGRKKRRQRRR-COO-), g (H3N+-(A)GGGG-COO-)
and g-TATP (H3N+-(A)GGGGYGRKKRRQRRR-COO-) was performed by Dr. André 
Ziegler on a solid phase resin using an Abimed EPS221 peptide synthesizer (Langenfeld, 
Germany) (Ziegler and Seelig, 2004). Before removing the resin and the protection groups, 
the amino terminus of g-TATP and g were covalently linked to fluoresceine isothiocyanate 
(FITC, F) via a thiourea bond (Ho et al., 2001). The beta-alanine (A) was required to prevent 
the loss of the FITC during the subsequent removal of the resin and the protection groups by 
treatment with trifluoroacetic acid. Peptide purification was performed by preparative high 
pressure liquid chromatography (HPLC). The masses of TATP (1560.8), g (704.7) and Fg-
TATP (2247.5) were determined by electrospray ionization mass spectrometry. Peptide purity 
(>97%) was assessed by analytical HPLC. 
Determination of Binding Parameters In Vitro 
The binding of Fg-TATP to heparan sulfate was assessed in vitro by static right-angle 
light scattering, fluorescence quenching and high-sensitivity isothermal titration calorimetry. 
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Buffer 
Solutions were prepared in 10 mM TRIS, 100 mM NaCl and pH 7.40. The samples were 
filtered (0.44 µm) and degassed immediately before use (140 mbar, 8 min). 
Static Right-Angle Light Scattering 
Static light scattering at right angle was measured with a Jasco FP 777 fluorimeter (Tokyo, 
Japan) at a wavelength [ = 350 nm and a temperature of 28 °C, under constant stirring. For 
light scattering experiments, quartz cuvettes of 3.5 mL volume and a cell length of 1 cm were 
used. The cells were filled with 2.8 mL of Fg-TAT-PTD solution and 4 µL aliquots of 
heparan sulfate solution were added at injection intervals of 1 minute. Control experiments 
were performed by injecting heparan sulfate into buffer, without the peptide. 
Isothermal Titration Calorimetry 
The binding process of TAT-PTD to heparan sulfate was measured with high-sensitivity 
isothermal titration calorimetry, using a Microcal VP-ITC calorimeter (Microcal, Northamton, 
MA, USA) with a reaction cell volume of Vcell = 1.4037 mL. For the unlabeled TAT-PTD, the 
calorimeter cell contained the heparan sulfate solution at a concentration 0HSC ~ 12 µM and 
aliquots of volume Vinj = 10 µL of a concentrated TAT-PTD solution ( 0pC ~ 800 µM) were 
injected. With each injection, the total peptide concentration in the calorimeter chamber 
increased by uC = 5.7 µM. The increase of the total reaction volume was also taken into 
account for the HS concentration and the correction factor applied was: 
0
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where ,i HSC is the heparan sulfate concentration after ni injections. For the peptide solution 
the corresponding correction factor is: 
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where ,i pC is the peptide concentration in the calorimeter cell, after ni injections. 
For the fluorescent-labeled Fg-TAT-PTD, a peptide solution of concentrations 0pC ~ 70-80 
µM was placed into the calorimeter cell and was titrated with glycosaminoglycan solutions of 
500 µM. 
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Control experiments were performed by injecting TAT-PTD and heparan sulfate solutions 
into pure buffer. The heats of dilution of the control titrations , typically -1 to +1 µcal for 
heparan sulfate and -10 to -20 µcal for the concentrated TAT-PTD solutions, were subtracted 
from the heats measured for the binding reactions. All solutions were degassed immediately 
before use by placing them in a 140 mbar atmosphere, for 8 min. 
Cytosensor Measurements In Vivo 
The equipment and measurement methods used for microphysiometry experiments using 
the Cytosensor™ Microphysiomenter were identical to that described in section 1.3 of the 
present work. 
Confocal Laser Scanning Microscopy In Vivo 
For CLSM analysis, mouse embryo fibroblasts were directly seeded onto sterile non-
coated microscopic cover slips especially inserted into six-well dishes. Cells aliquots were 
incubated for  48 h in order to reach a confluency of  40-60 % at the time of measurement.  
 
Figure 2.1. Perfusion chamber for Confocal Laser Scanning Microscopy. Cells are directly 
grown as monolayers on uncoated glass cover slips, until 40-60% confluence. For 
measurements, the cover glass is placed upside down on a microscopic glass slide, 
separated by an appropriately cut filter paper spacer of 1 mm thickness. The chamber is 
filled with DMEM to keep cell culture conditions. The construction allows microinjections 
using a micropipette. In addition, medium flow can be produced by placing an additional 
filter paper on the side opposite to the aperture of the chamber (not shown on the scheme). 
 
Cell-carrying cover slips were transferred in an up-side-down position on top of a custom-
made microscopic perfusion chamber (volume  0.25 mL), allowing image acquisitions and 
cover slip
spacer
cells
syringe
glass slide
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the injection of labeled peptides, simultaneously (see Figure 2.1). For the experiments, the 
perfusion chamber was initially filled with DMEM containing the fluorescent peptide, except 
for kinetic studies, for which the fluorescent peptide (or heparane sulfate) was injected into 
DMEM at the indicated time (see results). Confocal images were acquired using a Leica TCS-
NT-SP1 scanning system mounted on an inverted microscope DMIRBE (Leica Microsystems, 
Heerbrugg, Switzerland) with a PL APO (planapochromats) datapoints for both lateral 
dimensions of 250 µm (see section 2.2 for details). Monochromatic Argon laser excitation 
(488 nm) was used for the excitation of FITC and the recorded fluorescence intensity was 
plotted using a false-color green scale. Detection with a FITC/TRITC filter (emission bands 
of 503-533 nm and 582-622 nm, respectively) was used for simultaneous measurements of 
FITC and propidium iodide. 
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2.4 Results 
Uptake of Fg-TAT-PTD by Mouse Embryo Fibroblasts 
The uptake of the fluorescent HIV-1 TAT-PTD peptide by living mouse embryo 
fibroblasts, NIH-3T3, was investigated by confocal laser scanning microscopy and differential 
interference contrast microscopy. In order to preserve in vivo conditions, cells were directly 
grown in complete cell culture DMEM on sterilized uncoated cover slips and mounted 
immediately before the observation up-side down on top of a home-made microscopic 
perfusion chamber of volume V ~ 250 µL (see Figure 2.1). 
 
Figure 2.2. Confocal Laser Scanning Microscopy of Living Mouse Embryo Fibroblasts.
Simultaneous recordings of differential interference contrast images (DIC, upper row, green 
scale) and fluorescence signal at 520 nm (F520, lower row, false green scale). A) NIH-3T3 
cells were grown on uncoated cover slips and mounted upside down on top of a 
microscopic perfusion chamber filled with 0.25 mL of fluorescent marker peptide, Fg, at 20 
µM. Images were recorded 4 min after exposure to Fg. No uptake from the cells. B) 30 µL 
of 200 µM of Fg-TATP were added to the same fibroblasts, yielding to a concentration of ~ 
21 µM of Fg-TATP. Images depict the situation after 4 min from the injection of Fg-TATP. 
Note the appearance of dark spots (white arrow in DIC) and fluorescent labeling of the 
nucleus (F520 image). C) Same sample shown in B), 2 minutes later (different field of 
view), after being rinsed 3 times with 0.5 mL DMEM. The fluorescence in the extracellular 
space is removed, as well as the dark spots. D) Different fibroblast pool exposed directly to 
100 µM Fg-TATP for 4 min. Few dark spots and fluorescent cells are highlighted (white 
arrows). Bar represent 50 µm. 
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In a first set of experiments, the perfusion chamber was filled with a solution containing 
20 µM of the fluorescent marker peptide Fg. After a 4 minutes incubation, cells were 
observed under the microscope. As shown in the lower image of figure 2.2A), pronounced 
fluorescence became visible in the extracellular surroundings. No evident morphological 
changes of cells occurred and no sign of an uptake of the fluorescent compound could be 
observed. 
 
In a second step, 30 µL of a 200 µM solution of the fluorescent marker Fg, covalently 
linked to the HIV-1 TAT-PTD, were administered to the same fibroblasts population, 
corresponding to a final concentration of ~ 21 µM of Fg-TAT peptide. Figure 2.2B) reports 
the situation after a 4 minutes contact with the Fg-linked cell penetrating peptide HIV-1 TAT-
PTD. Two aspects deserve attention, i.e. i) the appearance of intracellular fluorescence in the 
F520 image (lower row), and ii) the formation of “dark spots” in the DIC image (highlighted 
by white arrows in figure 2.2). Further observations (see later in the text) confirm that there is 
a correspondence between the appearance of the “dark spots” and the uptake of the peptide. 
Moreover, it is interesting to note that the highest intracellular signal was localized in the 
nucleus. Figure 2.2C) shows the same fibroblasts population 2 minutes later than in figure 
2.2B), after being rinsed 3 times with 0.5 mL of DMEM, to remove the fluorescent 
compounds from the extracellular space. The difference of the cell distribution is simply due 
to the snapshot taken in another field of view. Here it is interesting that, after washing, the 
“dark spots” disappeared, and that the cells labeled with the fluorescent TAT peptide became 
better distinguishable. The pictures shown in figure 2.2D) illustrate another population of 
fibroblasts, immersed directly into 100 µM of Fg-TAT peptide, for 4 minutes. The situation is 
very much analogue to what observed in figure 2.2B) but with more cells labelled per 
population. 
 
Dynamical Morphological Considerations – Confocal Microscopy 
One advantage of confocal microscopy of intact living cells is the possibility to monitor 
the cellular incorporation of the fluorescent Fg-TATP with almost real-time (2s-resolution). 
Indeed, to our knowledge, uptake of CPP was never imaged with such a time resolution.
Dynamical recordings were performed by taking serial snapshots images under the confocal 
microscope, at intervals of 2 seconds, during the administration of 60 µL of a 500 µM solution 
of fluorescent Fg-TATP stock solution (corresponding to a final concentration CFg-TATP ~ 100 
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µM) to mouse embryo fibroblasts, NIH-3T3. The first appearance of the fluorescent label in 
the cell nucleus occurs as early as 4 seconds after the exposure of cells to the CPP.  
 
Figure 2.3. Kinetics of Fg-TAT-PTD uptake from Mouse Embyo Fibroblasts, NIH-3T3.
Dynamical recordings with DIC (gray scale images) and CLS microscopy (520 nm, green 
images) were performed every 2 seconds. At an instant defined as t = 0 s, 60 µL of a 500 
µM Fg-TAT-PTD solution were injected into the 250 µL perfusion chamber, yielding a 
final concentration of ~ 100 µM Fg-TAT-PTD. For practical reasons, only snapshots at 
times -2, 10, 30 and 300 seconds are shown. Note the time-dependent increasing size of the 
dark aggregates in DIC images, and the correspondent appearance of intracellular 
fluorescence in F520 images. The bar represents 50 µm. 
Graph: dynamics of Fg-TAT-PTD averaged over 11 different fibroblast populations. The 
number of labeled cells visible in the F520 images was divided by the total number of cells 
seen in the DIC images. The mean ratios obtained are plotted as a function of the exposure 
time to Fg-TAT-PTD (empty squares). Bars indicate standard deviations (n = 11). A fit of 
the mean values with a monoexponential function (f (%) = 0.68·(1-e^(-0.41·tmin))) is shown 
(solid line). 
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The percentage of cells incorporating the peptide increased with time of exposure in an 
exponential-like way (figure 2.3). However, a relevant fraction of cells (~ 50 % of the total 
population) did not incorporate Fg-TATP, even after 4 minutes. The time-dependent cellular 
uptake of the Fg-TATP was fitted for 11 different cell preparations with a monoexponential 
function , such as  
 
min( 0.41 )(%) 0.68 (1 )tLabeled Cells e  =   ,
leading to a half-time of ~ 1.8 min for the uptake of Fg-TAT by the cells, which corresponds 
to a first-order rate constant k = 0.007 s-1 at the particular peptide concentration employed in 
our measurement (CFg-TATP ~ 100 µM) (see graph in figure 2.3). 
 
Another interesting phenomenon observed is the temporal correlation between the 
incorporation of Fg-TATP and the formation of the “dark spots” on the cell surface. As 
mentioned above, the spots appeared only on cells that integrated the peptide. Moreover, i) the 
formation of the spots slightly preceded the intracellular appearance of fluorescence, and ii) 
the size of the spots increased as a function of the contact time of the fibroblasts with the 
peptide. As it will be discussed in the next section, the “dark spots” are considered to be 
molecular aggregates of the peptide and the cellular GAGs. 
 
Dynamical Functional Considerations – Microphysiometry 
We wanted to know whether the metabolism of the cells was affected by incorporation of 
the Fg-TATP. We exposed mouse embryo fibroblasts, NIH-3T3, to the CPPs and measured 
the proton extrusion rate with the Cytosensor™ Microphysiometer (Mcconnell et al., 1992). 
 
Extracellular acidification rates (ECAR) of fibroblasts were monitored in real time upon 
stimulation with increasing concentrations of TAT-PTD, i.e., 5, 50 and 500 µM. As shown in 
figure 2.4, the ECAR is influenced by the presence of TAT-PTD in a concentration dependent 
manner. Indeed, a 160 seconds exposure of fibroblasts to TAT-PTD resulted in a rapid 
decrease of the ECAR, which denotes an apparent slow down of the general cellular 
metabolism. After switching back to normal DMEM, the original basal ECAR was recovered 
completely within 2-4 minutes. Figure 2.4 depicts the ECAR alteration upon stimulation with 
5 µM (A), 50 µM (B), and 500 µM (C) of TAT-PTD. Three cell populations are displayed, 
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i.e., a control line stimulated only with normal DMEM (green), and two lines stimulated with 
TAT-PTD (red and black). No remarkable ECAR decrease was observed in the presence of 5 
µM TAT-PTD, However, a 10 % inhibition of the basal ECAR could be obtained upon 
addition of 50 µM TAT-PTD. In the presence of 500 µM TAT-PTD, fibroblasts reduced their 
ECAR by 25-40 % (the case reported in figure 2.4C) showed one of the strongest effects). 
Even at such high concentration, the basal ECAR could be re-stabilized completely in a short 
time. Repeated stimulations with 500 µM TAT-PTD (n > 4) ) led to a progressive decrease of 
the basal ECAR and thus to an incomplete recovery (data not shown). 
 
Figure 2.4. Concentration-Dependent ECAR decrease induced by TAT-PTD. The effect of 
TAT-PTD on NIH-3T3 mouse embryo fibroblasts (red and black lines) was tested by 
microphysiometry at concentrations of A) 5 µM, B) 50 µM and C) 500 µM. Control 
stimulations with only DMEM are also shown (green line). The extracellular pH change is 
measured every 2 min, during 20 sec., and expressed in percent of the basal ECAR. 
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 The effects of CPPs on the cellular metabolism could be neutralized by a simultaneous 
administration of HS. As shown in Figure 2.5B) a co-administration of 500 µM TAT-PTD 
and 36 µM HS (red and black lines) inhibited the effect of TAT-PTD on the ECAR, 
completely after 40 seconds stimulation (3d points from left) and slightly after 2’40’’ (4th 
points from left). The effect was even more pronounced by adding 72 µM HS to the TAT-
PTD (figure 2.5C)), which completely reversed TAT-PTD induced ECAR decrease after 40 s 
and reduced the effect of more than 50 % after 2’40’’. The behavior of two other cell 
populations measured simultaneously in different sensor chambers is shown in figure 2.5B) 
and C) (lines blue and magenta). Here, only HS was added. Exogenous HS alone also caused 
an ECAR decrease in NIH 3T3 fibroblasts of just 5 -7 % for both concentrations tested ( B) 
36 µM and C) 72 µM). 
 
Figure 2.5. Heparan Sulfate Inhibits TAT-PTD Activity. Cytosensor™ Microphysiometer 
recordings of NIH-3T3 mouse embryo fibroblasts extracellular acidification rate. A) cells 
were stimulated with 500µM TAT-PTD (red, black lines). B) Co-administration of 36 µM 
heparan sulfate and 500 µM TAT-PTD (red, black) and stimulation with only HS 36 µM 
(blue, magenta). C) Co-administration of 72 µM HS and 500 µM TAT-PTD (red, black) 
and stimulation with only 72 µM HS (blue, magenta). Control stimulations with DMEM are 
shown (green lines). 
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The effect of the TAT-PTD on the ECAR of 3T3 cells was further investigated by 
administrating equivalent amounts of amino acids, i.e., lysine, arginine, glycine, glutamine 
and tyrosine in the monomeric forms. The effect of monomeric aminoacids was significantly 
lower than that of the TAT-PTD peptide. All results are summarized in figure 2.6. 
 
Figure 2.6. Effect of TAT-PTD, Heparane Sulphate and Monomeric Amino Acids on NIH 
3T3 fibroblasts metabolism. Cells (5·105- 1·106) seeded in sensor chambers of a 
Cytosensor™ Microphysiometer were supplemented with ~ 120 µL/min medium. The 
extracellular pH was measured every two minutes cycles, during a “pump off” interval of 
20 seconds. Selective switch of perfusing medium were performed, to supplement cells for 
2 min 40 sec with the different compounds (indicated under the x-axis of the graph). 
Alteration of the ECAR upon selective stimulations are reported (black and gray bars). The 
ECAR recovery are depicted (white bars) 2 pump cycles after the end of stimulations, 
during which cells were supplemented with DMEM. All data are expressed in percent of 
the basal acidification rate measured before the stimulation. HS, heparan sulphate; TATP, 
TAT-PTD; X, glycine, glutamine and tyrosine each at 50 or 500 µM. (*, P < 0.05 versus 
baseline; #, P < 0.05 versus 500 µM TAT-PTD). 
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Heparane Sulfate Induces Fluorescence Quenching and Inhibits Fg-TATP 
Uptake 
We tested the effect of the glycosaminoglycan heparan sulfate on the uptake of Fg-TATP 
by NIH-3T3 cells. In a similar experimental setup for confocal microscopy as described 
above, a cell population already in contact with Fg-TATP for 4 minutes (figure 2.7A), upper 
image), was next exposed to heparan sulfate in a molar ratio of HS/Fg-TATP ~ 0.16.  
 
Figure 2.7. Exogenous Heparan Sulfate and Heparinase III affect Fg-TAT-PTD Uptake. A) 
Mouse Embryo Fibroblasts, NIH-3T3, were incubated in a 100 µM Fg-TAT-PTD solution. 
After 4 minutes, from Fg-TAT-PTD injection, exogenous heparan sulfate, HS, was added, 
yielding a molar ratio HS/Fg-TAT-PTD of ~ 0.16. CLSM F520 snapshots were recorded 
before (upper image) and directly after (lower image) HS addition. Note the extracellular 
fluorescence quench in the presence of HS. B) Magnification of one fibroblast from the 
preparation shown in A) (lower image). In both DIC (upper) and F520 (lower) images, 
aggregates of different size are visible on the cell surface (black arrow in DIC) and in the 
extracellular medium (dashed circles). C) Recordings a new preparation, 4 minutes after 
simultaneous administration of HS/Fg-TAT-PTD at a ratio of ~ 0.16. Intracellular labeling 
of fibroblasts and aggregates are conspicuously inhibited. D) Fibroblasts were grown 1 
hours in the presence of 15 mU heparinase III, then rinsed with DMEM, and exposed for 4 
minutes to 100 µM Fg-TAT-PTD. This treatment reduced the uptake of Fg-TAT-PTD. Bars 
represent 50 µm. 
 
N
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As a result, the fluorescence of the extracellular medium was quenched as shown in the 
lower image of figure 2.7A) and the preparation became similar to that seen after removal of 
the extracellular medium by repeated rinse, shown in figure 2.2C), i.e., the contrast of the 
intracellular versus extracellular fluorescence signal was definitely enhanced. 
 
At a higher magnification (figure 2.7B)), the appearance of tiny aggregates in the free 
medium was observed (dashed circles), presenting similar optical features than the “dark 
spots” occurring on the cell surface of labeled fibroblasts. 
 
The effects of heparan sulfate depended, however, on the sequence of its addition with 
respect to the peptide addition. While injecting HS 4 minutes after the cellular exposure to Fg-
TATP had only effects on the extracellular environment, the simultaneous addition of HS and 
Fg-TAT consistently inhibited the uptake of the peptide by the cells, as shown in figure 2.7C). 
Moreover, the efficiency of the inhibition of peptide uptake depended on the molar ratio of 
heparan sulfate/Fg-TATP. Indeed, a decrease of the fraction of CPP incorporating cells from 
46 % to 6 % was observed by changing the molar ratio heparan sulfate/Fg-TATP from 0/100 
to 16/100 (see graph in figure 2.8). 
 
Heparinase III reduces TATP Uptake 
 To further test the involvement of heparan sulfate in the binding and uptake process of the 
HIV1-TAT PTD peptide, we performed confocal microscopy measurements of fibroblasts 
populations previously treated with 15 mIU of heparinase-III (Suzuki et al., 2002), during 1 
hour.  
 
This enzyme is able to degrade the heparan sulfate chains at the low sulfation regions 
(Linhardt et al., 1990). The fraction of the cell population that integrated the peptide 
subsequently to the enzymatic treatment was reduced by 32 % as compared to preparations 
shown in figure 2.7D), 
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Figure 2.8. Quantitative analysis of Heparan sulfate- and heparinase III-induced Fg-TAT-
PTD uptake inhibition. NIH-3T3 cells were immersed into 100 µM Fg-TAT-PTD without i) 
and with ii) 4 µM and iii) 16 µM hepapan sulfate. iv) After 1 hour incubation with 
heparinase III. The number of fibroblasts that incorporated the peptide (counted in F520 
images) was divided by the total number of cells (counted in DIC images). Mean values 
obtained from 5 different experiments, and 4 different fields of view for each experiment 
(>150 cells), are depicted in the graph (mean±SD, n=5). P < 0.05 (*), and P < 0.001 (**) 
versus the peptide alone. 
 
In vitro assessment of Binding, Aggregate Formation and Fluorescence 
Quenching. 
 The experiments described above showed that the glycosaminoglycan heparan sulfate 
interacts with the uptake mechanism of TAT-PTD peptide. In order to better define the direct 
interaction of heparan sulfate with the cell penetrating peptide, in vitro analysis have been 
performed to quantify the binding strength between the two compounds and the efficiency of 
the fluorescence quenching observed with confocal microscopy. 
 
The thermodynamic parameters of binding were determined by high sensitivity isothermal 
titration calorimetry and are shown in figure 2.9A). 
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The binding of heparan sulfate to Fg-TATP, at 28 °C, is exothermic and the reaction enthalpy 
is eH0 = - 3.60 ± 0.23 kcal per mol of Fg-TATP. The binding constant is K0 = (4.6 ± 1.2) · 104
M-1 and is one order of magnitude smaller than what measured in a previous work for a non-
fluorescent TATP (Ziegler and Seelig, 2004). The difference between fluorescent and non-
fluorescent TATP is probably caused by the hydrophobic fluorescent reporter group. 
 
Figure 2.9. In Vitro Assessment of Fg-TAT-PTD Interactions with Heparan Sulfate. Binding 
Parameters, Aggregate formation, and Fluorescence Quenching.. A) The binding of HS to 
Fg-TAT-PTD was measured by isothermal titration calorimetry (ITC). Data () report the 
heat release from a titration of 2 µL HS (0.50 mM) aliquots into 78.1 µM Fg-TAT-PTD. 
Injections were performed every 5 min, at 28 °C. Thermodynamic analysis of the binding 
isotherm (line) yields a reaction enthalpy eH0 = -3.60 ± 0.23 kcal/mol of Fg-TAT-PTD, a 
binding constant K0 = (4.6 ± 1.2) · 104 M-1 and n = 6.7 ± 0.4 binding sites (at 28 °C). B) 
Right-angle light scattering at [ = 450 nm of a titration of 4 µL of 0.10 mM HS () or 4 µL 
pure buffer () aliquots into a 2.8 mL of a 15.6 µM Fg-TAT-PTD solution, at injection 
intervals of 1 min and 28 °C temperature. C) Fluorescence quenching in 2.8 mL of 15.6 µM 
Fg-TAT-PTD at 28 °C, after serial additions of 4 µL aliquots of 100 µM HS (), 5.2 mM 
KI (), or buffer (), respectively. Experiments were performed under constant stirring. 
 
The employed HS has a maximum of 6.7 ± 0.4 independent binding sites for Fg-TATP. A 
Fg-TATP molecule carries 8 positive charges, which allows a simultaneous interaction with 
several HS molecules. In a solution containing Fg-TATP and HS, crosslinking is likely to 
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occur, depending on the molar ratio of the two compounds. A consequence of crosslinking is 
the formation of aggregates. In our study, the tendency to aggregation was analyzed 
quantitatively as a function of the molar ratio HS/Fg-TATP, using right-angle light scattering. 
Figure 2.9B) shows a titration of Fg-TATP with heparan sulfate. The light scattering intensity 
at 450 nm is reported against the molar ratio HS/Fg-TATP. For the experiment, serial 
injections of 4 µL of HS 0.10 mM were performed at intervals of 1 min into a 15.6 µM 
solution of Fg-TATP. As a control, the same amount of pure buffer was injected instead of 
HS. From the graph in figure 2.9B) it can be observed that a concentration dependent light 
scattering occurs during the titration of Fg-TATP with HS. The light scattering intensity 
resulting from HS addition increased almost linearly up to a molar ratio HS/Fg-TATP = 0.16 
± 0.02 (solid squares). For higher concentrations of HS, the scattering intensity decreased 
again. Differently, the control titration using pure buffer showed no significant light scattering 
(empty squares). 
 
In a similar experiment, the fluorescence intensity of Fg-TATP was measured during a 
titration of the latter compound with HS. Figure 2.9C) shows the occurrence of fluorescence 
quenching of Fg-TATP upon addition of HS in vitro, at 28 °C, under constant stirring. 
Fluorescence intensity decreased during the serial injection of 4 µL aliquots of a 100 µM HS 
solution and reached a plateau for a HS/Fg-TATP molar ratio = 0.14, which corresponds 
virtually to a complete binding of the peptide (as shown by ITC, figure 2.9A)). Further 
addition of heparan sulfate had no longer significant effect on the fluorescence signal. This 
suggests that the presence of negative charges (HS) had a higher effect on the fluorescence 
quenching than the aggregation which disappeared after this equivalence point. As a 
comparison, the same experiment was performed by titrating Fg-TATP with 4 µL aliquots of 
potassium iodide, KI, 5.2 mM (figure 2.9C), empty circles), a commonly used salt for 
quenching the fluorescent signal of fluorescent proteins in a non-denaturing manner. Figure 
2.9C) shows clearly that the fluorescence quenching of HS was more efficient than an 
addition of 0.4 M potassium iodide. As a control, the same titration was performed with 
equivalent amounts of pure buffer (figure 2.9C), empty squares). No consistent reduction of 
the fluorescence intensity was observed in this case. 
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Assessment of Membrane Integrity 
 In order to determine whether the intracellular inclusion of Fg-TAT-PTD was related to an 
impairment of the cytoplasmic membrane of cultured fibroblasts and handling under the 
microscope, we performed a test to assess membrane integrity. A compound known to be 
unable to cross an intact lipid bilayer, namely propidium iodide, was taken for this purpose 
(fluorescence at [ = 617 nm). Cells were kept in the presence of 33 µM propidium iodide for 
4 minutes and then, after appropriate rinse with DMEM, analyzed by confocal microscopy by 
laser scanning at 617 nm. As shown in figure 2.10A), a small portion of cells were leaky (2 
cells visible in the field of view). Directly thereafter, ~ 100 µM Fg-TAT-PTD were injected in 
the perfusion chamber containing the same cell population. Four minutes later, the snapshot 
shown in figure 2.10B) was recorded at 520 nm. No correlation could be observed between 
Fg-TAT-PTD and a lack of membrane integrity. Indeed, from a comparison of figure 2.10A) 
and B), one can easily see that several intact cells not labeled with propidium iodide were able 
to integrate Fg-TAT-PTD. 
 
Figure 2.10. Assessment of Membrane Integrity in cultured NIH3T3 Mouse Fibroblasts.
The correlation of TAT-PTD uptake and possible damage of the cytoplasmic membrane 
was investigated. A) Mouse embryo fibroblasts were incubated for 4 minutes with 33 µM 
propidium iodide, a compound incapable of crossing an intact cytoplasmic membrane. Two 
minutes later, after washing twice with DMEM, cells were observed under a CLS 
microscope at [ = 617 nm. Two cells show incorporation of the dye (red signal). B) The 
same cells were then exposed to ~ 100 µM Fg-TAT-PTD. The image was recorded at [ =
520 nm, 4 minutes from the injection of Fg-TAT-PTD. There is no relation between Fg-
TAT-PTD and propidium iodide incorporation. Bar corresponds to 50 µm. 
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Notes on an Interesting Observation 
 The microliters-injection of Fg-TATP into the microscopic chamber used for confocal 
microscopy measurements requires particular attention. For example, air bubbles have to be 
carefully avoided. Indeed, a small air bubble between two close glass slides can have a 
dramatic effect on the cells grown on the microscopic cover slip. Figure 2.11 shows the 
passage of an air bubble over cultured fibroblasts, NIH-3T3, placed in the space of the 
perfusion chamber, between the two glass slides separated by the spacer of 1 mm (see figure 
2.1, in section 2.3).  
 
Figure 2.11. Effect of an Air Bubble-Induced Hydrostatic Pressure on Fibroblasts 
Monolayers in Microscopic Preparations. The perfusion chamber used for CLSM analysis, 
limited by two glass slides separated by ~ 1 mm, was filled with DMEM. The figures 
sequence shows the effect of the passage of an air bubble over mouse embryo fibroblasts, 
NIH-3T3, in the chamber. The dark shadow in the images taken at time t = 4, 6, 8 seconds 
is the migration front of the bubble. As a consequence of this, the cells were squeezed 
against the glass slide resulting in a drastically different, budding-like form (visible in 
images at t = 6, 8, and 12 s). This artifact is not observable by simple contact with air and it 
is distinctly different from the other observations in DIC microscopy, i.e., aggregates 
formation and Fg-TAT uptake. Bar corresponds to 50 µm. 
 
The front of the air bubble can be easily recognized by the large black front moving, in a few 
seconds, from the left lower to the right upper corner in the DIC images. The hydrostatic 
pressure created by the air bubble between the slides is apparently high enough to squeeze the 
cells. As a result, the fibroblasts assume a completely deformed shape, characterized by a 
pronounced budding of the cell membrane. This feature is distinctly different from the dark 
aggregates produced by Fg-TATP administration, described above. This bubbling effect is 
most pronounced for cells lifted from the glass plate, a situation that occurs periodically 
during the normal cell cycle of adherent cells in cell culture. In contrast, fibroblasts that are 
well spread on the slide, are less morphologically affected by the bubble-induced hydrostatic 
pressure. Indeed, the simple exposure of cells to air, or even artificial drying on a single glass 
plate does not produce a similar effect. 
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2.5 Discussion 
 
The biological mechanism of cell penetrating peptides is quite controversial, and not 
understood. The aim of the present work was to provide a better understanding of the 
interaction of a particular CPP, HIV1-Fg-TAT-PTD, with living mouse embryo fibroblasts, 
NIH-3T3, the cell line chosen as model for our experiments. 
 
Advantages of Confocal versus Epifluorescence Microscopy 
 The special feature of the present investigation was the use of confocal microscopy, which 
allowed a distinction between intracellular and extracellular fluorescence, without the need to 
remove the fluorescent peptide from the extracellular medium or without the need of chemical 
cell fixation. The spatial resolution was sufficient to identify the intracellular label: as shown 
in figure 2.2B), the number of cells that presented Fg-TAT uptake in unwashed preparations 
was not different from that after the removal of extracellular dye (figure 2.2C)). A rinse with 
DMEM is however of some usefulness to the improvement of the image contrast. 
 
A good distinction between intracellular and extracellular fluorescent signal in a 
microscopic preparation in vivo is only possible because of the confocal nature of the images. 
In the measurements reported here, the sampled image plane thickness was 0.5 µm, and was 
the same for the intracellular and extracellular peptide. In contrast, the conventional 
epifluorescence microscopy used in many earlier studies on TATP recorded the fluorescent 
signal from a larger sample thickness. Under such conditions, where the sample depth is 
usually 0.1 - 1 mm, the large amount of fluorescent dye in the extracellular layers above the 
cells is much more abundant than that at the interior of the cells, which have an axial depth in 
the order of ~ 10 µm. In conventional fluorescence microscopy, removal of the extracellular 
Fg-TATP and fixation of cells is a prerequisite for the detection of intracellular signal coming 
from Fg-TATP, thus excluding the possibility to observe the uptake phenomenon and to 
record kinetical data in living cells. 
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The Uptake of CPP is Not an Artifact of Fixation 
The present experiments clearly exclude the possibility that the uptake of CPP is due to an 
artifact occurring during cell fixation with paraformaldehyde or methanol (Lundberg and 
Johansson, 2001),, a procedure currently done for analysis with epifluorescence microscopy. 
The uptake of Fg-TATP showed in figure 2.2B-D is, to our knowledge, the first report of this 
phenomenon in intact, non fixated and living cells. As such, this observation supports more 
than 40 previously published studies on chemically fixated cells (see (Schwarze et al., 2000) 
for a review). The main critic to those studies published in the past was the potential damage 
of the cell membrane upon chemical fixation which could lead to an increased membrane 
permeability (Lundberg and Johansson, 2001). In the present work, any chemical fixation was 
avoided and physiological osmotic conditions were respected. Under these conditions, mouse 
embryo fibroblasts, NIH-3T3, incorporated the peptide Fg-TATP within a very short time, 
i.e., already after a few seconds, and definitely after 4 minutes. Therefore, the present results 
show that the uptake of Fg-TATP is not an artifact of cell fixation (Lundberg and Johansson, 
2001). Moreover, the control experiment reported in figure 2.2A) illustrates that i) the Fg 
marker dye alone is not able to penetrate into the fibroblasts, and that ii) the cell membranes 
were intact before the administration of the fluorescent dye. As shown in Figure 2.10, the 
integrity of the cell membrane was further tested by incubating cells with propidium iodide, a 
commonly used marker to assess plasma membrane integrity. Here, only a few damaged cells 
were present in the preparation (which is a normal fraction of cells grown in culture) as 
evidenced by confocal microscopy at 617 nm, the wavelength of propidium iodide 
fluorescence. However, healthy cells that resisted the uptake of propidium iodide, were able 
to incorporate Fg-TATP. This integrity of the cytoplasmic membrane of fibroblasts before the 
exposure to Fg-TATP cannot support a recent report where only cells with flawed membranes 
showed accumulation of TAT (Kramer and Wunderli-Allenspach, 2003). 
Morphological Alterations occur on The Cytoplasmic Membrane upon TAT-
PTD Exposure 
 Exposure of mouse embryo fibroblasts, NIH-3T3, to the cell penetrating peptide Fg-TAT 
leads to the appearance of “dark spots” on the cell surface, as shown in figure 2.2D). In 
general, there was only one spot per cell, sometimes two. The specific characteristics of the 
DIC (Nomarski, 1955) suggests that such dark spots are actually dense aggregates on the cell 
membrane of fibroblasts. It is interesting to note that the aggregates appeared only on the cells 
that integrated the fluorescent Fg-TATP. This aggregate formation was not reported in 
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previous studies, most probably due to the fixation procedures. Indeed, the aggregates could 
be removed by rinsing the cells 2-3 times with DMEM. Another reason could be the specific 
heparan sulfate/peptide ratio that is needed for aggregate formation (see figure 2.9B)). 
 
However, the aggregate formation observed in vivo is in excellent agreement with 
observations reported in a recent study in vitro (Ziegler and Seelig, 2004). The formation of 
aggregates was observed between the heparan sulfate and the non-fluorescent peptide HIV1 
TAT-PTD. Moreover, it was found that the size of the aggregates was dependent on the molar 
ratio and the order of mixing of the two compounds (the aggregates are larger, if the peptide is 
first in the tube/excess - this way a single HS added will cross-link several peptides). 
 
In analogy to these in vitro observations, the results obtained from the experiments in vivo 
suggested that the dark aggregates shown in figure 2.2 could result from the binding of Fg-
TATP to heparan sulfate or other type of glycosaminoglycans present on the plasma 
membrane of the fibroblasts. This hypothesis was tested by adding exogenous heparan sulfate 
to cells, after their exposure to the fluorescent peptide. As shown in figure 2.7B), the presence 
of free HS resulted in an additional formation of aggregates in the extracellular medium, 
previously limited to the cell plasma membrane only confirming that mixing Fg-TATP to HS 
also produces aggregates. It is important to point out that the free aggregates and those 
anchored to the cell membrane had the same image contrast in DIC microscopy. A major 
difference was the size. The aggregates found in the extracellular space had a diameter < 1 
µm, whereas those present on the cell surface were distinctly bigger, with a diameter < 5 µm. 
This may be due to different molar ratios of the compounds used, the time of exposure of the 
cells to the Fg-TATP (see dynamical observations) and differences in the chemical nature of 
the glycosaminoglycans involved in the reaction. Indeed, the exogenous heparan sulfate added 
consisted of a fraction of HS with a low molecular weight (average MW ~ 14’200), whereas 
heparan sulfate chains extracted from cellular proteoglycans of fibroblasts have molecular 
weights in the order of ~ 45’000 (Turnbull and Gallagher, 1991). 
 
Dynamics of Fg-TAT-PTD Incorporation by Fibroblasts 
 In the present work, it has been shown that the Fg-TATP is taken up by living mouse 
embryo fibroblasts, NIH-3T3, in a very short time. Indeed, fluorescent labeling of the nucleus 
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occurred already 4 seconds after the exposure to the peptide. Interestingly, and as already 
reported in previous works (Frankel and Pabo, 1988; Green et al., 1988; Hallbrink et al., 
2001), around 50 % of cells did not incorporate the Fg-TATP. The reason for this difference 
remains unclear yet. It could be speculated that this is due to a differential expression of 
glycosaminoglycans on the cell surface, at different steps of the cell cycle. The rate constant 
for the velocity of labeling of the cell population, calculated from our results as k = 0.007/s is 
also in agreement with what reported in other studies (Frankel and Pabo, 1988; Green et al., 
1988). However the uptake in the experiments reported here was faster than that obtained 
from studies based on a cell-coulter assay using a fluorescence quenching test, where a first-
order rate constant for TATP uptake was estimated around 0.0003/s (Hallbrink et al., 2001). 
Such differences could be attributed to experimental conditions chosen for the investigation 
and also to the cell strain employed. 
 
The temporal resolution obtained in our experiments allowed observations of the growth 
of the aggregates of Fg-TATP on the cell membrane. The aggregates preceded the appearance 
of the intracellular fluorescence by some seconds, and increased in size as a function of the 
contact time (afer 4 min up to ~ 5 µm). This phenomenon could suggest the hypothesis of an 
initial homogeneous distribution of glycosaminoglycans on the cell membrane, which could 
be consecutively recruited to a particular region of the cell, with a particularly favorable 
electrostatic environment for the binding of polycationic compounds like TATP. 
 
The accumulation of large aggregates on the cell membrane displays certainly an 
unphysiological condition and, as such, may be toxic for the cells. This is supported by 
previous reports. A 24 hours exposure of HeLa cells to similar concentrations of TATP as 
employed here was shown to induce cell necrosis in 60 % of the cells. 
 
Inhibition of Fg-TATP Uptake by Heparan Sulfate 
 The Inhibition of Fg-TATP Uptake by heparan sulfate is a further indication of the role of 
cellular glycosaminoglycans such as heparan sulfate for CPP uptake. The inhibition of Fg-
TATP uptake by the addition of exogenous HS is, however, not unique. In a previous work, 
the cellular uptake of cationic polylysine could be inhibited by a simultaneous administration 
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of exogenous heparin (Morad et al., 1984), an intracellular compound of similar structure than 
extracellular heparan sulfate. 
Fluorescence Quenching by Heparan Sulfate 
The fluorescent signal was an important parameter for the qualitative evaluation of the 
measurements. However, the intensity of confocal images depends on a variety of parameters 
and therefore it cannot be exploited for a quantitative evaluation of the Fg-TATP 
concentration in the cells or in the extracellular space: A possible binding to cellular 
compounds, such as heparan sulfate, could lead to fluorescence quenching and thus distort the 
analysis. 
Enzymatic Removal of HS results in a Decrease of TATP Uptake. 
 Further evidence that the recognition of Fg-TATP by cells occurs through a interaction 
with glycosaminoglycans was provided by the experiments shown in figure 2.7D). In these 
experiments, cells were treated with heparinase III prior to the administration of Fg-TAT. 
Under these conditions, a decrease in the number of labeled fibroblasts by ~ 30 % was 
observed. The fact, that the inhibition upon enzymatic digestion was not complete, suggests 
that other similar membrane polysaccharides, such as chondroitin sulfate, could be involved 
in the recognition process or that heparinase treatments cannot achieve a total removal of the 
glycosaminoglycans, for example because of sterical hinderance (Schulz et al., 1998).  
 
The role of glycosaminoglycans for the uptake of CPP is still a matter of debate. One of 
the first studies on TAT uptake (Mann and Frankel, 1991) proposed that the absorption of 
TAT proceeded via non-specific endocytosis, and that glycosaminoglycans were not involved 
in the uptake, because heparinase treatment could not inhibit TAT uptake completely (in 
analogy to the present experiments). Alternative uptake mechanisms were proposed by other 
groups (Derossi et al., 1996; Prochiantz, 2000) such as lipid binding. However, an increasing 
number of studies is now supporting the idea that TAT uptake proceeds through a specific 
binding to heparan sulfate (Belting, 2003; Rusnati et al., 1997; Sandgren et al., 2002; Tyagi et 
al., 2001). The findings of the present work are also in favor of the hypothesis of specific 
binding to HS. 
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TAT can alter Cellular Physiology 
 Only a few studies investigated the toxicity of TAT-PTD. In one work, it was observed 
that 100 µM of TAT-PTD induced necrosis in 60 % of cells after a 24 hours exposure time. 
However, no acute toxic effects were observed for exposure times < 30 min (Vives et al., 
1997). Observations made in the present work by microphysiometry, clearly show that TAT-
PTD was able to decrease the overall cellular metabolism of mouse embryo fibroblasts, NIH-
3T3. This phenomenon is an indicator of some cytotoxicity. However, the acute cytotoxic 
effect could be rapidly reversed when the peptide was removed from the culture medium. On 
the other hand, repeated exposures to high concentrations of TAT-PTD produced irreversible 
cell changes, decreasing permanently their basal ECAR. Combining CLSM and Cytosensor 
observations, one can conclude that the adsorption of TAT-PTD onto the plasma membrane 
results in a decrease of the metabolic activity. The molecular nature of this process remains 
unknown and could be a blocking of ion channels by aggregate formation, a transient 
membrane structure distortion (resulting in a general malfunctioning of membrane related 
energy-driven processes), or other mechanisms. 
 
Another interesting correlation can be made between CLSM imaging with the fluorescent 
TAT-PTD analogue and functional microphysiometry obtained with TAT-PTD. The presence 
of the glycosaminoglycan heparan sulfate could inhibit both the Fg-TAT-PTD uptake in the 
image experiments and the decrease of the TAT-PTD-induced extracellular acidification rate. 
These observations point again towards an interaction of TAT-PTD with cells associated 
GAGs because a competitive inhibition occurs between exogenous HS and the putative 
binding partners of TAT-PTD on the cells membrane. 
 
The toxicity of TAT-PTD is a property of the polypeptide only. Adding of the individual 
amino acids in their monomeric form and at concentrations employed for TAT-PTD does not 
produce any decreases in the ECAR. This suggests that cross-linking of TAT-PTD with the 
negatively charged binding partners is necessary for the internalization process, as well as for 
the ECAR alteration. It is also noteworthy that some amino acid sequences can act as key 
signals, for example for the entry into the cellular nucleus (Weis, 2003). As seen in CLSM, 
the nuclear internalization of Fg-TAT-PTD occurred also within seconds. 
 The observation of the fast intracellular labelling of fibroblasts with Fg-TAT-PTD, in 
particular the fast concentration of the dye inside the nucleus, may also explain the slow-
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acting toxicity of this peptide. Indeed, compounds with high DNA affinity, such as ethidium 
bromide, are well known for their mutagenic activity. Because of its large positive charges, 
TAT-PTD may bind very efficiently to the negatively charged nuclear DNA. Therefore, a 
mutagenic activity of TAT-PTD could be possible. 
 
2.6 Conclusion 
Mechanism of TAT-PTD Cellular Uptake 
 The aim of the present study was to investigate the mechanism(s) of the incorporation of 
HIV1 TAT-PTD into living cells. To this purpose, in vivo confocal microscopy and 
microphysiometry experiments were performed, extended by in vitro observations using 
isothermal titration calorimetry, right-angle light scattering and fluorescence quenching tests. 
Specifically we aimed at testing whether (i) cellular glycosaminoglycans could be involved in 
the CPP uptake, and ii) whether CPP incorporation is an artifact of cell fixations. 
 
In the present work the second point could be excluded by performing measurements in 
vivo, avoiding chemical fixation. An uptake of fluorescent FITC-labeled HIV1-TATP derivate 
was clearly observed under in vivo conditions. In particular, the uptake of the fluorescent 
TAT-PTD occurred within a few seconds from the time of administration. The appearance of 
the intracellular labeling was preceded by the formation of dense aggregates, exclusively 
associated with the cell surface of labeled cells. Neither aggregate formation nor intracellular 
fluorescence were observed for cells incubated only with the Fg-marker, indicating the 
specific role of the TATP fragment for transport through the membrane. 
 
The involvement of GAGs was tested to identify the nature of the observed dense 
aggregates. Co-administration of exogenous heparan sulfate with the peptide inhibited both 
the incorporation of TAT-PTD and the formation of aggregates. Moreover, heparan sulfate 
induced fluorescence quenching of Fg-TATP and the formation of aggregates in the 
extracellular medium. These aggregates had similar optical features than those observed on 
the cell membrane of fibroblasts. The same effects could be reproduced in vitro (isolated 
systems of heparan sulfate and Fg-TATP). 
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 The enzymatic removal of heparan sulfate GAGs from the fibroblasts led to similar 
results, i.e., the inhibition of aggregate formation and TATP uptake.  
 
To test cellular function, microphysiometry was employed and confirmed an activity of 
TATP on mouse embryo fibroblasts (NIH-3T3) on a similar time scale as observed with 
confocal microscopy. An exposure to the CPP resulted in a rapid, concentration-dependent 
decrease of the extracellular acidification rate (ECAR) of the fibroblasts. The decrease of the 
ECAR could be inhibited by a simultaneous administration of exogenous heparan sulfate. 
However, the ECAR decrease could not be mimicked by an equivalent concentrations of the 
same amino acids added as monomers. 
 
Ryser, in his work published in 1968 (Ryser, 1968), stressed already the difference 
between adsorption and uptake. In our study, these two concepts could be translated into A) 
“aggregate formation” and B) “fluorescent label internalization”. B) is most probably the 
consequence of A), and A) seems to require the presence of the GAG heparan sulfate in order 
to occur. These findings, in agreement with others (Tyagi et al., 2001), suggest that also the 
internalization of HIV-1 requires an adsorption at the cell surface with heparan sulfate or 
similar proteoglycans of the glycocalix. The aggregates observed in the present work are new 
findings for this particular CPP. However, a similar phenomenon has been reported in the past 
for specific antibodies against heparan sulfate (Martinho et al., 1996) and its proteoglycan 
syndecan-1 (Carey et al., 1994). Such antibodies induced aggregates on cells and enhanced 
the cellular uptake, including the transfer to the cell nucleus (Ishihara et al., 1986). 
Importantly, this phenomenon was also observed at 4 °C (Martinho et al., 1996) and is 
therefore in surprisingly close analogy to the reported, temperature-independence of the TAT 
uptake (Vives et al., 1997) and polylysine uptake (Ryser, 1968). 
 
While the adsorptive process of TATP seems to be confirmed with these experiments, it 
could not be answered how the subsequent internalization mechanism proceeds. It could be a 
new type of transport that include a rapid translocation to the nucleus, or a more classical 
adsorptive endocytosis. However, inverted micelle formation with lipids (Derossi et al., 1996; 
Prochiantz, 2000) appears to be very unlikely.  
 
Therefore, the evident adsorption reported in this work strengthens the hypothesis of 
endocytosis as a likely mechanism for the uptake of CPPs. Adsorptive endocytosis should 
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involve the formation of endosomes, which were seen in fixated cells (Console et al., 2003), 
but could not be observed with the techniques employed in the present study.  
 
Finally, as seen in microphysiometry experiments, the potential toxicity of CPP should be 
seriously taken into account and caution should be used before the formulation of attractive 
clinical methods for the improvement of drug delivery and gene therapies involving these 
CPPs. 
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Part Three: Functional Magnetic Resonance Imaging of 
the Mouse Brain 
General Introduction 
Functional magnetic resonance (fMRI) is one of the most modern imaging applications 
based on nuclear magnetic resonance (NMR). It is not the aim of this work to present the 
theory of NMR in general, as this is extensively reported in textbooks (Levitt, 2001). In order 
to outline the complexity of the experiments performed in the present project it is, however, 
necessary to shortly review the historical steps leading to the fMRI development both from 
the technical as well as from the biological point of view.  
 
The discovery of NMR, reported for the first time in 1946 (Bloch, 1946; Bloch et al., 
1946; Bloch et al., 1946; Purcell et al., 1946), awarded Edward Purcell and Felix Bloch with 
the Nobel Prize in Physics 1952. Twenty-five years later the first NMR experiment on living 
organisms was performed by Raymond Damadian (Damadian, 1971). In this experiment, 
Damadian found that the relaxation times of malignant tumors differed significantly from 
those of normal tissues, suggesting the potential use of 1H-NMR for clinical diagnostics. In 
the same period, Moon and Richards (Moon and Richards, 1973) showed how the 
intracellular pH could be determined in intact erythrocytes by chemical shift differences using 
high-resolution 31P-NMR spectroscopy.  
 
Between 1973 and 1974, Lauterbur (Lauterbur, 1973) and Mansfield (Garroway et al., 
1974) described the first NMR imaging experiment (or MRI, for Magnetic Resonance 
Imaging). This technique involved the superposition of position-dependent magnetic fields 
gradients to the static magnetic field, which allowed the reconstruction of the spatial 
distribution of spins in the form of an image. Further improvements of planar imaging 
techniques, included the 2-dimensional Fourier imaging technique (2DFT), introduced in 
1975 by Kumar, Welti and Ernst (Kumar et al., 1975; Kumar et al., 1975). Pulsed NMR in 
combination with Fourier Transform represents nowadays the heart of modern NMR 
experiments. The achievements of Richard Ernst in pulsed Fourier Transform NMR and MRI 
were acknowledged with the Nobel Prize in Chemistry 1991. The Nobel laureates in medicine 
were awarded to Mansfield and Lauterbur just recently (2003).  
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In 1977, Damadian demonstrated MRI of the whole body. In the same year, Peter 
Mansfield developed the echo-planar imaging (EPI) (Mansfield, 1977; Mansfield and 
Maudsley, 1977; Mansfield and Maudsley, 1977), a technique that allowed NMR imaging at 
video rates (30 ms / image). 
In 1980, Edelstein and coworkers adapted Ernst's technique to the imaging of the body 
(Edelstein et al., 1980; Edelstein et al., 1980; Hutchison et al., 1980). At this time, the 
temporal resolution of image acquisition was in the order of five minutes. By 1986, the 
imaging time could be reduced to about five seconds mainly as a result of stronger magnetic 
fields (no longer need for averaging) and faster switching gradients (for the use of EPI). 
 
Since then, improvement of technical aspects, e.g. superconducting technologies, allowed 
the construction of scanners with higher and more homogeneous magnetic fields. In 1987 
echo-planar sequences could be used to image a single cardiac cycle in real-time (Chapman et 
al., 1987). In the same year Charles Dumoulin was perfecting magnetic resonance 
angiography (MRA), which allowed imaging of flowing blood without the use of contrast 
agents (Dumoulin et al., 1987; Dumoulin et al., 1987; Wood et al., 1987). 
 
Functional MRI (fMRI) was developed in 1993 and included the use of Gadolinium 
(however, the effect of Gadolinium as contrast agent for MRI was already found in 1988 
(Villringer et al., 1988)). Functional MRI allows the mapping of activated regions of a living 
organism in response to a neuronal excitation. In neurosciences the development of fMRI 
opened up a new non-invasive way to map the activated brain regions responsible for 
cognitive and motor processes.  
 
In parallel, other imaging techniques were developed. In 1994, researchers at the State 
University of New York at Stony Brook and Princeton University developed MRI of 
hyperpolarized 129Xe gas for lung imaging (Albert et al., 1994). Lung imaging is a challenge 
because the thin alveoli have many air-to-tissue interfaces so that the local magnetic field is 
disturbed (susceptibility differences) resulting in non-coherent spins for MRI. Nowadays, 
NMR spectroscopy and MRI are world-wide used techniques, which find applications from 
routine clinical diagnostic and surgery (open scanners), to basic science solid-state 
spectroscopy, and cognitive sciences. 
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Chapter 3. fMRI of the Murine Brain 
3.1 Introduction 
Functional MRI finds its main application in brain research and neurocognitive studies 
using fMRI have rapidly increased in the last few years. The technique is based on the 
finding, that tissue activation causes changes of blood flow (hemodynamic modulations) and 
oxygen consumption. Various phenomena based on hemodynamic modulations of activated 
brain regions are exploited for fMRI acquisitions: i) blood-oxygenation level dependent 
(BOLD) effect (Ogawa et al., 1992), ii) arterial spin labeling (ASL) techniques, based on T1 in 
cerebral blood flow (CBF) (Kwong et al., 1992), and iii) relative cerebral blood volume 
differences (rCBV) (Belliveau et al., 1991; Belliveau et al., 1990). The latter method, also 
called bolus technique, requires the use of intravascular contrast agents that alter the magnetic 
susceptibility of the microscopic vessels. 
 
The promise of fMRI for mapping brain function extends also to animal models and thus 
has the potential to link fundamental and clinical research. The first application of fMRI to 
animal models goes back to Hyder and coworkers (Hyder et al., 1994) who could localize 
with BOLD contrast an activated volume of brain tissue in chloralose-anaesthetized rats 
during electrical stimulation of the forepaw. A similar experiment in rats highlighted the 
correlation between BOLD response and the frequency of electrical peripheral stimulation 
(Gyngell et al., 1996). These studies, together with T2*-weighted imaging (Brinker et al., 
1999), provided evidence that the hemodynamic signal observed with fMRI is tightly coupled 
to the neural electrical activity in the activated brain areas. This correlation is called 
neurovascular coupling.
As a result, fMRI in rat models has been extended to study cerebral tissue pathologies. 
Functional alterations upon pharmacological stimulation with the GABAA antagonist 
bicuculline could be observed in cases of ischemic seizures (Dijkhuizen et al., 2000; Hoehn et 
al., 2001; Reese et al., 2000). These findings highlighted the potential of fMRI for pre-clinical 
research. It is a non-invasive imaging modality able to provide functional, i.e. physiological, 
readouts for the assessment of brain function even in the absence of structural evidences for 
tissue impairment (see (Rudin et al., 1999) for review). 
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Other contrast methods, based on T1 (ASL) or T2 (CBV) weighted imaging, have been 
tested in fMRI preclinical studies on animals (see (Beckmann et al., 2001) for review), both 
during electrical (Kerskens et al., 1996; Silva et al., 1999) and pharmacological (Chen et al., 
2001) stimulation paradigms. Contrast agent enhanced fMRI techniques were shown to 
provide a signal-to-noise ratio (SNR) 1.5 to 6 times higher than BOLD imaging, depending on 
the magnetic field strength of the scanner (Mandeville et al., 1998). 
 
In parallel to the development of fMRI, an increasing number of animal models for 
various diseases have emerged, mainly based on transgenic mice. This requires further 
technical improvements due to the smaller brain size in mice as compared to rats. Indeed, the 
sensitivity of MR scans decreases with decreasing voxel size which directly affects the spatial 
resolution of the MR image obtained. This problem can be compensated by longer acquisition 
times (higher number of averaged scans). However, the fact that in vivo MRI with animals 
requires the employment of systemic anaesthesia limits the total experimental time. The 
monitoring and controlling of physiological parameters (body temperature, respiration, blood 
gas levels) is another fundamental requirement for performing fMRI on anaesthetized animals 
and this is still a challenge considering the small size of mice. Recently, the first fMRI studies 
on mice have been published by Müggler and coworkers (Mueggler et al., 2001; Mueggler et 
al., 2003; Mueggler et al., 2002). Using a state of the art equipment, these works reported for 
the first time relative CBV variations in healthy mice, using fMRI in response to a 
pharmacological stimulation (Mueggler et al., 2001). Subsequently, the same technique was 
applied to detect hemodynamic response impairments in transgenic amyloid precursor protein 
(APP23) murine models, using an electrical stimulation paradigm (Mueggler et al., 2002). 
The evolution of the hemodynamic response could be determined in a long-time scheduled 
experiment with the same model (Mueggler et al., 2003). Such methods will replace in part 
invasive techniques, and thus improve the animal welfare and decrease the number of animals 
that are currently employed in basic research. 
 
The aim of the present work was to apply functional MR imaging to the mouse brain, 
using a transgenic mouse model to measure the brain response to the neuro-transmitter 
gamma-amino-butyric acid (GABA). A first goal was to identify in vivo cerebral areas related 
to GABA(B) receptor activation. For this purpose, a pharmacological stimulation paradigm 
(using the acknowledged GABA agonist baclofen) was chosen. A second goal was to assess 
with fMRI functional differences between wild type and GABA(B)-R1-/- knock-out mice. In 
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1997, a gamma-amino-butyric acid receptor type B (GABA(B)) knock out mouse model was 
produced for the first time (Kaupmann et al., 1997). Mice with a GABA(B)-R1 knock out 
genotype present a number of phenotypic peculiarities, i.e., hyperactivity (typical clock-wise 
compulsive running in the cage), epileptic seizures, almost permanent piloerection (which is 
an indicator of a frightened attitude) and disordered behaviour (in burrow organization, social 
life). As a third goal, we investigated whether drugs suspected to interact with GABAB 
receptors act on specific brain regions. Among them was -hydroxy-butyrate (GHB), a 
precursor of -amino-butyric-acid (GABA). Recently, GHB has become a popular party drug. 
Indeed, people ingesting GHB are subject to hypnotic-like cognitive and emotional 
alterations, not devoid of side effects. Finally, the potential use of in vivo 13C-NMR 
spectroscopy to study the GHB metabolism in mice was evaluated. 
96 
3.2 Theory  
Measuring Relative Cerebral Blood Volume Changes 
 
Cerebral blood volume changes can be measured with fMRI with two different methods, 
using either exogenous intravascular contrast agents that can affect the protons relaxivity 
(Moseley et al., 1992) or the local magnetic susceptibility (Hamberg et al., 1996). The first 
method involves the fast injection of a contrast agent into the cardiovascular system of the 
organism. Subsequently, the signal drop during the first pass of the contrast agent through the 
microvasculature is quantified (see (Rudin et al., 1997) for a comparison between intra-
arterial and intravenous injection). This method is called Bolus technique or dynamic 
susceptibility contrast technique (for a detailed description of tracer kinetics, see (Buxton, 
2002), page 318). In short, this technique correlates the variation of the effective spin-spin 
relaxivity, eR2*, with the cerebral blood volume, CBV: 
 
20
( )R t dt CBV

   [1] 
 
According to this equation, CBV maps1 can be calculated from measured changes in eR2*
performed pixel-by-pixel. This relation is valid, because eR2* is proportional to the local 
concentration of the tracer, CT(t), that changes as a function of CBV. However, it seems that 
for spin-echo studies the relationship between eR2 and CT(t) is non-linear, which makes the 
calculation of the relative CBV (rCBV) less accurate compared to other techniques. 
 
The second method assumes a stable plasma concentration of the contrast agent in the 
brain. After an intravenous (i.v.) injection, the concentration of the intravascular contrast 
agent reaches a steady-state. The non-linear relationship between eR2 (or eR2*) and CT(t) 
does no longer affect the accuracy, because CT(t) is theoretically constant. In practice, the 
stability of steady-state depends on the half-life of the contrast agent in the vascular system, 
which can become a limiting factor in the duration of an experiment. The use of intravascular 
contrast agents with a long half-life in blood is recommended. 
 
1 CBV maps are images where the image intensity represents a certain CBV value. 
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 The measured NMR signal intensity in a particular brain area is influenced by the local 
contrast agent concentration that changes when the regional cerebral blood volume (CBV) 
changes. Consequently, changes in signal amplitude reflect changes of the rCBV in that brain 
area. This method is called steady-state contrast-enhanced technique.
After injection of the contrast agent, the transverse relaxation rate (eR2 or eR2*) in the 
animal brain varies from the pre-injection baseline. This change is proportional to the local 
CBV, times some function (f) of the plasma concentration of the paramagnetic contrast agent 
[P] (Belliveau et al., 1990); (Boxerman et al., 1995). Under steady-state conditions, the 
plasma concentration of the contrast agent is constant and the transverse relaxation rate is 
directly proportional to the CBV: 
 
2 ( ) ( )R t k CBV t
 =  [2] 
 
where the constant k depends on the injected amount of the contrast agent. 
 
Relative changes of CBV (%), for example during a functional stimulus, can be calculated 
assuming monoexponential decay of the MR signal and neglecting other interferences, e.g. 
BOLD effect: 
 
( )
0( )
TE K CBV tS t S e  = [3] 
 
where S0 is the equilibrium signal before injection of contrast agent, TE is the echo delay and 
k·CBV(t) describes the transverse relaxation rate R2 (= 1/T2) or R2* (= 1/T2*), for SE or GRE 
acquisitions, respectively. 
 
In functional imaging, the relative CBV change related to the functional stimulus can be 
calculated by correlating the signal intensities measured before the injection of the contrast 
agent, S0, the signal at steady-state after the injection of the contrast agent, S(0), and the 
signal during the functional stimulation, S(f). The resulting fractional volume change eCBV 
= CBV(t) – CBV(0) can thus be expressed as 
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During exogenous contrast enhanced functional imaging, an opposing effect can occur 
between increases in eR2* due to the increased blood volume and decreases in eR2* due to 
endogenous (deoxyhemoglobin) agent (BOLD effects). Therefore, sufficiently high amounts 
of exogenous contrast agent must be used in order to induce relaxation rate changes that 
significantly exceed BOLD effects. Recently, Scheffler and coworkers (Scheffler et al., 1999) 
could quantify rCBV changes and blood oxygenation level and thus separate the competing 
influences of oxygenation and blood volume changes in T2*-weighted images, by using an 
acoustic stimulation paradigm in humans. 
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 3.3 Material and Methods 
 
All animal experiments were performed according to the Swiss federal laws for animal 
protection (animal experiment licence #1897: “GABA-B Rezeptorstudien am Mausmodell”). 
 
Animal Models 
Wild type Balb/c and GABAB(1) – deficient (Balb/c GABAB(1)-/-) mice were kindly 
provided by Prof. Dr. Bernhard Bettler (Pharmazentrum, Basel, CH). For the transformation, 
the GABAB(1)  gene of Balb/c embryonic stem (ES) cells (Dinkel et al., 1999) was knocked 
out by homologous recombination with a targeting vector containing a neomycin (neo) 
resistance marker flanked by 4.6 and 1.4 kb of 129Sv DNA. The targeted mutagenesis caused 
a deletion of a 8.5 kb in the GABAB(1)  locus carrying the exons 7, 8, 9 and 10 which, together 
with exons 3-15, are responsible for the encoding of the N-terminal and transmembrane (TM) 
domains 1-6 of the polypeptidic receptor. The mutant genome was therefore isogenic for all 
Balb/c genes, except the 6kb recombined 129Sv DNA fragment that replaced the 8.5 kb of the 
GABAB(1) allele. The resulting GABAB(1)+/- Balb/c cells were injected into C57BL/6 
blastocysts and chimeric males were crossed with Balb/c females. The resulting F1 generation 
of inbred Balb/c GABAB(1)+/- mutant mice was thus heterozygous only for the GABAB(1) 
mutant allele. Finally, homozygous knocked-out Balb/c GABAB(1)-/- mice were obtained at 
Mendelian ratio from Balb/c GABAB(1)+/- X Balb/c GABAB(1)+/- breeding pairs (Schuler et al., 
2001). 
 
Balb/c GABAB(1)-/- mice present several phenotypic peculiarities at molecular, 
physiological and behavioural level, e.g., loss of detectable GABAB binding sites and GABA-
induced GTP[35S] binding, downregulation of the GABAB(2) subunit, loss of both pre- and 
postsynaptic GABAB responses, spontaneous epileptiform activity, hyperlocomotion, 
hyperalgesia and impairments in passive avoidance learning (Schuler et al., 2001). 
 
Compounds 
Sterile isotonic (0.9% NaCl, which is 9 g/L) NaCl solution was purchased from Fresenius 
(Stans, CH), Isoflurane was from Abbot (Cham, CH), Endorem (11.2 mg/mL) was from 
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Guerbet (France), -amino butyric acid (GABA) and -butyrolactone (GBL) were from Fluka,
baclofen was from Novartis (Basel) and 1-13C-labelled -hydroxy-butyrate was synthesized in 
our laboratory by Peter Ganz.  
 
NMR and MRI Scanners 
In Vivo functional Magnetic Resonance Imaging 
MRI and fMRI experiments were performed on a Biospec 70/20 (Bruker, Karlsruhe, 
Germany) with a gradient system of 14 cm inner diameter and a permanent magnetic field 
strength of 7 Tesla. All directives for the pulse sequences were managed through the Bruker 
manufactured softwares XwinNMR v3.1 and Paravision v2.0/v3.0 running on both Unix and 
Linux platforms. 
In Vitro High Resolution 1H and 13C NMR spectroscopy 
1H and 13C NMR spectroscopy of the compounds used were conducted on a Bruker DRX 
400 (9.4 Tesla) and experimental conditions were chosen as described in chapter 1. 
 
Animal Preparation for fMRI 
Prior to the measurements, mice were kept in type II cages (2-3 animals per cage) in a 
quiet environment with 12 hours dark/light cycles and had access to fresh water and complete 
food ad libitum.
For the experiments, wild type Balb/c mice and knock-out Balb/c GABAB(1)-/- mice were 
initially anaesthetized in a chamber where a gas mixture of 3 % Isoflurane in 200 mL·min-1 O2
and 600 mL·min-1 N2O was dispensed. Mice were then transferred onto a home-made cradle 
(wood and plexiglas) and kept under 1.5-2.5 % isoflurane anaesthesia through a mask. Mouse 
eyes were kept humid with eye protective cream (Cibavision), to avoid damage from drying 
during the anaesthesia. For the infusions, a cannulation of the tail-vein was performed with a 
30-gauge needle (Microlance3, 0.3 x 13 mm) connected to a syringe by a polyethylene tube 
(inner diameter = 0.4 mm). After cannulation, mice were carefully positioned in the cradle 
with removable adhesive tape. Particular care was necessary to immobilize the head (to avoid 
MRI motion artifacts), yet allowing free respiration at all times. A home-made respiration 
sensor was leant on the mouse abdomen, to record respiration frequency through 
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diaphragmatic/abdominal mouvements and adapt the dept of the anaesthesia. Finally, the 
prepared animal was introduced into the scanner for fMRI. 
 
When the homoeothermic mouse heating system became available (formerly only water-
operated system for rats), the cradle was replaced by a precasted electrical heating blanket and 
a lubricated rectal thermometer connected with the feedback heating system was employed to 
stabilize the mouse body temperature. 
 
MRI Protocol 
The radiofrequency probe was an Alderman-Grant of 30 mm inner diameter. The imaging 
protocol for relative CBV changes visualization consisted of a fast spin-echo relaxation 
enhancement (RARE) sequence. Parameters: TR = 1100 ms; effective TE = 45 ms; RARE-
factor = 8; FOV = 1.6 x 1.6 cm2; matrix dimension (MTX) = 128 x 128; slice thickness 
(SLTH) = 1 mm; frequency sweep width = 50 kHz; 7 slices, resulting in an acquisition time of 
18 s; number of averages/averaged experiments NA = 2 and NAE = 10, respectively, resulting 
in a total acquisition time of 6 min. 
fMRI Protocol 
The protocol developed for functional NMR imaging of relative CBV changes, consisted 
of an automated repetition (20 times) of the above described series, resulting in a total 
experimental duration of 2 hours. After 3 scans (18 min) of a pre-contrast base line, 50 mg 
Fe/kg body weight of superferromagnetic nanoparticles (Endorem®) were injected i.v. as 
contrast agent. After 4 more scans (24 min) to reach stady state, 5 mg baclofen/kg body 
weight or a correspondent volume of isotonic NaCl solution (placebo) were infused through 
the intravenous (i.v.) tail cannulation. 
 
Analysis of fMRI Acquisitions 
Images were analyzed according to signal intensity changes over time using the software 
BioMap 2.x (Martin Rausch, Novartis-Pharma AG, Basel) and CBVrel changes were 
calculated according to eq. 4.  
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Monitoring of Physiological Parameters 
Anaesthesia 
Mice were anaesthetized with a gas mixture of 0.7-3 % Isoflurane in 200 mL·min-1 O2 and 
600 mL·min-1 N2O, through a face mask. The animals were allowed to breathe spontaneously 
and the isoflurane concentration was regulated in order to keep a constant breathing rate of ~ 
60 min-1.
Respiration 
 The monitoring of the breathing rate was achieved using a home-made mechanical/fiber 
optic sensor, connected to the computer. The sensor (consisting of a thin plexiglas strip 
connected to a light gate) was carefully situated on the abdomen of the mouse, near the costal 
arch. Shifts of the plexiglas strip induced by the respiratory movements, in turn interrupted 
the passage of a fiber optic beam and were monitored on the computer. 
Temperature 
In initial experiments, regulation of the mouse body temperature could not be made. In a 
later moment, a homoeothermic blanket system (Harvard Apparatus, Holliston, MA, USA) 
became available. Here, mice were placed backside on the heating blanked and a rectal 
thermometer was used to record the body temperature. The thermometer was connected with 
a feedback system aiming at a stable measured temperature of 37 °C. 
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3.4 Results 
 
The purpose of the present chapter was to develop a fMRI protocol to identify specific 
activated brain regions in mice after pharmacological stimulation of GABA-B receptors. 
 
Determination of Tissue-specific Relaxation Times in the Mouse Brain 
 The sensitivity to detect minute changes in CBV measurements is highest if the effective 
TE of the fMRI sequence is chosen close to the T2 of the tissue (Figure 3.1). 
 
Fig. 3.1. Decay of the transverse magnetization Mxy after a spin excitation as a function of 
the relaxation times. Two spin populations with different relaxation times T2 = 60 and 100 
ms were plotted. Here, changes in R2 can be best detected at a time point where the 
difference between the relaxation curves is maximized, i.e. exactly between both relaxation 
times (here 80 ms). 
 
Therefore, determination of T2 in different brain areas are required especially with addition of 
the contrast agent Endorem® (see Figure 3.2)  
For this purpose, the relaxation times of different brain areas were measured by using a 
multislice-multiecho spin echo (MSME) imaging sequence, where the echo spacing between 
consecutive images were set to a 20 ms spacing. This sequence is a modified Carr-Purcell-
Meiboom-Gill (CPMG) sequence where the spins are first excited with a 90° pulse and the 
signal is repeatedly measured during consecutive 180° refocusing pulses:  
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Figure 3.2. Determination of tissue-specific T2 in the Mouse Brain using a multislice-
multiecho (MSME) spin-echo MRI sequence with a echo spacing of TE = n·20 ms between 
adjacent images; taken without (upper row) or after (lower row) intravenous injection of the 
intravascular contrast agent Endorem® (50 mg/kg body weight). Field strength B = 7T, TR 
= 2500 ms. The decay of the MR signal (due to the differential relaxation rates) in different 
brain areas represents a critical factor to choose (i) an optimal TE in fMRI  (ii) the 
preservation of sufficient signal from the fast-relaxing cerebral regions must be chosen. 
 
The images of Figure 3.2 show that the NMR signal in some brain areas relaxes slower 
than in others. A quantitative analysis of the image intensity in the different brain regions was 
fitted to M = M0[exp(-t/T2)]. Long relaxation times were found in the  brain areas with high 
water motility, such as ventricle (average T2 of 170 ms and 125 ms for normal brain and in 
the presence of 50 mg/kg body weight Endorem®, respectively) or a high fat content (average 
T2 = 90 and 80 ms). The shortest relaxation rates could be observed in the muscular tissues 
where the water motility is restricted (average T2 = 35 and 25 ms). Data are reported in 
Figure 3.3. 
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Figure 3.3. Tissue-specific Relaxation Time T2 in different Brain Areas. The spin-spin 
relaxation time T2 at 7T was calculated from MSME MRI scans in several brain areas of 
the mouse prior and after i.v. injection of 50 mg/kg body weight of the intravascular 
superparamagnetic contrast agent (Endorem®) according to the monoexponential decay 
function M = M0[exp(-t/T2)]. Average values resulting from the analysis are reported in the 
table on the right. 
 
As reported by Kaupmann and coworkers (Kaupmann et al., 1997), GABAB receptors are 
distributed homogeneously throughout the brain (see Figure 3.4). However, it is not possible 
to foresee which specific anatomical regions are activated upon systemic baclofen 
administration - an agonist of the GABAB receptor. The fact, that analogues compounds to 
baclofen, such as GHB (also found to be a weak GABAB agonist) affects emotional and 
sensorial processes, may suggest an involvement of brain regions connected to the limbic 
system. For our experiments, we thus adapted the TE of the RARE sequence to the T2 
measured in the cortical and amygdaloid regions in the presence of endorem (average T2 of 
60 ms). At the same time, however, we performed multislice (7) scans, in order to cover an 
extensive brain volume. 
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Figure 3.4 In situ hybridization analysis of GABAB-R1 transcripts in rat brain. Tissue 
sections were hybridized to 35S-labelled antisense probes. Darkfield illuminations of 
representative autoradiograms of coronal (a,b) and horizontal (e) sections. A) dorsal 
hippocampus plane; b) ventral hippocampus plane; c) dorsal tier of the brain. Transcripts 
are abundant in all cerebral cortical layers, especially in the layer IVb (LVIb), and many 
subcortical structures. CA1-CA3: pyramidal cell layer subfields of hippocampus; DG: 
dentate gyrus; MH: medial habenula; MG: nucleus geniculatus medialis; SNc: substantia 
nigra, pars compacta; VTA: ventral tegmental area; AN: amygdaloid nuclei; ARH: nucleus 
arcuatus hypothalami; MM: corpora mammillaria; P: Purkinje cells of the cerebellum; GL: 
granular layer of cerebellum. The pictures are a personal courtesy of Prof. Bernhard Bettler, 
university of Basel. Adapted from (Kaupmann et al., 1997). 
 
Baclofen-Induced Cerebral Blood Volume Changes in wt Mice 
To assess changes in the relative CBV of specific brain regions of wild type Balb/c mice, 
modulations of the MRI signal from the post-contrast base-line were recorded, then roughly 
screened on a pixel-to-pixel basis with a Paravision analysis tool and then with the software 
Biomap (Martin Rausch, Novartis-Pharma AG, Basel). After defining an intensity threshold, 
groups of voxels corresponding to specific brain regions were merged into selected regions of 
interest (Roi). From Roi, the relative cerebral blood volume change (CBVrel) upon baclofen 
systemic injection was calculated considering the NMR signal intensities pre- and post- 
injection of the contrast agent, according to the equation (4). After screening of several 
regions in the different slices of the mouse brain, one region was identified, that presented 
significant activation in both hemispheres, after injection of baclofen (5 mg/kg body weight). 
The two vertical red dashed lines define the brain volume included in the MRI scans shown in 
Figure 3.5 B) and C). As an histological reference, Figure 3.5 A) reports a pictorial 
representation of the murine brain surface. 
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Figure 3.5. Activated Regions of Interest (ROIs) in the Mouse Brain. A) Sketch of the 
murine brain surface: the dashed red lines display the imaging planes selected for fMRI 
scans B) and C); the indicative topography of the sulcus rhinalis (rs), cortex perirhinalis 
(areas 35 and 36) and cortex entorhinalis is highlighted in dark grey. A,P,D,V indicate 
anterior, posterior, dorsal and ventral orientations of the brain, respectively.  
B) and C): steady-state contrast enhanced fMRI of a Balb/c mouse (coronal scans): after 
reaching steady-state with the contrast agent (i.v. injection of 50 mg/kg body weight of 
Endorem®), a dose of 5 mg/kg body weight of the GABA agonist baclofen was injected i.v. 
The red areas include the regions of interest (Roi) in which a significant change in CBV 
was observed.  
RARE sequence at 7T: TR = 1100 ms; effective TE = 45 ms; RARE-factor = 8; FOV = 1.6 
x 1.6 cm2; MTX = 128 x 128; SLTH = 1 mm; frequency sweep width = 50 kHz; number of 
averages/averaged experiments NA = 2 and NAE = 10, number of repetitions NR = 20 
including pre-contrast scans. Slice positions are B) ~ -1 mm and C) ~ -2.5 mm from 
Bregma. 
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Figure 3.6 Histological Sections of the Mouse Brain. Slices positions: A) Bregma: -1.64 
mm; interaural: 2.16 mm; B) Bregma: -2.75 mm; interaural: 1.05 mm. The dashed white 
lines include the regions activated upon baclofen exposure, as shown by fMRI at 7T. 
Anatomical abbreviations: Ect: cortex entorhinalis; PRh: cortex perirhinalis; LEnt: cortex 
entorhinalis lateralis; AuV: auditory cortex, pars ventralis; Au1: primary auditory cortex;  
AuD: auditory cortex, pars dorsalis BMA, BMP, BLA, BLV, BLP: nuclei corpum 
amygdaloideum; S2: second somatosensory cortex; RSA, RSG: retrosplenial 
agranular/granular cortex; cg: cingulum; D3V: ventriculus tertius (dorsal part); CPu: 
putamen and ncl. caudatus (striatum); LGP: ncl. pallidus lateralis (ncl. lentiformis); 
CA1,CA2,CA3: hippocampal fields; DG: gyrus dentatus; fi: fimbria hippocampus; S: 
subiculum; mt: tractus mammillothalamicus; rf: fissura rhinalis; Pir: cortex piriformis; 
SNC, SNR: substantia nigra (pars compacta and pars reticularis); LV: lateral ventricle; 
S1BF, S1Tr, S2: somatosensory cortex (primary and secondary); M1, M2: primary and 
secondary motor cortex; V1M, V2B, V2L: visual cortex (primary and secondary); Th: 
thalamic area; VPM: thalamic nucleus (ventral posteromedial). Adapted from “The Mouse 
Brain Library” (National Institute of Mental Health, USA). 
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Figure 3.7. Baclofen-induced Brain Activation in Balb/c Mice. Relative CBV changes are 
plotted as a function of time since administration of baclofen (min). In a group of four 
Balb/c mice (black squares), i.v. injection of baclofen at a dose of 5 mg/kg body weight 
was injected. In a control animal (dark diamonds), a correspondent volume of saline 
isotonic solution (NaCl 0.9 %) was administered instead of baclofen.. A significant 
(P<0.001) eCBV(%) of ~ 10-12 % appears bilaterally in cortical regions including 
auditory, perirhinal and entorhinal cortex. Vertical bars represend SD. Mice are freely 
breathing. No heating system. Isoflurane concentration of 0.6-1.2% in the gas mask. 
 
Figure 3.7 displays the relative change of CBV in wild type Balb/c mice brain, against 
time. The data were extracted from the highlighted region of interest situated in the brain 
cortex (Figure 3.5 B) and C), red ROI), comprising the auditory, perirhinal and entorhinal 
cortical areas (see Figure 3.6). In figure 3.7, the first three points (corresponding to scans 0-2), 
were considered as steady-state baseline Endorem concentration. In a group of 4 mice, the 
injection of the GABA agonist baclofen caused a decrease of the signal intensity in the 
selected cortical area, corresponding to a CBVrel increase of ~ 5 %. The eCBVrel reached a 
maximum of 10-12 % after 18 minutes after the agonist injection (black squares). The 
baseline was reached again after 48 minutes. Data correspond to mean values ± standard 
deviation from 4 different animals. As a control, an equivalent amount of isotonic NaCl 
solution was injected in a mouse of the same progeny (black diamonds). In this case, no larger 
changes in eCBVrel were observed. The difference in the median hemodynamic response 
0 20 40 60 80
-4
-2
0
2
4
6
8
10
12
14
16
18
20
 C
B
V
( %
)
Time [min]
baclofen: 5 mg/kg
control: NaCl 0.9 %
110 
measured between the control and positive subjects was assessed by non-parametrical analysis 
(Mann-Whitney) and showed statistical significance (P<0.001). 
 
These initial experiments were performed without an appropriate system to keep a 
constant mouse body temperature. Considering the temperature evolution reported in Figure 
3.9, it is clear that the animals were measured in hypothermic conditions and the consequence 
of this will be discussed in the next section. We therefore limited the number of animals used 
to 5 (4 positive stimulations and 1 placebo control). 
When a homoeothermic blanket system became available (see material and methods in 
section 3.2), further experiments were performed with the new experimental setup. In these 
cases, two wild type and one knock out model were measured at a constant measured rectal 
temperature of 37 °C. For the evaluation of the temperature regulation device, a few 
observations deserve attention: 1) to keep a rectal temperature of 37 °C, the blanked surface 
had a temperature of 54 °C, which is a dangerous condition for the animal skin in contact; 2) 
under these heated conditions, the same concentration of 5 mg/kg body weight of baclofen 
was much less tolerated than under hypothermic conditions which resulted in a deep 
respiratory depression at the limit of respiratory failure. We therefore limited the investigation 
with this second experimental setup to 3 animals (2 wt and 1 ko). Future experiments should 
aime at reducing the baclofen concentration at these temperatures and at stabilizing the 
temperature over a longer time (to avoid larger T differences between rectum and blanket).  
 
Comparison between wt and ko strains led to the following conclusions: paralysis and 
strong respiratory depression after baclofen administration was only observed in wt mice and 
such instability was not only limited to the brain, but was a generalized effect (oscillation 
even in muscular tissues), fMRI data show (Figure 3.8) that a change in CBV in wild type 
mice was observed, in contrast with GABAB-R1 k.o. animals. However, this significant 
cortical activation observed in the first experimental setup (see Figure 3.7) could not be 
reproduced when using the heating device. The possible reasons for these differences will be 
discussed in the next section. 
111 
 
Figure 3.8. Baclofen-induced Brain Activation in Balb/c Mice. Percent CBV changes in 
cortical Roi as in Figure 3.5 are reported as a function of time (min), after administration of 
baclofen at 5 mg/kg body weight. Experiments were performed with two Balb/c wild type 
(black squares and triangles) and one GABAB-R1 knock-out (black circles) mice. Freely 
breathing animals. Rectal temp. = 37 °C kept stable through electrical heating blanket. 
Isoflurane concentration of 2-2.5% in the gas mask. 
 
0 10 20 30 40 50 60 70
-8
-6
-4
-2
0
2
4
6
8
10
12
C
B
V
(%
)
Time [min]
WT1
GABAB-R1 K.O.
WT2
S2 GlobalRoi
C
B
V
(%
)
112 
Correlation Between Mouse Body Temperature, Respiration and Anesthesia 
 
In our experiments, mice were allowed to breathe freely and were kept under anaesthesia 
through a face mask. Under anaesthesia, the endogenous capacity to regulate body 
temperature is impaired. For this reason, we investigated the evolution of body temperature of 
anaesthetized mice left at room temperature (20 °C), in the absence and presence of a heating 
device. In parallel, we monitored the breathing rate and the concentration of isoflurane 
required to keep the mouse anaesthetized. 
 
Figure 3.9. Evolution of temperature and Breathing Rate during Anaesthesia. The plots 
report: A) the measured rectal temperature of a Balb/c mouse breathing under face-mask 
anaesthesia with Isoflurane/O2/N2O; B) the breathing rate of the animal during the same 
experiment (blue squares), and C) the required concentration of Isoflurane necessary to 
keep the animal anaesthetized (green line). 
 
In figure 3.9 A) the variation of mouse body temperature is displayed against time (black 
squares). Here, the temperature decreases exponentially with time. In the experiment shown, 
already in the first minutes, the rectal temperature decreases by approximately 0.4 °C/min. 
After 60 minutes, the temperature decreased to 29.3°C indicating the need for a heating 
device. At time t = 62 min., the heating blanket was turned on, leading to a rapid increase of 
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the body temperature up to 37 °C, which was the programmed temperature in the 
homeothermic system. At all times, the concentration of isoflurane was adjusted to limit 
respiratory depression and stage IV narcosis (= asphyxia), (Figure 3.9 C), green line): after 10 
minutes, isoflurane was set to 1.2 % and the mouse came to a breathing rate of 30-35 
breathes/min (Figure 3.9 B). Note that at this time the rectal temperature droped to 33 °C. By 
keeping this isoflurane concentration, the respiration frequency increased a few minutes later 
up to 100 breathes/min and the mouse tended to wake up. The isoflurane was shortly 
increased to 2.0 %. As a consequence, a respiration was depressed again to 40 breathes/min. 
After 40 min, however, isoflurane concentration could be decreased again to 1.2 %, without 
waking up the mouse (in other mice, isoflurane concentration could be even kept as low as 0.6 
%) having a rectal temperature of 30 °C. 62 minutes after the beginning of the experiment, the 
mouse rectal temperature was of 29 °C. The heating blanket was then turned on, leading to a 
rapid increase of the mouse rectal temperature up to 37 °C. As a consequence of the 
temperature increase, the breathing rate increased distinctly after a 2-3 minutes delay, and the 
mouse started to wake up. The isoflurane concentration was subsequently increased, to keep 
the animal anesthetized. At a rectal temperature of 37 °C, the mouse could not be kept under 
anesthesia with an isoflurane concentration lower than 2 %. These observations indicate that a 
heating device is necessary to maintain the mice at physiological temperatures even during 60 
min fMRI experiments and that a tracheal intubation (artificial ventilation) of the mouse 
would facilitate the regulation of the anaesthesia. 
 
Analysis of GABA precursors for in vivo 13C-NMR spectroscopy 
 
Activation of brain regions with GABA agonist leads to the question of how the GABA 
agonists are metabolized in the mouse brain. With the goal to investigate the GABA 
metabolism in the mouse brain in vivo, we first recorded in vitro high resolution 13C-NMR 
spectra in order to characterize the molecules of interest. Three compounds, namely GABA, 
GBL and GHB, were considered. 
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Figure 3.10. 13C-NMR Spectroscopy of GABA and Related Metabolites. (A) GABA, (B) 
GHB and (C) baclofen. 
 
In Figure 3.10, 13C-NMR Spectra of GABA, GHB and baclofen are shown. The main 
differences are represented by the C-4 shift induced by the -OH residue of GHB (in 
comparison to GABA) and the phenyl ring of baclofen, indicated by the resonances C'. 
The biosynthesis of GABA occurs in the brain via decarboxylation of glutamate by 1- 
Glutamic Acid Decarboxylase (GAD). The metabolism of GABA proceeds via transamination 
to succinic semialdehyde by the enzyme GABA transaminase (GABA-T). After a 
dehydrogenase step, the molecule re-enters the TCA cycle as succinate acid (Daikhin and 
Yudkoff, 1998). The resonances C-4 and C-3 should thus be sensitive in vivo NMR 
parameters as they are strongly affected by all 3 enzymatic steps. Small changes in carbon C-
3, however, will be hard to detect by in vivo spectroscopy because it overlaps with much 
stronger signals from tissue lipids (-CH2- groups, 24-32 ppm) - in contrast to C-4. Carbon C-
1 is also unsuited for 13C labeling experiments because it also overlaps with tissue lipids (-
COOH group, 180 ppm) and has a long relaxation T1 time which causes signal saturation 
during rapid pulsing experiments. 
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3.5 Discussion 
The aim of the present study was to develop an fMRI protocol for imaging mouse brain 
activity after GABAB activation. To target GABABergic activation, we chose a 
pharmacological stimulation paradigm involving a systemic infusion of the known GABA 
agonist baclofen. The experiments were carried out on Balb/c mice. In addition to wild type 
mice, our study included a recently established strain derived from Balb/c mice by Bettler and 
coworkers (Schuler et al., 2001), in which the genes coding for GABAB-R1 receptor subunits 
have been stably knocked out. The goal was to compare wild type vs K.O. mice, in order to 
elucidate neural patterns underlying cerebral GABABergic activity. We were also interested 
in `-hydroxybutyrate (GHB), a GABA derivative with agonistic affinity for GABAB 
receptors (Lingenhoehl et al., 1999) which is increasingly employed as life style drug (Wong 
et al., 2004). 
 
In a group of four Balb/c wild-type mice, a significant transient increase (30-40 min) of 
CBVrel in the order of 10-12% was observed after the systemic injection of 5 mg/kg body 
weight of baclofen. The hemodynamically activated brain regions included parts of the 
perirhinal, entorhinal and ventral auditory cortical areas. The maximum eCBVrel was 
observed at ~20 min after baclofen infusion and returned to basal values after ~ 1 hour.  
The activation could be monitored by fMRI at 7T with a spatial resolution of 125 x 125 
µm in the in-plane dimensions and a slice thickness of 1mm.  
Especially for small animals with limited tissue volume such as mice, MRI tends to be a 
compromise between image resolution and physiological stability: the higher the resolution, 
the less signal per voxel, the more signal averaging (= accumulation time) is required for an 
acceptable contrast. Signal averaging, however, is not only limited because of the stability of 
the animal in anaesthesia, but also because of the time window of the observed effect and the 
desired temporal resolution to follow such processes. In our experiments, the pharmacological 
GABAB receptors stimulation was expected to result in a long-lasting effect (slow synaptic 
inhibition; in the order of minutes), different from an electric stimulation with only a short 
transient effect (in the order of seconds). Considering a total experimental time above one 
hour, the number of averages were chosen such as to yield a good image quality, yet still a 
good temporal resolution for the drug effect: the time to record 7 brain slices was 6 min for 
the present experiments. 
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Relation between observed CBV Changes, Physiological Parameters and 
Anesthesia 
The appropriate monitoring and control of physiological parameters such as respiration, 
body temperature and blood gases concentration is crucial for a correct experimentation and 
interpretation of experimental results especially in fMRI. The small size of mice, which are 
one order of magnitude smaller than rats, make this task particularly challenging. 
 
In the present experiments, the mice had no tracheal intubation which is routinely used in 
humans in clinical anaesthesia. This procedure allows a mechanical regulation of the 
breathing rate, though this might cause severe injuries of the trachea when performed in such 
small organisms as mice. Therefore, the anaesthesia gas was provided by a face mask and the 
breathing rate was maintained at 60/min by adjusting the amount of isoflurane (reciprocal 
correlation). At physiological temperature (38°C in mice), the drop from 100 breathes/min to 
60/min as caused by the isoflurane provides usually a reasonable anaesthesia. On the one 
hand, free breathing is advantageous for handling. On the other hand, respiratory depression 
caused by anaesthesia and pharmacological stimulation, together with the physiological 
breathing irregularities, such as respiratory sinus arrhythmia (Neff et al., 2003) can lead to 
artifacts (blood gases and blood pressure changes) and critical conditions for the animal. 
The anaesthesia regulation used in our experiments has an important co-variable that 
might be fundamental for the discussion of the fMRI results: the breathing rate does not only 
depend on the amount of isoflurane (reciprocal relation), but also on the temperature 
(proportional relation). 
The first set of experiments was carried out in the absence of the appropriate mice heating 
device. To keep a stable mouse body temperature at physiological conditions (38 °C), an 
electrical homoeothermic feedback system was introduced in the later experimental setup. By 
inducing a hypothermic state (29°C) when the mouse heating device was not yet available, the 
first group of mice lowered their breathing rate already by hypothermia, so that less isoflurane 
was required to adjust the breathing rate to 60/min (0.5 - 1.2% instead of 2 - 2.5%, compared 
to mice at 37°C). The anaesthesia was less pronounced in this group of mice and the mice 
were more sensitive to sensorial (auditory and olfactory) stimulation under the influence of 
baclofen. In contrast, the thermo-stabilized mice (37°C) experienced a more profound 
anaesthesia (higher isoflurane content 2-2.5%). Therefore, the previously observed brain 
activation was not observed in the second group. In addition to the more pronounced 
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anaesthesia, isoflurane causes a general lowering of neural processes (Simon et al., 2001; 
Sugimura et al., 2001), has strong vasodilatory effects (Matta et al., 1999) and can interact 
with baclofen activity (Sugimura et al., 2002). 
Comparison of both mice groups allows the following two conclusions: (i) in fMRI, the 
existence of activated brain areas might be highly dependent on the depth of the anaesthesia. 
(ii) In order to eliminate breathing artefacts, the breathing gas should be administered by 
mechanical ventilation. 
The mice heating device could also be improved: heat was provided only by a half-body 
through which lacked a heating blanket on top of the animal. The feedback system, however, 
is regulated according to the input from the rectal thermometer and mice have a very low 
thermal inertia because of the high body surface/volume ratio. To keep 37°C rectal 
temperature, the single-sided heating blanket needed a temperature of 54°C, which is a 
dangerous condition for the mouse skin. Consequently, the surface temperature of the 
abdomen is much colder, because of its contact with cold air in the MRI tube (16-18 °C). This 
strong temperature gradient results in an instability of the vascular circulation, and thus 
affects the CBF and eCBVrel measurements in fMRI. This technical system could be 
improved either by a double-sided heating device or by heating the entire MRI tube (including 
the mice) with hot air. However, this would be only possible in combination with intratracheal 
intubation. 
Beside the less pronounced anaesthesia, also the direct effects of hypothermia on CBV 
could be responsible for the large CBV changes observed in the first group of mice. 
Hypothermia reduces CBF and CBV as a consequence of the reduced metabolism (Thomas et 
al., 2001). Such conditions have been shown to increase the signal amplitude originating from 
CBVrel changes during fMRI (T. Mueggler, personal communication). 
 Finally, the biological effects of baclofen on respiration (Olpe et al., 1978) and its 
different pharmacodynamics at different temperatures must also be considered. Besides its 
relaxant activity on muscles, baclofen has been shown to reduce the respiratory rate in rats, 
(Sved and Tsukamoto, 1992; Trippenbach, 1995). Moreover, it can alter blood dependent 
parameters such as CBV although there is non consense in the existing literature. Depending 
on the dose and site of injection (Chahl and Walker, 1980), baclofen can lower the blood 
pressure (Saito et al., 1999), especially in combination with anaesthesia (Brouillette and 
Couture, 2002; Lyew et al., 2003) or induce an increase of arterial pressure (Landulpho et al., 
2003) and heart rate (Trippenbach and Lake, 1994). In contrast, it has also been reported that 
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baclofen has no effect on arterial pressure, but modulates the carotid chemoreceptor reflex 
(Suzuki et al., 1999). 
It can be concluded that the moderate hypothermia and anaesthesia technique used for the 
first group of mice had some advantages to detect CBV changes after systemic baclofen 
infusion. 
 
CBVrel Changes in the Auditory Cortex after Systemic Baclofen Infusion in 
Wild-type Balb/c Mice. 
The discussion of the observed brain activation (auditory cortical areas) requires a brief 
summary of known brain anatomy. The auditory pathways starts from the nervus 
vestibulocochlearis, which projects separately toward vestibular and cochlear nuclei. From 
there, the auditory tract continues through the corpus trapezoideum and the lemniscus 
lateralis, and the information is projected to the colliculus inferior (IC), which is a crucial 
switching centre for acoustic reflexes. Through the pedunculus colliculi inferioris, the 
auditory tract continues to the medial geniculate body, which is then connected tonotopically 
to the auditory cortex. Few years ago, highly organized corticocollicular projections were 
described (Herbert et al., 1991). 
The colliculus inferior was recently shown to be sensitive to baclofen (Ma et al., 2002; 
Zhang and Wu, 2000). According to those findings, GABAergic inhibition in the auditory 
midbrain can be suppressed by a presynaptic activation of GABAB receptors. Here, 
stimulation with baclofen was shown to decrease the amplitude of inhibitory postsynaptic 
potential (IPSP) in the inferior colliculus (Ma et al., 2002), and thus promote the induction of 
long-term potentiation (LTP), in the presence of electrical activity in more peripherical 
regions of the auditory network, such as the lemniscus lateralis (Zhang and Wu, 2000). 
Our fMRI data show an activity change in auditory cortical areas, in terms of CBVrel 
changes, under the influence of baclofen. In our experiments, a continuous auditory 
stimulation is provided by the MRI gradients noise. Baclofen in the CNS could open the “IC 
gate”, which would lead to the alteration of the auditory excitation. Ultimately, this temporal 
pattern would correlate with a metabolic degradation of baclofen. On the basis of this auditory 
stimulation, it becomes more evident why one group of mice (not thermoregulated, ~ 0.5 – 1.2 
% isoflurane) did show this activation, whereas another group of mice (thermostabilized, ~2 – 
2.5 % isoflurane) was no longer sensitive to this baclofen-enhanced auditory stimulation. Our 
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project started with the screening of brain regions that could be activated under the influence 
of baclofen. Now that an activated brain region has been found and plausible interpretations 
have been proposed, a more detailed investigation should test this hypothesis. For example, 
the experiments could be repeated by isolating the animal from external auditory stimuli, 
using different degrees of anaesthesia and sire more attention to anatomical parts connected 
with the auditory network, such as the IC. 
 
CBVrel Changes in the Perirhinal/Entorhinal Cortex after Systemic Baclofen 
Infusion in Wild-type Balb/c Mice. 
 
Baclofen systemic administration resulted in a selective activation of cortical areas 
comprising brain regions including the auditory, perirhinal and entorhinal cortex of Balb/c 
wild-type mice. 
On the basis of the present experiments, it is not possible to elucidate the 
neurophysiological mechanisms causing the activation. However, a comparison with other 
studies allows a better understanding of how the activation of GABAB receptors could lead to 
such regional CBV changes. 
 
The effect of baclofen and other GABA agonists (such as GHB) on the functioning of 
memory has been discussed before (Teter and Guthrie, 2001). Behavioural studies in rats and 
mice describe impairing (Pitsikas et al., 2003; Stackman and Walsh, 1994), as well as 
enhancing (Saha et al., 1993; Sharma and Kulkarni, 1993) effects of baclofen on the 
achievement of memory requiring tasks. Memory and learning are highly complex tasks that 
involve many brain areas that are part of the limbic system. A schematic representation of the 
connections between these brain regions is shown in Figure 3.11. It is assumed that long-term 
potentiation (LTP) plays a crucial role in memory formation and that LTP induction is 
modulated through GABAB autoreceptors involved in the limbic system (Davies et al., 1991). 
As a GABAB agonist, baclofen directly interferes with these processes. Elucidation of such 
GABA activations in fMRI would ideally require the absence of anaesthesia. However, 
sensory stimuli may still influence the cerebral activity of an anesthetized animal, allowing a 
pavlonian-like conditioning under moderate anaesthesia (A. Lüthi, personal communication). 
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In the pathways involved in recognition, the perirhinal cortex, as well as the entorhinal 
cortex and hippocampus occupy a crucial role (Brown and Aggleton, 2001; Wan et al., 1999). 
Only the first two areas were found to be activated in the present study (in addition to the 
already discussed auditory cortex). The following outline could provide an interpretation for 
such selectivity. 
The perirhinal cortex is connected with the medial dorsal thalamic nucleus, while the 
hippocampus is connected with the anterior thalamic nucleus and the entorhinal cortex has 
both connections. Perirhinal and parahippocampal cortex together provide two thirds of the 
connections with entorhinal cortex, which is the gateway to the hippocampus. 
Although perirhinal cortex and hippocampus are anatomically linked, they are not necessarily 
dependent on each other, as shown, for example, in their independent roles in encoding 
episodic information and familiarity-based recognition (Aggleton and Brown, 1999).  
Studies focusing on the perirhinal cortex have shown differences in GABA transmission 
between temporal and entorhinal inputs including the differential activation of presynaptic 
GABAB receptors and differential regulation of inhibitory synaptic transmission in this 
region. These properties may be important in the control of neuronal activity in this region  
(Garden et al., 2002) and thus in its selective activation under specific stimulation. 
Unfamiliar information has shown to activate selectively perirhinal and parahippocampal 
regions, whereas retrieval activates more hippocampus and subiculum (Gabrieli et al., 1997). 
 
Moreover, the perirhinal cortex is strongly connected with the amygdala, a centre 
responsible for emotional processes. An activation in this regions upon GABAB receptor 
stimulation could be therefore expected, considering the amnesic and hypnotic effects 
observed in patients treated with other GABAB agonists, such as GHB (Teter and Guthrie, 
2001). 
 
Properties that distinguish the perirhinal cortex from the hippocampus, include parameters 
that could suggest why we observe an activation in these areas under our experimental 
conditions. The most studied memory-requiring tasks involve the visual system. However, the 
perirhinal cortex can receive multimodal sensory inputs (Burwell et al., 1995). For example, 
perirhinal/entorhinal cortex, but not hippocampus, were shown to be involved in olfaction-
based recognition (Petrulis and Eichenbaum, 2003). 
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Recent works support an influence of baclofen on the olfactory system in vitro (Belluzzi et 
al., 2004; Isaacson and Vitten, 2003) and on olfactory related learning tasks in rats in vivo 
(Okutani et al., 2003). 
Considering also the fact, that in the rodent brain, the olfactory system is more developed 
than in humans, the localization of CBV change in the perirhinal cortical areas of mice may 
be triggered by some incidence of the experimental conditions, i.e., a synergistic effect of 
baclofen and an olfactory stimulation coming from isoflurane under moderate hypotherma. 
Indeed, the pungent odour of isoflurane is a well known adverse feature of this inhalant, so 
that in the clinical literature it is often suggested to treat patients with other pre-medication 
anaesthetics, such as short acting barbiturates. Under deep narcosis, the patient is obviously 
not conscious of such irritant aspect of isoflurane. However, especially in the light anaesthesia 
of the first animal group and considering the rodent olfactory system, it is probable that the 
substance can induce a neural excitation in the olfactory bulbs, and thus transmit information 
to the linked cortical areas, in particular the perirhinal cortex. According to this hypothesis, 
the GABAergic modulatory effect of baclofen would induce CBV changes in this region. 
A future study could look systematically at these originally unexpected factors to prove 
whether this effect can be avoided by switching the administration of isoflurane from the face 
mask to an intratracheal intubation of the animal, which, by directly reaching the bronchi, 
would suppress the trigger of olfactory receptors. 
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Figure 3.11 Schematic diagram of the principal pathways underlying encoding and 
recollection of information in the brain. The areas where eCBVrel changes were observed 
by fMRI upon baclofen systemic administration (auditory, perirhinal, entorhinal cortex) are 
highlighted in red boxes. The influence of additional sensorial stimulation (olfactory, 
auditory) is reported over a classical diagram that relies brain structures of the limbic 
system involved in the encoding of episodic information and recollective aspects of 
recognition. The relative thickness of the lines indicates the putative importance of the 
connections. 
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Practical Considerations for in vivo 13C-NMR Spectroscopy on GABAB ko Mice 
 
In vivo 13C-NMR spectroscopy is much less sensitive than 1H-NMR imaging. First, the 
carbon atoms has 2 isotopes, 98.9 % 12C and only 1.1 % 13C. The latter is the isotope able to 
produce a NMR signal. This results in a much lower sensitivity, compared to the NMR signal 
generated from 1H. Secondly, the gyromagnetic ratio of the 13C nucleus is smaller than that of 
1H, which again affects the sensitivity. Moreover, spectroscopy does not focus on the single 
resonance from abundant tissue water, but on the spectral dispersion of compounds that are 
much less concentrated in living tissue (usually < 5 mmoles/L tissue), compared to water (40 
moles/L tissue). 
 
For two types of metabolites, namely lipids and glycogen, their concentration in living 
tissues is sufficient to quantify differences using just the natural abundance 13C signals. In 
most cases, however, 13C-NMR spectroscopy of natural abundance 13C signal is not sensitive 
enough to differentiate minute changes in tissue metabolites (concentration usually < 5 
mmoles/L tissue). In addition, the "background" 13C signals of lipids may mask the smaller 
signal from metabolites. Therefore, 13C NMR spectroscopy most often relies on stable isotope 
labelling. The molecule of interest, or a metabolic precursor, is synthesized with one or more 
selected carbon atoms replaced entirely by the 13C isotope. In this way, the 13C-NMR 
sensitivity can be increased by up to a factor 102, depending on how much of the endogenous 
metabolite can be replaced within the tissue (= fractional enrichment). To maintain 
physiological conditions, the absolute tissue level of the metabolite should not change, 
whereas for a good NMR observation, the fractional enrichment should rapidly increases to 
100% at the same time. This goal can only be achieved if the turnover rate of this molecule is 
very high or after longer infusion times. 
 
The background signal from lipids, which in general changes slowly over time, is simply 
subtracted during the infusion of the 13C enriched compounds. In this way, the pathway and 
the rate of metabolism for the 13C labelled molecule can be followed throughout the catabolic 
(or anabolic) process. For several reasons, however, the position of the 13C label within the 
molecule must be chosen with care.  
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Carbon atoms with a short NMR T1-relaxation time (e.g. methyl groups) are usually 
preferred over those with a longer relaxation time (e.g. carboxylic groups), in order to avoid 
saturation of the signal (and thus sensitivity decrease) induced by too rapid a pulsing. Indeed, 
to maintain an equal signal strength, carbons with a long relaxation time would require a very 
long repetition time (TR > 5 · T1) between the repetitive RF pulses, which is not suitable for 
in vivo experiments. 
 
Another factor that must be considered for the design of an appropriately labelled 
compound is its metabolic fate. An early “loss” of the labelled atoms in the metabolic 
pathways (e.g. via decarboxylation) should be avoided, in order to follow the metabolite for a 
sufficient number of metabolic steps. A third reason is purely technical: not every carbon 
position of a molecule is easily accessible for chemical labelling. 
 
Considering the aspects mentioned above, the neurotransmitter and drugs used in the 
fMRI experiments were subjected to various NMR measurements and considerations in order 
to focus on what carbon position would be the most appropriate for in vivo 13C NMR 
spectroscopy on mouse brains. Figure 3.12 shows the chemical structures of the compounds 
investigated, namely the endogenous neurotransmitter GABA (A), the medical GABA agonist 
baclofen (B) and the "party drug" GHB (C).  
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Figure 3.12. Chemical Structures of GABA and related Compounds. 
 
Using high resolution 13C NMR at 9.4 T, the following parameters were investigated, i.e., i) 
the chemical shift of the carbons with special consideration of a possible overlap with lipid 
resonances, ii) the effect of in vivo repetition times (~ 2 s) on relaxation/saturation, and iii) 
expected signal-to-noise ratios for a 60 min spectrum. The latter factor is based on the 
assumption that for a mouse of 30 g body weight, doses of GHB and baclofen of not more 
than 60 µg and 1.35 mg, respectively, can be administered because of the toxicity of the 
compounds. Indeed, the LD50 is 2 mg/kg (i.v.; male rats) and 45 mg/kg (i.v.; male mice) for 
GHB and baclofen, respectively (data from The Merck Index 12th ed.). In the case of 
baclofen, the dose used in our fMRI experiments was ~ 5 mg / kg mouse, and presented 
already toxic effects in few cases. For the evaluation of the signal-to-noise in a realistic in 
vivo MRS experiment (repetition time of 2s and 2000 scans), the effective amount of baclofen 
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present in the mouse brain has to be considered, which would be a small percentage ( 2-4% 
of the body volume) of the total amount injected. This would correspond to ~ 6 µg baclofen 
for an injection of 5 mg/kg body weight into a 30 g mouse. For 13C-MRS, 6 µg baclofen 
enriched with 13C to 100% would correspond to an equal amount of 13C present in ~ 0.6 mg of 
natural abundance baclofen (at only 1.1% fractional enrichment). The latter amount of non-
enriched compound was therefore chosen for in vitro 13C-NMR spectroscopy, as shown in 
Fig. 3.10. 
 
From a metabolic view, positions 2 to 4 are much more appropriate to be labelled, because 
the position C-1 can undergo rapid decarboxylation. Figure 3.10 C) also illustrates that under 
usual in vivo spectral conditions (repetition time = 2 s), the carboxylic C-1 is highly saturated 
and the signal-to-noise is much worse than for all other carbons. Although recorded at 9.4 
Tesla (and not at 7 Tesla as in the in vivo magnet), these spectra give a good estimate for the 
expected signal-to-noise at 7 Tesla. Labelling the position C-1 for in vivo experiments is 
inappropriate for a third reason: the carboxylic C-1 group of all compounds in Figure 3.10 
overlaps with the carboxylic resonances of lipids (175-185 ppm). Slight changes in the lipid 
composition during the experimental time might cause severe artifacts when subtracting NMR 
spectra before and after the infusion. An overlap with the lipid resonances at 22-32 ppm (-
CH2-) and 55-65 ppm (glycerol backbone and N-(CH3)3 groups) is also expected for the C-3 
of all compounds and the C-4 of GHB, respectively, so that positions C-2 (eventually C-4) 
seems to be the most appropriate position to be labelled for in vivo 13C spectroscopy. 
Despite these obvious disadvantages to label position C-1 for in vivo NMR spectroscopy, 
C-1 is the easiest position to label from a chemical point of view. 
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3.5 Conclusion 
 
In the present study, fMRI could be successfully applied to in vivo measurements of mice. 
Baclofen-induced changes in cerebral blood volume (CBVrel) were detected in healthy mice in 
vivo. The CBV changes were localized in the auditory and perirhinal brain regions and might 
reflect the baclofen-enhanced response to sensorial (auditory and olfactory) stimuli. 
 
Several conclusions can be drawn, i.e., i) functional information can be obtained from 
fMRI in mice; ii) monitoring and stabilization of physiological conditions is of fundamental 
importance in such experiments for the appropriate evaluation of cerebral hemodynamic 
responses; iii) concomitant sensory stimulations can influence the localization of 
hemodynamic changes. This is an important aspect for the choice of new technical methods in 
the study of systemic pharmacological compounds acting on a wide area of the CNS, and 
especially with pharmaca that induce sensorial alterations, such as baclofen or GHB. 
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